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ABSTRACT
COMPUTATIONAL ANALYSIS OF EXPRESSED SEQUENCE TAGS 
FOR UNDERSTANDING GENE REGULATION 
I. Elizabeth Cha 
July 30, 2008 
High-throughput sequencing has provided a myriad of genetic data for thousands 
of organisms. Computational analysis of one data type, expressed sequence tags (ESTs) 
yields insight into gene expression, alternative splicing, tissue specificity gene 
functionality and the detection and differentiation of pseudogenes. Two computational 
methods have been developed to analyze alternative splicing events and to detect and 
characterize pseudogenes using ESTs.  
A case study of rat phosphodiesterase 4 (PDE4) genes yielded more than twenty-
five previously unreported isoforms. These were experimentally verified through wet lab 
collaboration and found to be tissue specific. In addition, thirteen cytochrome-like gene 
and pseudogene sequences from the human genome were analyzed for pseudogene 
properties. Of the thirteen sequences, one was identified as the actual cytochrome gene, 
two were found to be non-cytochrome-related sequences, and eight were determined to 
be pseudogenes. The remaining two sequences were identified to be duplicates.  
As a precursor to applying the two new methods, the efficiency of three BLAST 
algorithms (NCBI BLAST, WU BLAST and mpiBLAST) were examined for comparing 
ix 
 
 large numbers of short sequences (ESTs) to fewer large sequences (genomic regions). In 
general, WU BLAST was found to be the most efficient sequence comparison tool. 
These approaches illustrate the power of ESTs in understanding gene expression. 
Efficient computational analysis of ESTs (such as the two tools described) will be vital to 
understanding the complexity of gene expression as more high-throughput EST data is 
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CHAPTER I  
INTRODUCTION 
Since the laws of inheritance were described by the Augustinian monk Gregor 
Mendel in 1866 (1-4), the genomic basis for heredity has been a topic of interest. The 
discovery of nucleic acids by Friedrich Miescher (5) in 1869 moved the study of genetics 
to a molecular level. Fueled by the basic ‘truth’ of the Central Dogma of Molecular 
Biology (6), molecular biologists have worked towards understanding the complex 
relationship between deoxyribonucleic acids (DNA), ribonucleic acids (RNA) and amino 
acids as they create proteins providing structure, function and regulation to a biological 
system.  
The possibility of decoding the genomic DNA for a species through DNA 
sequencing has led to the ability to glimpse at the genetic blueprint for an individual. The 
vast amount of genomic data resulting from projects such as the human genome project 
provides a treasure chest of data waiting to be explored. This has led to the emergence of 
the field of Bioinformatics to provide computational means for handling and mining such 
data. The focus of this dissertation is to provide Bioinformatics' approach to 
understanding the complexity involved in gene regulation. In order to adequately address 
the problem at hand, the rest of this chapter is devoted to a background on basic genetics, 
molecular biology, DNA sequencing, genes, and bioinformatics, as well as a brief 




 1.1 Basic Genetics 
The field of genetics traces its roots to 1866 with the published observations of 
the Augustinian monk Gregor Mendel (1-4). Mendel performed pea plant experiments to 
study the inheritance of genetic traits, such as tall vs. dwarf plants, wrinkled vs. round 
peas, violet vs. white flowers, etc. He concluded that the characteristics of living 
organisms are passed from generation to generation through replication.  
Several major discoveries since have advanced the study of genetics at a 
molecular level. In 1869, nucleic acids were isolated and studied by Friedrich Miescher 
(5). In 1944, Avery, MacLeod and McCarty determined that DNA is the carrier of 
hereditary information (7;8) through four nucleic acid bases: adenine (A), cytosine (C), 
guanine (G) and thymine (T). This tetranucleotide hypothesis was verified in the late 
1940s and early 1950s by Erwin Chargaff and his colleagues (9;10). In 1953, Watson and 
Crick discovered the structure of a double helix for DNA (11). These discoveries opened 
the door to many more advances in genetics over the past 60 years in the field of 
molecular biology, the branch of life science which studies cells at a molecular level, 
including nucleic acids, amino acids, proteins and fundamental biochemical reactions 
within a cell. 
 
1.2 DNA 
Deoxyribonucleic acid, or DNA, is composed of four nucleic acid bases –  
adenine (A), cytosine (C), guanine (G) and thymine (T) – which are arranged in different 
ways to form sequences. The International Union of Pure and Applied Chemistry 
(IUPAC) and the International Union of Biochemistry (IUB) published a code in 1985 for 
2 
 
 representing DNA sequences (12) (Table 1.1). A single letter signifies a single nucleotide 
or nucleotide alternative, as shown in columns one and two. 
 
Table 1.1: IUPAC-IUB Nucleic Acid and Amino Acid Codes 
Nucleotide Acid Codes Amino Acid Codes 





A Adenine Glycine GLY G 
C Cytosine Alanine ALA A 
G Guanine Valine VAL V 
T  
Thymine in DNA; Uracil in 
RNA  Leucine LEU L 
M A or C Isoleucine ILE I 
R A or G Phenylalanine PHE F 
W A or T Proline PRO P 
S C or G Serine SER S 
Y C or T Threonine THR T 
K G or T Cysteine CYS C 
V A or C or G; not T Methionine MET M 
H A or C or T; not G Tryptophan TRP W 
D A or G or T; not C Tyrosine TYR Y 
B C or G or T; not A Asparagine ASN N 
N   A or C or G or T Glutamine GLN Q 
Aspartic acid ASP D 
Glutamic acid GLU E 
Lysine LYS K 
Arginine ARG R 
Histidine HIS H 
 
As Watson and Crick revealed (11), DNA is structured as a double helix, where 
two strands are held together and rotated around a horizontal axis. These two strands are 
“anti-parallel,” with one strand running from a 5’ to 3’ direction and the other strand 
3 
 
 running from 3’ to 5’, where 3’ and 5’ represent structural properties in nucleic acids1. 
The two strands are held together by the energy of hydrogen bonds in complementary 
sequences where an A always pairs with a T, and a C always pairs with a G (and vice-










Figure 1.1: A diagram of a sugar-ring molecule with carbons labeled numerically. 
 
 
Figure 1.2: Double strand DNA sequences. 
 
1.3 RNA 
RNA stands for ribonucleic acid. Three of the four DNA bases are the same in 
RNA, with the exception that thymine (T) is substituted by uracil (U). Unlike DNA, RNA 
can leave the nucleus of a cell to perform functions and is normally a single-stranded 
molecule. There are three major, functionally-distinct varieties of RNA: messenger RNA 
(mRNA), ribosomal RNA (rRNA) and transfer RNA (tRNA). mRNA is involved in the 
                                                            
1 Directionality in molecular biology refers to the end-to-end chemical orientation of a single strand of 
nucleic acid. The chemical convention of naming carbon atoms in the nucleotide sugar-ring numerically 
gives rise to a 5’ end and a 3’ end (usually pronounce “five prime end” and “three prime end”). Therefore, 
the 5’ end designates the end of the DNA or RNA strand that has the fifth carbon in the sugar-ring of the 
(deoxy)ribose at its terminus. The 3’ end has the third carbon in the sugar-ring as its terminus (Figure 1.1). 
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 transmission of DNA information. rRNA functions in the synthesis process of producing 
proteins. tRNA enables another part of protein synthesis by bringing together chains of 
amino acids (13). There are some other types of RNAs, such as RNA interference 
(RNAi), microRNA (miRNA) and silencing RNA (siRNA). They will be discussed in 
Section 1.6, Central Dogma. 
 
1.4 Amino Acids 
Amino acids are the basic elements of proteins. They form short polymer chains 
called peptides or longer sequences called polypeptides. In an mRNA sequence, every 
three nucleic acids form a codon2 that describes one amino acid. Since there are four 
nucleic acids, A, C, G and T, a codon can have up to 4 × 4 × 4 or 64 different 
combinations, yet there are only twenty common amino acids. In 1962, Marshall 
Nirenberg (14-16) uncovered the genetic code, which allows for multiple codons to code 
for the same amino acid as shown in Table 1.2. During the translation process, a sequence 
begins with the initiator codon AUG and ends with any of the three terminator codons: 
UAA, UAG or UGA. 
   
                                                            
2 A codon is a sequence of three adjacent nucleotides constituting the genetic code that determines the 
insertion of a specific amino acid in a polypeptide chain during protein synthesis or gives the signal to start 





Table 1.2: The Genetic Code (RNA to Amino Acids) 
Second letter 






















UUC UCC UAC UGC C 
UUA 
Leu 
UCA UAA Stop UGA Stop A 











CUC CCC CAC CGC C 
CUA CCA CAA 
Gln 
CGA A 











AUC ACC AAC AGC C 
















GUC GCC GAC GGC C 
GUA GCA GAA 
Glu 
GGA A 




 …CH-CO-NH… is the common chemical composition of all twenty amino acids, 
where C stands for carbon, H for hydrogen, O for oxygen and N for nitrogen. Attached to 
each CH is attached a small group of atoms – often called R by chemists, where R is a 
side-chain in the molecule. The side-chains provide for differentiation for the common 
twenty amino acids are listed in Table 1.3. 
 
Table 1.3: Structure and Classification of the 20 Common Amino Acids 
One Letter Three Letters Name Linear Structure 
A Ala Alanine CH3-CH(NH2)-COOH 
C Cys Cysteine HS-CH2-CH(NH2)-COOH 
D Asp Aspartic acid HOOC-CH2-CH(NH2)-COOH 
E Glu Glutamic acid HOOC-(CH2)2-CH(NH2)-COOH 
F Phe Phenylalanine Ph-CH2-CH(NH2)-COOH 
G Gly Glycine NH2-CH2-COOH 
H His Histidine NH-CH=N-CH=C-CH2-CH(NH2)-COOH 
I Ile Isoleucine CH3-CH2-CH(CH3)-CH(NH2)-COOH 
K Lys Lysine H2N-(CH2)4-CH(NH2)-COOH 
L Leu Leucine (CH3)2-CH-CH2-CH(NH2)-COOH 
M Met Methionine CH3-S-(CH2)2-CH(NH2)-COOH 
N Asn Asparagine H2N-CO-CH2-CH(NH2)-COOH 
P Pro Proline NH-(CH2)3-CH-COOH 
Q Gln Glutamine H2N-CO-(CH2)2-CH(NH2)-COOH 
R Arg Arginine HN=C(NH2)-NH-(CH2)3-CH(NH2)-COOH 
S Ser Serine HO-CH2-CH(NH2)-COOH 
T Thr Threonine CH3-CH(OH)-CH(NH2)-COOH 
V Val Valine (CH3)2-CH-CH(NH2)-COOH 
W Trp Tryptophan Ph-NH-CH=C-CH2-CH(NH2)-COOH 
Y Tyr Tyrosine HO-Ph-CH2-CH(NH2)-COOH 
Abbreviations: C, carbon; H, hydrogen; O, oxygen; N, nitrogen; S, sulfur;  






Proteins are linear polymers built from amino acids. They carry out all of a cell’s 
activities. Proteins serve different roles in a cell. As enzymes, proteins can accelerate the 
rate of metabolic reactions. As hormones, proteins perform regulatory functions inside a 
cell, such as activating genes. As membrane receptors and transporters, proteins 
determine what types of substances enter or leave the cell and give instructions on how a 
cell should react. There are many additional functions provided by proteins (17).  
The specific amino acid sequence forming a protein gives the cell its unique 
property. Proteins may work alone in a cell or they can also work together to achieve a 
particular function. Proteins will often associate to form stable complexes in the cell. 
 
1.6 Central Dogma of Molecular Biology 
The journey from genes to proteins involves several steps in the Central Dogma 
of Molecular Biology. In transcription, a DNA gene is copied to a primary RNA 
transcript. During the splicing process, exons (coding regions) join together and introns 
(non-coding regions) are discarded, turning the primary RNA transcript into messenger 
RNA (mRNA). Later, through the process of translation, mRNA is transformed into a 
protein sequence. This Central Dogma was first described by Francis Crick in 1958 (6). 
 
 




 RNA is synthesized in the nucleus of cells. When a promoter3 is recognized, RNA 
polymerase4 binds to it, catalyzes the insertion to open the DNA double helix strands, 
and starts to make an RNA transcript. The process will not stop until the enzyme 
traverses the entire gene and meets a termination signal. Then the transcribed RNA 
molecule is released from the DNA. 
The initial RNA transcript passes through an excision and rejoining process, 
called splicing. The introns are removed and the exons are recombined together, creating 
mRNA. This mRNA associates with the ribosome and presents a series of codons that 
will only match to specific amino acids. Each amino acid is attached to a tRNA molecule. 
The tRNA with three consecutive ribonucleotides that complement the codon will be 
paired with the section of mRNA (See Figure 1.4). The amino acids combine to form 
protein (18;19). 
 
Figure 1.4: tRNA. 
                                                            
3 A promoter is a sequence of DNA that specifies the sites of transcription initiation for an RNA 
polymerase. 
4 A polymerase is an enzyme that can synthesize new DNA strands using a DNA template while several 
such enzymes exist. 
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 The concept of the Central Dogma has been challenged by a series of discoveries 
revealing the complexity of gene expression. The first challenge came in 1970 with the 
discovery of reverse transcription. Reverse transcription allows a double stranded DNA 
molecule to be curated from a single strand RNA template. At first, reverse transcription 
sequences was found mostly in viruses. But after large-scale sequencing techniques were 
established, close to half of the sequences in the human genome were found to be 
retroelements and their remnants (20). 
In 1988, the discovery of RNA interference (RNAi) by Andrew Fire and Craig 
Mello solved the problem of retroelement recognition (21-26). They found that it is 
common for animals and plants to utilize enzymatic machinery in order to silence 
translation. Short RNAs (22-25 base pairs in length), called small interfering RNA 
(siRNA), can traverse intracellular spaces to enter cells and trigger degeneration of 
homologous RNAs before they are translated to proteins. Both RNAi and siRNA are 
microRNA (miRNA). 
In addition, prions, the microscopic protein particles similar to viruses but lacking 
nucleic acids, may be the simplest exception to the Central Dogma. Prions have been 
thought to be the infectious agent responsible for scrapie and certain other degenerative 
diseases of the nervous system, such as Creutzfeldt-Jakob and mad cow disease. 
The mystery of non-coding RNA is still a hot topic. RNAi is the most recent 
RNA-based phenomenon to catch biologists’ attention. There may be more secrets 





 1.7 DNA Sequencing 
DNA sequencing is the method used to determine the order of the nucleotide 
bases, A, C, G and T, in a DNA oligonucleotide5. The methods were first developed in 
1977 with the publication of two approaches. One was developed by Frederick Sanger 
(27) which became known as Sanger sequencing. It is based on enzymatic synthesis from 
a single-strand DNA template with chain termination using four dideoxynucleotides 
(ddNTPs)6 as chain terminators – terminator A, terminator C, terminator G, and 
terminator T. Another method was designed by Maxam and Gilbert (28) that involved 
chemical degradation of end-radio-labeled DNA fragments. Both methods depended on 
four-lane, high-resolution polyacrylamide gel electrophoresis7 to separate the labeled 
fragments so the sequence can be read in a staggered ladder-like platform. The Sanger 
method allows for the DNA to be combined in a single experiment due to the unique dyes 
identifying each nucleotide. Therefore, it became the major DNA sequencing method 
(32). 
In Sanger sequencing, the ddNTP lacks a 3’OH group. Thus, DNA polymerases 
cannot extend the template copy chain beyond the incorporated ddNTP. In other words, 
ddATP terminates chains at every A (adenine) occurrence in the sequences. The other 
three ddNTPs, ddCTP, ddGTP, and ddTTP, work in the same way for their respective 
bases. They are placed in a test tube with a DNA fragment and DNA polymerase. The 
strands then placed on a gel to run electrophoresis. Since the ddNTP is phosphorescently 
                                                            
5 An oligonucleotide (or oligo) is a short polymer segment of RNA or DNA, length ranges from two to 
twenty bases. 
6 ddNTP, which stands for dideoxynucleotide, represents one of the four portions: ddATP, ddCTP, ddGTP 
and ddTTP. 
7 Electrophoresis is a method of separating substances, especially proteins, and analyzing molecular 
structure based on the rate of movement of each component in a colloidal suspension while under the 
influence of an electric field. This method was introduced by Arne Tiselius in 1937 for separating proteins 
in solution (29-31). 
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 labeled, the locations where the chain terminators were incorporated for one of the four 
particular nucleotide, is known and the DNA sequence can be determined based on the 
order of incorporated ddNTPs (32). 
 
 
Figure 1.5: Sequence ladder by radioactive sequencing compared to fluorescent 
peaks. 
 
1.7.1 Evolution of Sequencing 
The demand for DNA sequence information has never been greater, especially 
with the popularity of the Human Genome Project (Section 1.7.3). However, the Sanger 
sequencing method is costly, time consuming and labor intensive. Therefore, several 
emerging technologies have tried to improve Sanger’s method to deliver fast and 
affordable genome sequencing (33). These methods include traditional electrophoretic 
approaches (slab gel electrophoresis, capillary electrophoresis, and microfabricated 
capillary arrays) and nonelectrophoretic methods (pyrosequencing, massively parallel 
signature sequencing, and sequencing by MLDI-TOF mass spectrometry) (34).  
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 Acrylamide slab gel electrophoresis uses radioactive (32P) labels and 
autoradiograms for the de novo sequencing of DNA fragments. The fluorescently labeled 
DNA fragments are loaded into acrylamide gel. An electric current to causes the 
fragments migrating through the gel to separate by the weight of the nucleic acids. Then a 
detection system scans these radioactive labeled bands and reconstructs the original 
nucleotide sequences. This method can process up to 96 samples in a 9- to 11-hour run 
and can read sequences ranging in length from 650 to 750 bases (34).  
The capillary array electrophoresis (CAE) method applies the same process as 
slab gels, except CAE adds a single sample in each capillary to avoid tracking problems. 
In addition, CAE allows more rapid heat dissipation. Therefore, the CAE method 
accommodates higher operating voltages and produces a faster run time. The CAE 
method can run 128 capillaries at one time and provide readings 500 bases long (34).  
Microfabricated capillary arrays tried to perform the sample preparation, thermal 
cycling and electrophoretic separation on a single chip. This method etches a very large 
number of capillaries onto a single wafer at a low cost for parallel operation. In addition, 
this method allows the instrument designer to control the size of the injected DNA plug. 
It can handle 16-channel devices at the same time and produce average read lengths over 
450 bases (34).  
In the 1980s and 1990s researchers started to work on finding nonelectrophoretic 
separation methods for sequencing. Pyrosequencing monitors the concentration of 
pyrophosphate (PPi) during real-time DNA synthesis. First, it anneals an oligonucleotide 
primer to a single-stranded DNA template in the presence of DNA polymerase. Then, the 
first of four deoxynucleotide triphosphates (for example, dATP) is added to the reaction 
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 mixture. When dATP encounters the right complement in the target sequence (adenine), 
the DNA polymerase releases PPi because the nucleotide reacts to the 3’ end of the 
nascent strand. The concentration of PPi in the system is monitored using enzymatic 
reactions. Next, dATP is removed and another deoxynucleotide triphosphate is added to 
repeat the process. Each of the other three deoxynucleotide triphosphates (dCTP, dGTP 
and dTTP) will release PPi in the presence of their respective nucleic acids (34). 
Massively parallel signature sequencing (MPSS) is another sequencing strategy. 
This method examines cDNA libraries by combining the highly parallel nature of 
expression microarrays with the robust statistical digital output from gel-based 
sequencing. The process uses 32-mer tags to compose of strings of eight 4-mer “words”. 
Each bead carries approximately 100,000 cDNA copies of a unique mRNA. These 
microbeads are sorted by a fluorescence-activated cell sorter. Then they are delivered to a 
micromachined flow cell to form a planar. Close to one million cDNA-coated beads can 
be analyzed in a single flow cell using conventional fluorescence microscopy (34). 
Another method for sequencing DNA is matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF-MS). It extends concepts from 
mass spectrometry used to detect macromolecules. The DNA sample is treated with a 
short pulse of ultra-violet (UV) laser that is absorbed by the 3-hydroxypicolic acid to 
form ionized DNA fragments. These ions are extracted by a high-voltage pulse and 
accelerated in an electric field. A mass spectrum is generated and peaks identifying the 
weights for the ionized DNA fragments are evaluated by comparing them to the pre-built 
internal standards (34). 
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 One idea for the next-generation of sequencing is to create a factory-like 
sequencing center. This would involve automated capillary electrophoresis and analyzing 
the sequences in parallel (35). 
Next-generation sequencing may also improve the length of reads. Generally 
speaking, sequencing-by-synthesis technology provides reads 400 bases long. Advances 
in combining the emulsion polymerase chain reaction (PCR) with pyrosequencing for the 
bias-free amplification of single DNA molecules will eliminate the competition of 
multiple templates with limited DNA polymerases. This process could be performed in 
parallel by generating a visual signal for processing by a computer system (35). 
These improvements could reduce cost and allow assessment at functional levels. 
As a result, they would facilitate individual genome sequencing for personalized 
treatment (34-36). 
 
1.7.2 Expressed Sequence Tags 
The mRNA molecule is not stable outside of the cell. In order to preserve genetic 
information, mRNA can be reverse transcribed into complementary DNA (cDNA). The 
cDNA usually contains an oligo(dT) primer8. This end of the cDNA derives from the 
polyadenyl (poly-A) tail9 at the end of the mRNA. The resulting cDNA is cloned into a 
vector. Expressed sequence tags (ESTs) are segments of cDNA that have been 
sequenced. Sequence of cDNA can be identified from either the beginning portion (which 
is called a 5’ EST) or the end portion (which is called a 3’ EST) (18;19;37-39). 
                                                            
8 A primer is a segment of DNA or RNA that is complementary to a given DNA sequence and that is needed 
to initiate replication by DNA polymerase. 
9 A polyadenyl (poly-A) tail is a sequence of 50 to 250 adenine (A) residues that are added to the 3’ end of 
an mRNA sequence after being cleaved. This reaction is catalyzed by polyadenylate polymerase. 
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 An EST, which is usually 300 to 600 nucleotides long, represents a segment of a 
cDNA from a corresponding mRNA. It helps to identify unknown genes expressed in a 
given cell and can be used to map their positions within a genome. 
 
 
Figure 1.6: An overview of how ESTs are constructed. 
 
1.7.3 Human Genome Project (HGP) 
The push to map the human genome was initiated by a 1988 report from the 
National Academy of Science (NAS) Committee which maintained that the human 
genome could be sequenced in 15 years, plus an additional two years to fill in gaps and 
correct mistakes. The project was submitted to Congress where it was approved and 
received $3 billion in funding. It began in 1990 (40). 
The goals of the HGP were to “identify all the approximately 20,000-25,000 genes 
in human DNA, determine the sequences of the 3 billion chemical base pairs that make 
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 up human DNA, store this information in databases, improve tools for data analysis, 
transfer related technologies to the private sector, and address the ethical, legal, and 
social issues (ELSI) that may arise from the project” (40;41). 
In February 2001, the work of the HGP and Celera published the first draft of the 
human genome (41-44). In 2003, 95% of the gene-containing part of the human sequence 
was mapped to 99.99% accuracy.  
After the human genome was available, researchers started to think about what 
could be done with this information. One option is to design personalized medicine for 
more effective treatment. In order to design an individualized medicine, however, 
researchers must be able to sequence an individual genome. On June 1st, 2007, 454 Life 
Science Corporation in collaboration with scientists at the Human Genome Sequencing 
Center at Baylor College of Medicine (45), announced that they had sequenced James 
Watson’s personal genome. Later at the end of the same month, the Cold Spring Harbor 
Laboratory (CSHL) announced that an online sequence browser for Watson’s genome 
was available (46). Watson, who was the CSHL Chancellor and is currently serves as an 
advisor for the newly-formed Allen Institute for Brain Science10, said, “I am putting my 
genome sequence on line to encourage the development of an era of personalized 
medicine, in which information contained in our genomes can be used to identify and 




10 Allen Institute for Brain Science, located in Seattle, Washington, was founded in 2003 by philanthropists 




 1.7.4 ENCODE Project 
The ENCyclopedia of DNA Elements (ENCODE) project was initiated in 
September 2003. It brought several dozen laboratories together to identify the functional 
elements in the human genome. Two components – a pilot phase and a technology 
development phase – were proposed when the project started. 
The aim of the pilot phase was to evaluate a variety of different methods for use 
in later stages. A portion of the genome equal to about 1% (30MB) was carefully chosen 
and analyzed using new and existing methods. Transcripts and gene models, protein-
binding sites, epigenetic marks, promoters and enhancers, and DNA replication regions 
were the fundamental items involved in the research. The conclusions of this pilot project 
were published in June 2007 (47-56). 
The technology development phase promoted several new technologies and 
protocols to generate high throughput data on functional elements for use in the 
ENCODE project. A third phase the production phase began in September 2007. A Data 
Coordination Center at the University of California at Santa Cruz (UCSC) was created to 
track, store and display the ENCODE data. In addition, a Data Analysis Center was 
established. All data generated by the ENCODE participants is released by the Data 
Coordination Center (49). 
 
1.8 Genes 
1.8.1 What is a Gene? 
Genes are pieces of DNA that provide the fundamental physical and functional 
information of heredity. Through the processes of transcription and translation, the DNA 
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 of a gene controls the manufacturing of specific proteins for regular usage throughout all 
cells and organ systems. Each sequence, appearing in a particular location of a particular 
chromosome, encodes a unique function. 
Genes include coding regions (exons) and non-coding regions (introns). Coding 
regions contain information used to specify amino acids in the synthesis of proteins. Non-
coding regions do not. Genes are spliced to have alternative combinations of exons to 
produce various proteins in specific organs (57;58). This allows cells in different organs 
to serve different functions. 
In 2007, Gerstein et al.(51) published a review of the changing definition of genes 
from the 1860s to the early 2000s, just before the ENCODE project (Section 1.3.4). 
Between the 1860s-1900s, each gene was treated as a discrete unit of heredity, based on 
the concept developed by Gregor Mendel in 1866 (1-4). The word ‘gene’ was introduced 
by Wilhelm Johannsen in 1909, by combining two Greek words, genesis (meaning 
‘birth’) and geno (meaning ‘origin’). Mendel’s work was rediscovered by Correns, von 
Tschermak-Seysenegg and de Vries in 1900 (59-61). 
In the 1910s, the gene became defined as a distinct locus11. Thomas Hunt Morgan 
demonstrated that genes are carried on chromosomes and are the mechanical basis of 
heredity. Hunt and his students (62) represented genes using a linear model from studying 
mutation in fruit flies (Drosophila melanogaster). The ability of genes to cross-over to 
each other was proportional to the distance that separated them. Mutations and 
recombination were two methodologies that early geneticists proposed, “so the gene was 
essentially a locus whose size was determined by’ mutations that inactivated a trait of 
interest and by the size of the recombining regions.” 
                                                            
11 A locus is a position that a given gene occupies on a chromosome. 
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 In the 1940s, the gene was seen as a blueprint for a protein. This gave rise to the 
statement “one gene, one enzyme” and soon evolved to “one gene, one polypeptide.” 
Hence, in the biochemical pathway, genes provided the information behind the individual 
molecules. 
In the 1950s, after Muller published an observation of mutations caused by X-
rays, the gene was described as a physical molecule. Later, in the mid 1950s, Hershey 
and Chase found from their study of bacteria that inheritance came from DNA and not 
protein. After Watson and Crick announced the three-dimensional structure of DNA, the 
gene was explained as transcribed code in the 1960s. Crick further presented a hypothesis 
of gene expression from nucleic acid to protein, which soon became known as the 
“Central Dogma” (Section 1.6). Molecular biology developed rapidly during this period 
of time. 
Between the 1970s-1980s, Sanger developed sequencing and cloning technology 
(63). In parallel, computational tools were developed to utilize algorithms in order to 
identify genes based on sequential characteristics. Therefore, the gene became defined as 
an open reading frame (ORF) sequence pattern.  
After the HGP was announced, a gene became further defined as “a DNA 
segment that contributes to phenotype/function. In the absence of demonstrated function 
a gene may be characterized by sequence, transcription or homology” according to the 
Human Genome Nomenclature Organization (64). 
After the ENCODE pilot project (Section 1.7.4), the definition suggested by the 
ENCODE consortium was concisely summarized as “the gene is a union of genomic 
sequences encoding a coherent set of potentially overlapping functional products” (51). 
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 1.8.2 Alternative Splicing 
Alternative splicing is process of mRNA transcription through which the coding 
regions for a eukaryotic gene, called exons, are extracted and connected to produce 
alternative mRNA molecules. The event leads to a number of distinguishable proteins for 
a single transcriptional region. The resulting mRNA molecules, known as isoforms or 
splice variants, are becoming increasingly valued as an important biological method of 
producing complexity and diversity.  
There are different kinds of alternative splicing: alternative promoter selection, 
alternative polyadenylation sites, exon skipping, exon retention, exon extension, exon 




A pseudogene is an inactive sequence of genomic DNA that shares sequence 
homology to a functional gene. In 1985, Vanin suggested “that pseudogenes (should) be 
used only to describe sequences found to be both related and defective” (65). Because of 
the high percentage of similarity to an existing decoded gene, pseudogenes are 
considered as evolutionary relatives to normally functioning genes. 
Pseudogenes are created in two fundamentally different ways: retrotransposition 
and duplication of genomic DNA. Pseudogenes resulting from retrotransposition are 
called processed pseudogenes and pseudogenes resulting from DNA duplication are 
known as duplicated pseudogenes. Figure 1.7 provides a basic illustration of how 
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 processed and unprocessed pseudogenes are produced. Pseudogene detection and 
characterization are research interests of this dissertation discussed in Chapter 5. 
 
 
Figure 1.7: Two types of pseudogenes: processed pseudogenes and unprocessed 
pseudogenes. 
 
1.9 Bioinformatics and Computational Biology 
Bioinformatics is a compound word combining “bio” and “informatics.” As the 
word suggests, this field of research is related to both biology and information. A related 
term, “Computational Biology,” invokes the idea of using computers to perform 
calculations for biology. 
From the perspective of computer science, biological data can be formalized into 
an alphabetic containing letters, such as A, C, G and T for DNA; A, C, G and U for RNA; 
or 20 letters for amino acids. This alphabet can then be used to produce “words” for 
sequences of DNA, RNA, or amino acids (66). 
Bioinformatics and Computational Biology refer to applications of computers and 
computational techniques to deal with the storage and analysis of biological data (57). 
They use tools to implement algorithms into software to retrieve and analyze the 
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 biological data and manage data storage. Compared to other sciences, Bioinformatics and 
Computational Biology are relatively young disciplines. 
In earlier years, “Bioinformatics” was used more frequently in Europe and the 
United Kingdom. Research in Bioinformatics centered on data management. 
Computational Biology, on the other hand, which was used more often in the United 
States, referred mostly to algorithm development. In recent years, the boundary between 
Bioinformatics and Computational Biology has become less clearly defined. Both fields 
now work on managing data and constructing algorithms to analyze it. Therefore, the 
research directions of these two fields are merging. 
Bioinformatics and Computational Biology involve the disciplines of Chemistry, 
Biochemistry, Molecular Biology, Genetics, Genomics, Molecular Evolution, Computer 
Science, Statistics and Mathematics. Input from these disciplines allows the results of 
Bioinformatics to be interpreted in many different ways. Research in Computational 
Biology often includes system biology.  
Major research efforts in Bioinformatics and Computational Biology involve 
sequence alignment, gene annotation, genome assembly, protein structure alignment, 
protein structure prediction, prediction of gene expression, protein-protein interactions, 
the modeling of evolution and analysis of the mutations in cancer. In summary, research 
efforts have progressed from sequence alignment to finding sequence similarity, 
verifying gene annotation, observing protein structure, and then even further to analyzing 
mutations and modeling the evolution of genes. 
Luscombe, Greenbaum, and Gerstein (67) proposed that “the aims of 
bioinformatics are three-fold.” The first aim is to provide the simplest way for researchers 
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 to access and submit their produced work. The second aim is to “develop tools and 
resources that aid in the analysis of data.” The last aim is to use these established tools to 
analyze the data and give “results in a biologically meaningful manner.” 
 
1.10 Introduction to Main Projects 
This dissertation utilizes techniques from Computational Biology and 
Bioinformatics for gene recognition. The following sections briefly describe the main 
projects for this research. 
 
1.10.1 Comparison of BLAST Software 
The computational power required to search exponentially growing databases, 
such as GenBank (68), has increased dramatically. Several tools were developed in the 
past few years for rapid DNA and protein sequence comparison. One of the most widely 
used sequence alignment tools, known as BLAST (Basic Local Alignment Search Tool), 
was released in 1990 by the researchers at the National Center for Biotechnology 
Information (NCBI) (69). In 1995, one of the original authors of BLAST began 
development of the algorithm at Washington University (WU), independent of the NCBI 
effort. In the same year, the first release of WU BLAST (version 1.4) was released. Since 
the original development, a number of changes have been incorporated (70). In order to 
evaluate the effectiveness of BLAST for sequence comparison at a nucleotide level, a 
study was performed of three current versions of BLAST software: NCBI BLAST, WU 
BLAST and mpiBLAST. 
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 In general, WU BLAST was found to be most efficient when the database and 
query sequences are unknown. NCBI BLAST appeared to work best when the database 
contains a small number of sequences, while mpiBLAST showed the power of database 
distribution when the number of bases per target database is large. The optimal number of 
compute nodes in mpiBLAST varies depending upon the database, yet in the cases 
studied, remained surprisingly low. A detailed description of the project will be discussed 
in Chapter 3, Sections 3.4 to 3.8. 
 
1.10.2 Alternative Splicing Recognition 
Studies in alternative splicing have found that a gene may produce more than one 
protein in order to fulfill different requirements and needs in cells. One gene with a large 
number of known splice variants is phosphodiesterase 4 (PDE4).  
PDE4 is an enzyme that has been targeted for inflammatory disorders, including 
asthma, chronic obstructive pulmonary disease (COPD), and central nervous system 
(CNS) injury/disease. PDE4 has a large number of potential isoforms with apparent tissue 
and functional specificity. Potential roles of the different PDE4 isoforms within the CNS 
and other tissue types were studied using all four known rat PDE4 paralogs (PDE4A, 
PDE4B, PDE4C and PDE4D).  
In order to see how ESTs can be used to detect novel isoforms and tissue 
specificity with alternative splicing for PDE4, a computational method to align rat ESTs 
to the corresponding chromosomal and mRNA sequences was developed. The splice 
pattern and tissue type for each EST was examined in order to gain more insight into 
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 PDE4 isoform tissue specificity. Further discussion will be provided in Chapter 4, 
Sections 4.4 to 4.9. 
 
1.10.3 Pseudogene Detection and Characterization 
As genes provide the heredity information for an organism, pseudogenes are 
regions sharing sequence homology to the functional genes yet are unable to operate as 
genes. Pseudogenes can create difficulties in detecting genes in silico. A method to 
uncover pseudogenes and to differentiate between functional genes and pseudogenes is 
desired. Chapter 5 discusses an algorithm which was designed and implemented to detect 
and differentiate pseudogene. 
 
1.11 Organization of Dissertation 
The focus of this dissertation is to design and implement algorithms to analyze 
data computationally and the use of ESTs through three different but inter-related 
projects – comparison of current BLAST software in nucleotide sequences, alternative 
splice pattern recognition, and pseudogene detection and characterization. Chapter 2 
introduces the necessary data components. Chapter 3 reviews the preprocessing methods 
for sequence alignment and examines the comparison of current BLAST software. 
Chapter 4 discusses the computational method for alternative splice pattern recognition 
and gives a case study in discovering rat PDE4 sequences. Chapter 5 details the 
methodology of pseudogene detection and characterization and provides a scoring 





discussed in Chapters 3 to 5 to draw conclusions regarding computational analysis for 
understanding gene regulation and provide ideas for extending the research in the future. 
CHAPTER II 
DATA SOURCES AND DATA PREPROCESSING
Since the invention of automated genome sequencers, a large amount of 
biological sequence data has been made available to the public. GenBank (68) was 
established in 1982 by the National Institutes of Health (NIH) to help advance scientific 
discovery worldwide. According to a news released from NIH, dated April 3, 2008, this 
comprehensive database has collected sequences from more than 240,000 organisms. The 
number of base pairs in GenBank doubles about every 19 months. Recently, the public 
collection of DNA and RNA sequences has reached approximately 110 million sequences 
and 200 billion base pairs (71). This data is maintained and exchanged on a daily basis 
under the International Nucleotide Sequence Database Collaboration (INSDC), which 
includes GenBank at the National Center for Biotechnology Information (NCBI), 
European Molecular Biology Laboratory (EMBL) and the DNA Data Bank of Japan 
(DDBJ). Every two months, a new version of GenBank is released. The three main 
sources of data for the three projects discussed in dissertation are ESTs, mRNA and 
genomic sequences from the GenBank and University California Santa Cruz (UCSC). 
 
2.1 Sequence Data 
2.1.1 dbEST 
dbEST is division of GenBank that collects ESTs submitted from around the 
world. It contains sequence data and its annotation information from numerous organisms 
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 (72). Newly discovered ESTs are submitted to dbEST daily. About every two weeks, 
dbEST releases an update on the number of entries. In addition, approximately every two 
months, GenBank releases a new version of flat format files which allow researchers to 
download the newest data to their workstations. Table 2.1 provides the top 25 organisms 
 in GenBank/dbEST released on May 30, 2008 
 (http://www.ncbi.nlm.nih.gov/dbEST/dbEST_summary.html). The total number of 
public entries in this release was 52,858,766. The human genome had the largest number 
of entries for all organisms (15.40%). 
Table 2.1: Top 25 Organisms in dbEST (as of May 30, 2008) 
Organism # of entries 
Homo sapiens (human) 8,137,747 
Mus musculus + domesticus (mouse) 4,850,258 
Arabidopsis thaliana (thale cress) 1,526,133 
Bos taurus (cattle) 1,517,053 
Sus scrofa (pig) 1,476,357 
Zea mays (maize) 1,462,614 
Danio rerio (zebrafish) 1,379,829 
Xenopus tropicalis (western clawed frog) 1,271,375 
Oryza sativa (rice) 1,220,876 
Triticum aestivum (wheat) 1,051,465 
Ciona intestinalis (sea squirt) 996,088 
Rattus norvegicus + sp. (rat) 895,894 
Xenopus laevis (African clawed frog) 677,784 
Oryzias latipes (Japanese medaka) 609,699 
Gallus gallus (chicken) 599,383 
Drosophila melanogaster (fruit fly) 573,212 
Brassica napus (oilseed rape) 567,177 
Hordeum vulgare + subsp. vulgare (barley) 478,734 
Salmo salar (Atlantic salmon) 433,337 
Glycine max (soybean) 394,370 
Canis familiaris (dog) 365,909 
Vitis vinifera (wine grape) 352,984 
Branchiostoma floridae (Florida lancelet) 346,107 
Pinus taeda (loblolly pine) 334,502 
Physcomitrella patens subsp. Patens 328,628 
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 2.1.2 Reference Sequence (RefSeq) 
The Reference Sequence (RefSeq) database (73-76) is a collection of annotated 
DNA, RNA and protein sequences from major organisms, including plasmids, organelles, 
viruses, archaea, bacteria, and eukaryotes. RefSeq contains data extracted from GenBank, 
and involves varying levels of computational and experimental verification from 
authoritative groups. Each RefSeq provides non-redundant information on genomic 
location, sequence and text annotation as well as genome annotation12, gene 
characterization, mutation analysis, expression studies and polymorphic discovery. In 
addition, the database supports sequence standards for genomes and transcripts or 
proteins, providing a foundation for unambiguous comparison of functional information 
(76). 
RefSeq is updated daily with new records added to the collection, sequence 
updates, and annotation changes. The May 2008 RefSeq collection (Release 29, dated 5-
9-2008, http://www.ncbi.nlm.nih.gov/RefSeq/) was comprised of sequences from over 
5,000 distinct taxonomies, ranging from viruses to bacteria to eukaryotes. It included 
whole chromosomes, organelles, plasmids, viruses, transcripts and more than 5,400,000 
proteins. Table 2.2 shows the number of species in each sub-directory and the counts of 
accessions and length per type of molecule. 
   
                                                            
12 Genome annotation is a process of assigning biological information to sequences. The process is based 
on two main steps: identifying elements on the genome and adding the biological information to the 
elements. An annotation is a note added by way of commentary and explanation. Once a genome is 
sequenced, it needs to be annotated and clarified. 
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 Table 2.2: Statistical Information of RefSeq Sequences (as of May 9, 2008) 
Species # of organisms   Accessions bp / residues 
complete 5,168 genomic 1,510,537 102,394,850,748
fungi 99 RNA 1,382,728 2,276,250,402
invertebrate 353 protein 5,482,876 1,870,214,220
microbial 1,494
mitochondrion 1,384








2.1.3 UCSC Genome Browser 
The University of California Santa Cruz (UCSC, http://genome.ucsc.edu) has 
created a variety of tools, including a graphical tool for viewing a specified region of a 
genome and a collection of aligned annotations (77-81). The database for the UCSC 
Genome Browser provides integrated sequence and annotation data for a large collection 
of vertebrate and model organism genomes, including human, mouse, rat, and fruit fly 
(Table 2.3). Each sequence in the UCSC Genome Brower database includes assembly 
data, comparative genome annotations, and mRNA, EST and RefSeq gene alignments 
from GenBank. The browser is updated whenever a revised genome is released. 
Beginning in 2006, UCSC publishes an annual article with information on the latest 









human, cat, chicken, chimpanzee, cow, dog, fugu, guinea pig, 
horse, lamprey, marmoset, medaka, mouse, opossum, 
orangutan, platypus, rat, rhesus, stickleback, tetraodon, X. 




armadillo, bushbaby, elephant, european hedgehog, rabbit, 
shrew, tenrec, tree shrew 
Deuterostomes C. intestinalis (sea squirt), lancelet, S. purpuratus (purple urchin) 
Insects 
A. gambiae (African malaria mosquito), A. mellifera (western 
honey bee), D. ananassae , D. erecta, D. grimshawi, D. 
melanogaster (fruit fly), D. mojavensis, D. persimilis, D. 
pseudoobscura, D. sechellia, D. simulans, D. virilis, D. 
willistoni, D. yakuba, T. castaneum (red flour beetle) 
Nematodes 
C. brenneri (small nematode), C. briggsae (small nematode), 
C. elegans (nematode), C. remanei (worm), P. pacificus 
(roundworm) 
Other genomes S. cerevisiae (baker's yeast), SARS13
 
2.1.4 Data Information 
For this study, EST sequences were downloaded from GenBank/dbEST (72) at 
NCBI. The latest downloadable version was NCBI-GenBank Flat File Release 165.0 
dated 4-15-2008 (http://www.ncbi.nlm.nih.gov/dbEST/). The mRNA sequences were 
downloaded from RefSeq (76) at NCBI. The latest release was NCBI Reference 
Sequence (RefSeq) Database Release 29 dated 5-4-2008  
(http://www.ncbi.nlm.nih.gov/RefSeq/).  It contained 5,168 organisms and 8,376,141 
entries, including 1,510,537 genomic sequences (102,394,850,748 bases), 1,382,728 
                                                            
13 SARS, or severe acute respiratory syndrome, is a severe form of pneumonia which appeared in outbreaks 
in 2003. It is transmitted especially by contact with infectious material (as respiratory droplets or body 
fluids), and is characterized by fever, headache, body aches, a dry cough, hypoxia and usually pneumonia. 
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 RNAs (2,276,250,402 bases), and 5,482,876 protein sequences (1,870,214,220 bases). 
Human and rat genomes were downloaded from the UCSC Genome Browser 
(http://genome.ucsc.edu/) (79). The latest release for the human genome was hg18 in 5-
2004. The latest version of the rat genome was rn4 dated 11-2004. 
 
2.2 Data Format 
Sequences retrieved from the NCBI website can be displayed in several formats. 
These include ASN.1 (abstract syntax notation one) (82), FASTA (83), XML (extensible 
markup language) (84), and GenBank Flat File (85). Researchers can choose the specific 
format in order to receive the information they need. The two most common formats are 
GenBank and FASTA. 
When a sequence is submitted to NCBI, it is recorded in the GenBank Flat File 
Format (85;86). The basic information for this format includes locus, definition, 
accession, version, keywords, source (a sub-category includes the organism), reference 
(sub-categories include authors, title, journal, medline, and pubmed), comment, features 
(sub-categories include source, coding region (CDS), gene), base count, and origin. 
Figure 2.1 shows a representative GenBank file for GenInfo Identifier (GI) 1392161. 
SOURCE and LOCUS can be used to determine from which organism the 
sequences are derived and the size of the sequences. For a detailed description of each 






Figure 2.1: Example GenBank file 1392161. 
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 A sequence in FASTA data format (83) begins with a greater-than symbol ‘>’, 
followed by single line description. In strict FASTA format, the data includes the GI 
number, locus name, source organism, gene name/protein name, and molecular type. The 
symbol ‘|’ is used to separate each piece information. The next few lines are sequence 
data, the combination of A, C, G and T nucleic acids or twenty different amino acids for 
that GI number. An example of the FASTA format for GI number 1392161 is shown in 
Figure 2.2. In a text file containing more than one sequence, the greater-than ‘>’ symbol 
can be used to determine the beginning of the next sequence. 
 
 
Figure 2.2: Example FASTA format 1392161. 
 
GenBank and FASTA file formats both provided the necessary information for 
this research project. However, FASTA files are much smaller than files in GenBank 
format due to the exclusion of various annotations. Once the appropriate data was 
downloaded, it was preprocessed for use in each project. Section 2.3 covers the necessary 





 2.3 Preprocessing Data 
After the appropriate data was downloaded, it needed to be preprocessed. This 
involved filtering sequences by organism, masking repetitive elements and locating low 
complexity regions. 
 
2.3.1 Filtering by Organism 
Sequences in dbEST are submitted by researchers all over the world and 
organized into files according to the time they were received. Therefore, several different 
organisms may be represented in each of the dbEST files (release 165.0 included 713 
files). Since the project examined ESTs on an organism-by-organism basis, the sequences 
had to be reorganized by organism before they could be analyzed. 
Each sequence from the downloaded files was stored in GenBank flat file format 
(85). To re-organize the sequences by organism, the SOURCE field, which shows the 
scientific name of the organism, was used. A Perl script was written in order to read 
through the SOURCE field and assigned sequences to files according to organism. 
A GenBank flat file format contains more annotation than is necessary for the 
purpose of sequence comparison. To align and compare two sequences, only the 
identifier and sequence data are needed. Therefore, a program called gb2fasta in the WU 
BLAST software package was used to convert the sequences into FASTA data format 






 2.3.2 Masking Repetitive Elements 
Raw ESTs which have been organized by organisms are not ready for sequence 
mapping and clustering. Repetitive elements are sequences that appear more than once in 
a genome. Most genomes contain repetitive elements. For instance, over 40% of the 
human genome is composed of repetitive elements (42;44). The presence of such 
sequences can severely lengthen the search time. Thus, these regions should be removed 
or masked from consideration within raw EST files. 
RepeatMasker is a software package that was designed to screen DNA sequences 
for repeats (87;88). RepeatMasker compares input sequences to a library of repetitive 
elements including interspersed and internal repeats. For this study, repetitive elements 
were masked by hard masking, which replaces each of the nucleotides in a repetitive 
region with 'N'. Soft masking can also be used to replace the DNA characters with their 
lower case equivalent. The computational time for sequence comparisons is decreased 
after the repetitive elements are masked (57).  
 
2.3.3 Filtering Low Complexity Regions 
Low complexity regions are those "regions of biased composition including 
homopolymeric runs, short-period repeats, and more subtle overrepresentation of one or a 
few residues" (89). They occur in both nucleotide and protein sequences. A low 
complexity sequence is a sequence with a biased nucleotide or amino acid composition 
that differs significantly from the general composition observed in either the sequences or 





Masking these regions leaves biologically relevant regions available for matching 
and increases computational speed. The DUST (70) and SEG (70;90) programs are 
designed for this purpose. DUST is used especially for masking or filtering low-
complexity regions in nucleic acids and SEG targets in amino acids. The low-complexity 
nucleic acid regions are masked with N's and amino acid regions are masked with X's. 
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There are many methods available for finding the percentage of similarity 
between two sequences. The two main types of alignment are global and local. Global 
alignment refers to aligning the entire length of two sequences. Local alignment looks for 
significant similarities in smaller sections of the sequences. 
An exhaustive algorithm will search through all possible alignments to find the 
best match between two sequences. However, such an approach requires intensive 
computation. Even if the sequences are only 10 bases long each, there are O(210×210) = 
O(210+10) = O(220) = 1,048,576 ~ 1M comparisons. Therefore, more efficient approaches 
are needed and used. 
 
3.1 Dynamic Programming Algorithm (DPA) 
Dynamic programming is a method of solving the problems when the solutions 
can be determined recursively by building upon known solutions of a subspace. The term 
dynamic programming was first used by Richard Bellman in the 1940s (91). This type of 
problem has the properties of overlapping subproblems and optimal substructure. A 
famous example is finding the nth member of the Fibonacci sequence (See Equation 3.1). 
Later results are bas
 Dynamic programming can be used in sequence alignment by combining 
solutions from aligning sequence prefixes which are computed once and saved in a 
matrix (92). There are three steps in a basic DPA: matrix initialization, matrix scoring fill 
and traceback. A DPA can locate the minimal matching or mismatching bases and edit 
the distance between two strings by inserting or deleting gaps. DPA has an O(m×n) time 
and space complexity where m and n are the size of the strings. 
Global alignment requires an alignment of one entire string X to a second entire 
string Y. Gaps may be inserted in either or both sequences to achieve the best result. The 
Needleman-Wunsch algorithm, which was proposed in 1970 by Needleman and Wunsch, 
is the most famous algorithm used to create a global alignment. It was the first instance of 
dynamic programming being applied to biological sequence comparison and it is 
guaranteed to find the alignment with the maximum score, given a scoring scheme (93). 
Local alignment finds matching pairs of segments, each a part of a longer 
sequence, which have significant similarity. The Smith-Waterman algorithm, created in 
1981, is one of the most famous algorithms used in local alignment (94). 
In 1983, Ukkonen suggested a method to reduce computational complexity by 
adding an additional matrix in order to restrict the search space in the main matrix to a 
linear approach (95). In 1986, Myers used this approach and reduced the time to O(nd) 
time in the worst case and O(n+d2) on average, where n is the length of the longer string 
of the two strings and d is the Hamming distance14 between the sequences. In addition, a 
penalty cost is included to deal with the gaps between two sequences (94;96).  
 
                                                            
14 If two sequences of length N differ from each other at n sites, then the proportion of differences, n/N, is 
referred as the Hamming distance or the degree of divergence. 
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 3.2 Heuristic Algorithm 
DPA will produce the optimal alignment for sequence comparisons. However, 
DPA is still computationally complex in terms of space and time. Therefore, a heuristic 
algorithm which “can make an approximation of the best solution without exhaustively 
considering every possible outcome (89)” like FASTA and BLAST, can reduce time and 
space complexity in calculation. 
 
3.2.1 FASTA 
 FASTA stands for FAST-ALL. Developed by Pearson and Lipman, it combines 
local searching with a heuristic algorithm (97) to search a database for sequence 
homology. FASTA compares protein or nucleotide sequences to report the best matches 
of sequences for local alignment. 
The FASTA program first generates a lookup table for matching sequence 
patterns of amino acids or nucleotides in a query sequence to sequences in a database 
without gaps. A parameter ktup is used, with a word size of 3-6 for nucleotide sequences 
and 1-2 for amino acid sequences, to screen the database for the pattern and insert 
matches into the lookup table. A scoring matrix is then used to determine the ten best 
aligned regions. Third, gaps are inserted between the high-scoring regions to join them 
together. Finally, a Smith-Waterman algorithm is used to align the highest scoring 
sequences. The optimal alignments of the query sequences to the best database matches 





 BLAST stands for Basic Local Alignment Search Tool. It is the most widely used 
software package for rapid DNA and protein sequence comparison. It can be used to 
detect high scoring areas of local similarity between a query sequence and a target 
database of sequences. 
BLAST searches sequences one-by-one in the database. If the current sequence in 
the database shares similarity to the query, BLAST returns the result to the user. 
Otherwise, BLAST will search the next sequence in the database. 
The initial filter of the BLAST algorithm searches for seed sequences of a 
particular length, 11 bases for NCBI nucleotide-nucleotide BLAST, with 100% 
conservation between the target and query sequences. Initial hits of seed sequences are 
then extended to check for larger regions of similarity. Through these searches, BLAST 
makes it possible to look for sequence homology within sequences by performing 
database searches, motif searches, and gene identification for both DNA and protein 
sequences. 
There are two versions of BLAST used widely in research. One is free, the 
version produced by the National Center of Biotechnology Information (NCBI), called 
NCBI BLAST. The other requires an academic license agreement. This is the version 






 3.2.3 Current BLAST Tools 
The BLAST software was first published in 1990 by researchers at the National 
Center of Biotechnology Information (NCBI). In the nearly 18 years since its original 
development, a number of changes have been made. As mentioned previously, the most 
widely used versions of BLAST are NCBI BLAST and WU BLAST. Both versions of 
BLAST offer a suite of programs. These programs perform nucleotide-nucleotide 
comparison (blastn), protein-protein comparison (blastp), nucleotide-protein 
comparison (tblastn), and translated nucleotide-nucleotide comparison (tblastx). 
In addition, the NCBI suite offers two programs for looking at patterns gathered 
from multiple alignments of sequence conservation as seeds into sequence alignment. 
These two programs are position specific iterated BLAST (PSI-BLAST) and pattern hit 
initiated BLAST (PHI-BLAST) (101;102). 
Speed is a problem in searching large quantities of DNA and protein sequences, 
even with heuristic algorithms such as BLAST. However, BLAST has qualities that lend 
it to being parallelizable. 
 
3.2.4 mpiBLAST 
An open source of parallelization of BLAST was developed as mpiBLAST by the 
Los Alamos National Laboratory and released at the High Performance Computing 
Revolution 2003. This tool attempts to reduce disk I/O in a single machine and parallelize 
NCBI BLAST on PC clusters. 
mpiBLAST splits a large database into smaller fragments and performs the 
master-worker scheme of job running. Through the technique of message passing 
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 interface (MPI) (103;104), mpiBLAST sends out sequence database fragments to 
different nodes. Each node individually performs the computation of NCBI BLAST on 
the query sequence and assigned fragment of original database. When all requested nodes 
finish their sub-tasks, the master node combines the results and send it back to the job 
sender (105;106). 
 
3.3 EST to Genome Alignment Algorithms  
Several programs align ESTs to genome sequences. Each of them has its own 
purpose. For example, sim4 is designed to quickly align a cDNA sequence to its parent 
sequence with high accuracy (107) while Spidey aligns cDNA sequences without 
considering the length of introns (108). Compared to more commonly used tools like 
BLAST, these programs incorporate more specific goals of distinguishing the boundaries 
of exons and introns. 
Specific nucleotide pairs, such as the canonical CT/AG and GT/AG (109-113), are 
usually found at exon/intron boundaries. est2genome, Spidey, sim4, GMAP and EXALIN 
can help to find the positions of exon/intron boundaries, for fine tuning the alignments. 
 
3.3.1 est2genome 
est2genome is a tool used to predict genes by finding sequence homology. It 
implements a linear space dynamic programming algorithm to compare spliced sequences 
with their genomic counterparts on both the forward strands and reverse complement. 
est2genome will report a list of the exons and introns and indicate the predicted gene 




Spidey was designed in 2001 to accomplish two main goals: “finding good 
alignments regardless of intron size” and “avoiding getting confused by nearby 
pseudogenes and paralogs” (108). It uses BLAST and a DPA type dot-plotting method 
(115) called DotView to align a single genomic sequence to a group of mRNA 
sequences. The hits resulting from these local alignment tools are sorted and assigned 
into different windows. Another round of BLAST is performed with the entire mRNA 
sequences in each window. A summary of the alignment is reported. 
 
3.3.3 sim4 
The program sim4 aligns a cDNA sequence with another genomic sequence 
rapidly and accurately (107;116). It starts with a BLAST-like computation to find high-
scoring pairs (HSPs) of aligned regions between two sequences. Next, sim4 uses DPA to 
choose a set of HSPs which might represent a gene in increasing order. sim4 allows for 
introns in the calculation, but the introns must be distinguishable in the results. Therefore, 
sim4 determines the boundaries of exons and computes the alignments (107).  
 
3.3.4 GMAP 
GMAP stands for Genomic Mapping and Alignment Program. It aligns mRNA 
and EST sequences to genomic sequences. Before processing GMAP, the data is entered 
into an indexed database file. Then GMAP finds and reports the location of an EST, 
aligns the EST to genomic sequences, and provides an integer interval tree to store the 
look up information associated with a given cDNA’s position in the genome. It can map 
45 
 
 and align a cDNA over multiple genomic sequences at the same time. However, GMAP 
does not provide statistical analysis of alignments and therefore users cannot filter results 
based on statistical significance (117).  
 
3.3.5 EXALIN 
EXALIN, which was released in 2006, compares sequences one by one. Its 
approach is based on a novel method for searching spliced alignment, comparing 
sequence similarity with that obtained from position specific scoring matrix (PSSM) 
splice site models. In order to maximize the power of discrimination in sequence 
alignment and comparison, the scoring systems are chosen based on genomes. Currently, 
the scoring matrices and splice site models for human, mouse, rice and Caenorhabditis 
elegans are available. Dynamic programming was implemented in the tool to find the 
optimal computational result. Although dynamic programming returns the best result in 
alignment, it is slow in computation. Therefore, input output from blastn as an 
optional choice in EXALIN would help speed up the comparison (118). 
 
3.4 Case Study in Comparison of Current BLAST Software 
Sections 3.2.2 to 3.2.4 described how BLAST works. NCBI BLAST, WU BLAST 
and mpiBLAST all have a level of parallelization built in. The default setting of NCBI 
BLAST is to run on a one processor using multithreads. WU BLAST runs two threads15 
at the same time in one processor machine. mpiBLAST requires at least two nodes, but 
can run on an unlimited number depending on the number of processors available. 
                                                            




 Theoretically, searching for sequence similarities in a parallel fashion on multiple 
machines should be faster than using a single processor on the same data set. With this 
pre-assumption, mpiBLAST should be the fastest of the three BLAST programs.  
As discussed in Section 1.10, ESTs are used to detect novel isoforms and tissue 
specificity for alternative splicing events. In addition, ESTs are used to identify the 
possible locations of pseudogenes in chromosomal sequences. All of these processes start 
with alignment of ESTs to the genome. Therefore, a study was conducted to compare the 
efficiency of each version of BLAST software: ncbiBLAST, wuBLAST and mpiBLAST. 
Finding the most efficient BLAST algorithm would speed up the initial alignment of 




Comparisons were made by focusing on human EST and genomic data. Thirteen 
representative human EST sequence files and five representative chromosome sequence 
files were chosen (Table 3.1). Each sequence file contained data for multiple sequences. 
These files were chosen based on the total number of sequences in the file, the total 
number of nucleotide bases in the file and the average sequence length to ensure that they 




 Table 3.1: Data Used for BLAST Comparison 
  
Sequence 





Genome chr14 88,935,052 1 87,191,216 
chr22 35,039,241 11 34,352,072 
chr17 80,964,851 30 79,346,966 
chr9 120,146,880 60 117,790,386 
  chr1 231,366,553 91 226,828,929 
EST est283 3,350 7 2,593 
est277 7,259 15 5,781 
est136 300,995 521 210,054 
est147 724,214 1,085 563,737 
est149 1,603,440 2,433 1,244,897 
est126 2,466,032 3,031 2,053,889 
est241 3,312,648 4,991 2,502,256 
est176 7,002,704 10,149 5,274,323 
est113 19,434,153 20,347 16,714,000 
est270 16,447,012 24,764 12,934,924 
est1 19,969,430 36,800 14,021,420 
est91 33,883,614 50,522 27,683,871 
  est166 33,064,286 71,748 25,130,960 
Abbreviations: chr, chromosome; No., number. 
Chr1 represents chromosome 1; est1 represents dbEST file 1. 
Table adapted from Table 1 in (119).
 
EST sequence data was downloaded using the GenBank Flat File Release 141.0, 
dated 4-15-2004 (72). The resulting 305 dbEST files were parsed to include only those 
with Homo sapiens as the organism. After the human ESTs were identified, they were 
masked for repetitive elements using RepeatMasker (87;88). 
The repeat masked human goldenpath genomic assembly hg16-Jul200316, dated 
7-2003, was downloaded for use from UCSC Genome Browser (http://genome.ucsc.edu) 
                                                            
16 The genomic sequences in goldenpath genomic assembly hg16-Jul2003 version were split in pieces in 
most chromosome in 2003 because the sequences were still under debugging process. In addition, the 
technique to save contents in a text file has its upper limit in file size. The latest version of hg18-Mar2006 
has merged most contigs from the same chromosome into one complete sequence. Those pieces that are not 
clear defined are placed in the random sequence. Therefore, for most chromosomes in the Human Genome 
would have up to two sequences in file. 
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 (77-81). Each contig17 for a particular chromosome was placed into a file based on its 
cytogenetic position as an individual sequence entry. Blastable databases for each 
chromosome were created using the appropriate tool (xdformat for wuBLAST; 
formatdb for ncbiBLAST; and mpiformatdb for mpiBLAST) (92;106). 
For mpiBLAST, the database was also segmented into fragments using the 
command mpiformatdb. Each fragment might not contain the same number of 
sequences, but should be nearly equal in overall size. In order to determine the number of 
fragments to use in mpiBLAST, three different sequences, chr22, chr1 and est166 were 
examined. The number of fragments, and therefore nodes used, was determined 
according to the resulting fragment size. The results are shown in Table 3.2. 
Table 3.2: Fragment Information in mpiBLAST 
sequence No. of fragments size per fragment 
chr22 9 ~1MB 
  8 ~2MB 
  5 ~4MB 
  3 ~9MB 
  1 ~35MB 
chr1 44 ~2MB 
  30 ~5MB 
  25 ~8MB 
  20 ~11MB 
  15 ~19MB 
  10 ~19MB 
  1 ~227MB 
est166 26 ~1MB 
  13 ~2MB 
  7 ~4MB 
  1 ~26MB 
Abbreviations: chr, chromosome; No., number 
Table adapted from Table 2 in (119). 
 
                                                            
17 A contig is a continuous sequence of DNA created by the assembly of overlapping sequenced fragments 
of a chromosome. It is also a group clones representing overlapping regions of a genome. 
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 3.5.2 Types of Sequence Searches 
The factors affecting speed are the size of the database, the size of the query, the 
number of database sequences and the number of query sequences. Types of sequences 
searches can be:  
- A single, relative short sequence (such as a single EST) vs. a larger database;  
- A larger database of smaller sequences (with different lengths) vs. a large 
database of smaller sequences;  
- A large database of smaller sequences vs. a large database of large sequences;  
- A large database of large sequences vs. a large database of larger sequences. 
In order to determine the efficiency of the various versions of BLAST, the 
representative EST and genomic data were used in four separate comparisons between 
different target database (T) and query sequences (Q): EST (T) vs. EST (Q); chromosome 
(T) vs. chromosome (Q); chromosome (T) vs. EST (Q); and EST (T) vs. chromosome 
(Q). 
EST vs. EST compared the computational efficiency when sequences in both the 
database and query are short. Chromosome vs. chromosome tested for situations when 
both query sequences and target databases are large sequences. Compared to an EST 
sequence, which contains only 300-600 bp on average, the number of nucleotide bases in 
a chromosome contig is much larger. However the number of sequences in each 
chromosome file is smaller, ranging from one sequence (chr14) to 91 sequences (chr1) 
for the representative sequences. Therefore, in chromosome vs. EST, the longer (in base 
length) sequences, or ESTs, were used as a database and the smaller sequences were used 
as the query. In the fourth comparison, we reversed the database and query sequences as 
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 EST vs. chromosome in order to determine if the order of comparison had an impact on 
computational results. 
 
3.5.3 System and Software 
The comparisons were based on the current version of the appropriate BLAST 
software available at the time of analysis. ncbiBLAST 2.2.9 (release date 5/12/2004) was 
downloaded from NCBI (http://www.ncbi.nlm.nih.gov/BLAST/). For wuBLAST, an 
academically licensed version 2.0MP WashU (release date 8/22/2004) was downloaded 
from Washington University BLAST Archives (http://blast.wustl.edu). mpiBLAST 1.2.1 
(release date 2/6/2004) was downloaded from mpiBLAST18.  
In order to test the parallel versions, a 16-node (32 CPU) Microway Athlon MP 
GigaCluster™ with an additional master node was used. Each node on the cluster has a 
dual AMD Athlon™ MP 2400+ 384KB cache, 512 MB DDR, 266 MHz ECC/REG low 
profile, plus a 40GB hard drive. Red Hat Linux version 7.3 (120) with MPICH (103;104), 
Portable Batch System (PBS) (121), and Microway Cluster Management Software were 
installed. wuBLAST, ncbiBLAST and mpiBLAST were run on three different systems. 
Each job was sent and managed by PBS. 
wuBLAST and ncbiBLAST were also compared using two identical PCs. These 
PCs were equipped with a dual AMD Athlon™ MP processor 2800+ 512KB cache. 
These machines also had a 640KB system RAM, a 2048 Extended RAM and a 120GB 
mass drive as a storage system. The operating system was Suse Linux version 9.1 (122), 
2.6.4-52-smp i686 machine, and i386 hardware platform. 
                                                            
18 The mpiBLAST website used for this study was hosted by the Los Alamos National Laboratory 
(http://mpiblast.lanl.gov) at the time the project was developed. Since then two of mpiBLAST's main 






3.6.1 EST vs. EST 
The first series of comparisons involved short length sequence database versus 
short length sequence queries. All thirteen representative EST sequence files (Table 3.1) 
were placed into individual blastable databases. Each database was aligned to the thirteen 
representative EST sequences files one at a time. 
The test revealed that when the number of sequences in the database is small, 
ncbiBLAST seems to perform marginally better than wuBLAST (Table 3.3). The results 
indicated a delay of up to ~690 sec (~11.5 min) for wuBLAST on the data used. 
However, as the number of sequences in the database increased, the processing 
time for wuBLAST tended to be smaller in comparison to ncbiBLAST (Table 3.4). This 
is especially evident in the four comparisons of the last two sequences, est91 vs. est91, 
est91 vs. est166, est166 vs. est91, and est166 vs. est166, where it took wuBLAST 
3,699~7,702 seconds (61.2~128 minutes) to complete the work while it took ncbiBLAST 
8,557~14,312 seconds (142.6~238.5 minutes), or approximately twice as long, to do the 
same job. 
It took more time complete each task for est270, which contained 24,764 
sequences, especially using wuBLAST. When est270 served as a query, it required more 
time than the other three longer sequences: est1, est91, and est166. When est270 was 
used as both the query and database, it took 12,822 seconds (237 minutes) to perform the 
comparison. This made the cumulative time to complete the whole series higher than any 
other series in Figure 3.1. 
  





est283 est277 est136 est147 est149 est126 est241 
wu ncbi wu ncbi wu ncbi wu ncbi wu ncbi wu ncbi wu ncbi 
est2  83 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0   
est2  77 15 0 0 0 0 0 0 0 0 0 0 0 0 0 1   
est136 521 10 5 10 5 15 10 16 11 18 14 22 14 21 18
est147 1,085 21 10 21 12 27 20 35 28 41 47 41 35 52 70
est149 2,433 47 23 47 25 59 44 71 62 98 118 88 77 120 175
est126 3,031 59 30 60 33 77 58 82 67 104 87 132 115 124 135
est241 4,991 96 48 97 53 116 91 142 127 199 232 176 162 244 364
est176 10,149 197 98 197 108 262 189 299 236 387 402 414 321 460 573
est113 20,347 395 212 402 226 492 384 535 425 629 505 771 686 725 742
est270 24,764 472 241 485 259 749 436 758 496 965 691 1430 769 1302 947
est1 36,800 693 344 698 369 834 615 910 709 1071 975 1238 1014 1341 1325
est91 50,522 959 495 970 527 1242 888 1253 1025 1435 1263 1697 1544 1820 1777













est176 est113 est270 est1 est91 est166 
wu ncbi wu ncbi wu ncbi wu ncbi wu ncbi wu ncbi 
est283 7 1 1 1 1 1
 
 
1 1 1 1 2 1 2 
est277 15 1 1 1 1 1 1 1 2 2 2 2 3 
est136 521 43 28 60 43 175 44 66 50 88 74 63 74
est147 1,085 79 100 99 109 190 114 122 124 163 187 137 186
est149 2,433 168 242 212 234 385 252 247 277 337 417 295 406
est126 3,031 226 194 378 357 749 366 368 349 584 590 435 585
est241 4,991 329 496 430 488 756 526 502 574 676 860 601 847
est176 10,149 890 1021 1158 1014 3160 1067 1251 1136 1793 1749 1364 1754
est113 20,347 1207 1101 2860 2789 4064 2314 1980 2148 3729 4240 2642 3836
est270 24,764 3475 1451 3565 2834 12822 3384 5114 2614 6911 4214 4341 4236
est1 36,800 2078 2003 2785 3114 5307 3237 3446 3720 4203 5424 3781 5443
est91 50,522 2800 2607 4722 5021 7227 4846 4343 4928 3669 9882 5772 8557
est166 71,748 3109 3653 4857 6319 6978 6362 5316 6613 7727 11210 7702 14312
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Figure 3.1: Cumulative results of wuBLAST and ncbiBLAST in EST vs. EST 
comparison. 
(283: est283; 277: est277; and so on) Image adapted from Figure 2 in (119). 
 
After scanning the sequences in the est270 file, one possible reason that it took 
longer to complete, with the longest time occurring in comparisons of est270 with itself 
in wuBLAST, is that there are poly-A tail sequences in the file. This kind of sequence can 
waste a lot of computation time. If a low-complexity filter, like DUST (70) or SEG 
(70;90), was utilized, this type of sequence could be masked or skipped, allowing the 
program to proceed to the next comparison. However, when the test was run, both 
wuBLAST and ncbiBLAST were operating by the default setting. In ncbiBLAST, low-
complexity filter DUST is turned on by default for the blastn program and SEG is 
turned on by default for the blastp program. But in wuBLAST, users must add an 
additional command of “filter=dust” to activate the low-complexity filter. This 
55 
 
 would explain why wuBLAST took significantly more time than ncbiBLAST to process 
the est270 vs. est270 comparison. The wuBLAST program was attempting to compare 
the low-complexity sequences. 
To run an mpiBLAST search, the minimum size of a database fragment is 1MB. 
Therefore, the chosen EST sequence files under 1MB could not be tested in mpiBLAST 
because they could not be segmented into more than one database fragment. 
The results for mpiBLAST using an EST vs. EST comparison are shown using 
est166 as the database, and four of the representative EST sequence files as the query 
(est136, est147, est241 and est176). All mpiBLAST searches were tested using 1-15 
nodes, excluding the master node, due to the upper limitation of having 16 nodes on the 
system. The results indicated that as the number of nodes used to complete the search 
increase, the total search time decreased (Figures 3.2 and 3.3). However, mpiBLAST did 
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Figure 3.2: est166 target database vs. est136 and est147 query sequences. 
Image adapted from Figure 3a in (119). 
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Figure 3.3: est166 target database vs. est241 and est176 query sequences. 




 3.6.2 Chromosome vs. Chromosome 
It is possible the performance would vary drastically when both the target 
database and query contain a large number of bases per sequence due to a high memory 
load and increased disk I/O. In order to test this hypothesis, all five chromosome contig 
files were placed into individual blastable databases. Each database was compared to the 
five representative chromosome sequences separately. 
Twenty-five comparisons were generated and the four cumulative results are 
presented in Figure 3.4. As the number of nucleotide bases, or size of the sequences 
increased, the cumulative time for both wuBLAST and ncbiBLAST to complete the 
series increased proportionally. In general, ncbiBLAST took 1.7~2.8 times longer to 
complete the series of work for each chromosome than wuBLAST. The cumulative time 
to complete the whole series of comparisons for chr1 as the database in wuBLAST was 
53,301 seconds (~14.8 hours) (result not shown). It took almost a month to perform the 
same series of comparisons in ncbiBLAST. The reason for the tremendous increase in 
time in ncbiBLAST for chr1 is unknown, but could be related to a heavy memory load 
caused by the large number of sequences (91) and bases (226,828,929). 
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Figure 3.4: Cumulative results of wuBLAST and ncbiBLAST using chromosome vs. 
chromosome. 
Image adapted from Figure 7 in (119). 
 
3.6.3 Chromosome vs. EST 
Comparing chromosome to EST uses larger sequences as target databases and 
smaller sequences as queries. The gain in efficiency of running mpiBLAST instead of 
ncbiBLAST appeared after using chromosome sequences as the database. The results for 
mpiBLAST were derived by using chr22 and chr1 as databases and two representative 
EST sequences, est136 and est147, as the queries. The results from wuBLAST, 
ncbiBLAST and mpiBLAST are shown in Figures 3.5 and 3.6, with a variable number of 
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Figure 3.5: chr22 target database vs. est136 and est147 query sequences. 
Image adapted from Figure 6a in (119). 
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Figure 3.6: chr1 target database vs. est136 and est147 query sequences. 




 While mpiBLAST ran on multiple nodes in the cluster, wuBLAST and 
ncbiBLAST ran on a single node in the same cluster. The database is divided into 1,3,5,8, 
and 9 segments for chr22 and 1,10,15,20, 25, 30 and 44 segments for chr1 (Table 3.2). 
These numbers are listed as mpiBLAST-number_of_segments. The number of nodes 
used to complete the task is listed in the parentheses. 
wuBLAST worked the best. The speed of mpiBLAST increased when the 
database was divided into more than 1 segment. However, if the database had only one 
segment, mpiBLAST performed slightly worse than ncbiBLAST due to the time it took 
for the master-worker scheme to deliver commands. It is worth noting that 
communication overhead for mpiBLAST has a significant impact on the database for 
searches with one segment. 
 
3.6.4 EST vs. Chromosome 
Comparisons using smaller sequences for the database and larger sequences as 
queries are unlikely in real world situations. However, in order to determine if the order 
in which these comparisons are made makes a difference on software performance, EST 
vs. chromosome was studied. 
As in EST vs. EST, all thirteen representative EST sequence files were placed 
into individual blastable databases. Each database was searched for similarity to the five 
representative chromosome sequence files consecutively. 
Each database search was performed as a series of five queries. Figure 3.7 shows 
the comparison between wuBLAST and ncbiBLAST as the cumulative time to finish 
each series of searches. 
61 
 





































Figure 3.7: Cumulative results of wuBLAST and ncbiBLAST for EST vs. 
chromosome. 
(283: est283; 277: est277; and so on) Image adapted from Figure 4 in (119). 
 
Generally speaking, wuBLAST performed better than ncbiBLAST. ncbiBLAST 
took 1.6~4.5 times longer than wuBLAST to accomplish each series of comparisons. 
The cumulative time taken by ncbiBLAST increased proportionally to the number 
of sequences in the database. This was not the case for wuBLAST. For instance, est270 
took less time for wuBLAST to process than est113. According to Table 3.1, the reason 
might be that est270 has more sequences (24,764) but bases (12,934,924) than est113 
(20,347 sequences, 16,714,000bp). Therefore the average number of bases per sequences 






Figure 3.8 shows the results obtained by using different numbers of database 
fragments segmented for mpiBLAST with est166 as the database and est136 as the query. 
Theoretically, the relationship between the number of nodes and the speed of 
computation should be linear, as long as the number of fragments does not exceed the 
number of available processors. For example, for the thirteen fragments in Figure 3.8, the 
result of running on two nodes should be half of the result of running on one node. 
Likewise the result of running on three nodes should be one third of the result of running 
on one node, and so on. Thus, running thirteen nodes should produce the best result 
because there are thirteen fragments. However, as Figure 3.8 illustrates, dividing the 
database into seven fragments and running on three to four nodes provided the best result. 
If the database was divided into either thirteen or 26 fragments, the best results were 
obtained by running on six to seven nodes. For a single database fragment, the number of 
nodes did not make difference, as Figure 3.9 illustrates. 
One notable exception is that the time for 26 fragments dropped when thirteen 
nodes were used in cluster. 26 ÷ 13 = 2. The reason might be that equal number of 
fragments were routed to the worker nodes so that each node ran balanced jobs. 
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Figure 3.8: est166 target database vs. est136 query sequence in mpiBLAST. 
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Figure 3.9: chr1 target database vs. est136 query sequence in mpiBLAST. 





As mentioned in Section 3.6.1, the comparisons were made using the default 
settings for the BLAST tools. In general, wuBLAST worked the best, if we do not 
consider the number of bases in a sequence and the size of the database. What causes 
wuBLAST to run faster is difficult to examine because it is not open source.  
For biologists, ncbiBLAST is considered standard because it was the first of the 
BLAST tools developed for sequence comparison. However, this study suggests 
wuBLAST is worth the extra licensing fees and installation effort. 
The average number of bases per sequence for each chromosome was much larger 
than the average number of bases per sequence for the ESTs. Hence, if both the size of a 
chromosome fragment and the size of an EST fragment was ~1MB, the chromosome 
fragment would contain fewer sequences with a larger average size than the EST 
fragment. 
blastn compares sequences one by one between the database file and the 
queries. Fewer similarities between the database and query will result in a smaller time 
requirement for the comparison.  
mpiBLAST attempts to decrease disk I/O. It performs better than ncbiBLAST 
because the content of each fragment can easily fit into cached memory. It avoids the 
allocation problem of large contents in memory causing more disk I/O. However, sending 
the database fragments to different nodes to complete the whole task required time for 
communication between the master node and slave/worker nodes. Figures 3.5, 3.6, 3.8 





flow. A network bottleneck could be a problem if lots of data needed to be transported at 
the same time. 
In addition, breaking the database into pieces could affect the E-value. It would 
not be the same as the E-value calculated at once in any singular BLAST. Moreover, 
mpiBLAST itself does not change any I/O method to speed up its calculation. It first 
passes the database fragments to the slave/worker nodes and calls ncbiBLAST to run in 
parallel on those worker nodes. 
 
3.8 Conclusion 
To help identify any organism’s transcriptome or transcribed portion of the 
genome, clustering a large number of sequences is necessary. It requires not only 
thousands of comparisons, but rather searching billions of records. Therefore, finding the 
best technique to compare sequences in parallel becomes paramount. 
Based on the results, wuBLAST generally performs the best of the three tools 
using the default settings. However when dealing with a smaller number of sequences in 
the database, ncbiBLAST performs better. mpiBLAST decreases search time when the 
number of sequences in a fragment is small but the number of nucleotide bases is large. 
The user can choose a suitable BLAST based on the size of the data and the number of 
sequences. Note that these results are based on nucleotide sequences. There could be a 
different result in comparison of amino acids/protein sequences. 
CHAPTER IV 
COMPUTATIONAL METHOD FOR ALTERNATIVE SPLICE PATTERN 
RECOGNITION
4.1 Introduction 
4.1.1 History of Alternative Splicing 
As discussed in Section 1.6, a DNA sequence is translated into a fully-functioning 
protein through transcription, pre-mRNA processing, translation and protein folding 
(Figure 4.1). During this process, the cellular machinery may splice out an exon or retain 
an intron in whole or in part before producing the final copy of mRNA transcript, 
resulting in the synthesis of a greater variety of proteins. This is called alternative 
splicing. Exons of the primary gene transcript are separated and then reconnected to 
produce an alternative ribonucleotide arrangement. 
 
 
Figure 4.1: Central Dogma. 
 
The mechanisms for alternative splicing were first uncovered during the late 
1970s and early 1980s. In 1977, Phillip A. Sharp of the Massachusetts Institute of 
Technology (MIT) and Richard J. Roberts of New England Biolabs discovered that in the 
primary RNA transcripts, the non-coding regions – introns – were discarded for the final 
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 version of mRNA (123;124). Sharp and Roberts received a joint Nobel Prize in Medicine 
in 1993 “for their discoveries of split genes.” In 1980, Randolph Wall of University of 
California Los Angeles (UCLA) showed that this basic view of pre-mRNA splicing, in 
which the introns are always discarded and all exons are always included in the mRNA, 
does not invariably hold true. In fact, the cellular machinery can “decide” to splice an 
exon or to leave an intron in the final mRNA transcript (125). In 1984, Tom Maniatis, 
Michael Green and their colleagues at Harvard University developed a test-tube 
procedure to reveal the molecular machinery performing the cutting of introns and 
pasting together of exons (126-128). 
 
4.1.2 Splicing Mechanism 
The biological mechanism which controls splicing was first described in 1984 as a 
splice machine now commonly known as a spliceosome (126). The spliceosome is a 
complex of five small nuclear uridine rich (snRNA19) molecules labeled U1, U2, U4, U5 
and U6 along with protein factors. Spliceosomes recognize exon/intron boundaries 
through a 5’ donor site, a 3’ acceptor site, a branch point and a polypyrimidine tract. 
The canonical donor site recognized by the spliceosome complex is marked by the 
nucleotide GT, while the canonical 3’ acceptor site is AG. There are other patterns 
confirmed within mammalian genomes including GC/AG, AT/AC, GT/GG and TT/AG 
(129;130). The canonical pattern GT/AG is predicted to occur 99.24% of the time. 
GC/AG occurs 0.69%, AT/AC occurs 0.05%, and the other patterns account for the 
remaining for 0.02% of all splice sites in mammals (129;130). The pattern AT/AC has 
                                                            
19 A snRNA is a small RNA molecule that functions in the nucleus by guiding the assembly of 




 been shown to result from a separate spliceosome complex involving U11 and U12 
snRNA. 
When canonical splicing begins, the U1 snRNA binds to the 5’ end of the splice 
site and recruits several protein factors to form a commitment complex (131-133). This 
creates a branch site in which exons can attach at the donor’s G nucleotide through a 
phosphodiester linkage. As part of the process, the U2 snRNA binds to the branch site. 
Afterwards, the U4-U5-U6 complex arrives and U6 replaces the U1. U1 and U4 
disassociate from the complex. U2 and U6 link with the lariat intron that gets removed. 








 4.1.3 Alternative Splicing Modes 
There are a number of alternative splicing events, including: alternative promoter 
selection, alternative polyadenylation sites, exon skipping, exon retention, exon 























































































Figure 4.3: Alternative splicing events.  
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 1. Alternative promoter selection 
In alternative promoter selection, alternative aminyl ends are produced in the 
processed mRNA by alternatively selecting promoter regions. These regions occur in the 
5’ untranslated region (UTR) of the mRNA. Such events do not alter the final protein 
product. This is the only method that can produce an alternative N-terminus domain in 
proteins. Different sets of promoters can splice certain sets of other exons. 
 
2. Alternative polyadenylation sites 
In some cases, the 3’ UTR of the processed mRNA is alternatively spliced 
producing alternative polyadenylation sites. Once again, these events will not alter the 
translated protein product. 
 
3. Exon skipping 
This method of alternative splicing works by choosing certain exons to remove 
from the final processed mRNA. As a result, each exon can be thought of as a “cassette” 
that can potentially be removed. Exon skipping results in an altered translated proteins 
(134-136). This is the most commonly found version of alternative splicing in mammals.  
 
4. Exon retention 
In exon retention, additional exons located in the place that is normally an intronic 





 5. Exon extension 
In exon extension, sequences are added around a cassette exon at either the 5’ or 
3’ ends. This results in a slightly modified mRNA sequence and produces a different 
protein (134;135;138). 
 
6. Exon truncation 
Exon truncation occurs when a cassette exon is not fully added to an mRNA 
sequence. The 5’ end, 3’ end or both ends of the exon are removed, resulting an altered 
translated protein (137). 
 
7. Intron retention 
This method of alternative splicing occurs when an intron is retained in the final 
mRNA transcript (134;135;138). As long as an expressible stop codon is not located in 
the intron, an altered translated protein is produced which is still functional. Intron 
retention is commonly found in plants and in lower multicellular organisms. 
 
4.1.4 Characteristics of Alternative Splicing 
Alternative splicing results in transcriptome/proteome complexity and gene 
function diversity. It is also highly relevant to human diseases. For instance, the breast 
cancer gene BRCA2 is a typical example of an exon skipping event (139). In addition, 
alternative splicing alters important protein features, such as phosphorylation, 




 4.1.5 Rates of Alternative Splicing 
Initially, alternative splicing was thought to be an anomaly (125). In the early 
1990s, it was predicted that about 5% of all human genes provided alternatively spliced 
isoforms (124). By the late 1990s, researchers concluded that alternative splicing is much 
more prevalent than previously thought, with the potential for 50% of human genes to 
undergo alternative splicing (141;142). In recent studies, it has been found that up to 74% 
of human genes are alternatively spliced (143).  
The average mammalian gene has between seven and eight exons (42). While this 
number seems small, this provides the possibility of over two hundred different cassette 
exon patterns. The largest number of known isoforms for a single coding region is the 
Drosophila DScam gene which has 38,016 distinct forms (144).  
The ability of human genes to produce a number of different proteins helps 
explain the diversity among organisms that still have a relatively small percentage of 
variation in DNA. Among humans the similarity is measured to be around 99.5-99.8%. 
This leaves a small difference of only 0.2-0.5%. Yet this difference results in up to 15 
million different nucleotides in humans (145). 
 
4.2 Research in Alternative Splicing Detection 
4.2.1 Automatic Methods for Detecting Alternative Splicing 
Several research groups have used computational methods to analyze alternative 
splicing in the past decade. Some of them have studied ESTs through sequence 
alignment. Others have used different data sources, such as microarray data. 
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 Automatic methods which use ESTs to detect splicing variants generally go 
through several steps. First, mRNA sequences are aligned to genomic contigs20. Then, 
available ESTs are aligned to contigs. Next, sequences are clustered according to the 
genomic region where they are located. Finally, the alternative splices are defined as 
conflicting, contiguous, transitive or gapped. Most methods search for splice variants in a 
single organism. Other methods focus on detecting alternative splicing for a specific 
genome, such as the human or mouse genome. There are some methods that analyze 
splice variants by comparative analysis across species (140;142;146). 
There are other forms of analysis which do not use EST sequences as a reference 
for identifying alternative splicing. Researchers can also search for a set of possible exons 
and splice sites among all exon concatenations for the highest homology to a protein 
domain. Other methods analyze microarray data to monitor splicing events based on 
known spliced variants (147). The tiling microarray uses probes21 that cover the entire 
genome or contigs of the genome in an unbiased fashion (148;149). One method uses 
Pfam22 information when clustering alternative splicing (150). Another process 
incorporates annotation integration resources (151). 
 
4.2.2 Research of Automatic Applications in Alternative Splicing Detection 
In the past decade, several papers have described different approaches for the 
automatic detection of alternative splicing. In 1999, Moronov used The Institute for 
                                                            
20 A contig is a continuous sequence of DNA created by the assembly of overlapping fragments of a 
chromosome. The term also refers to a group of clones representing overlapping regions of a genome. 
21 A probe is a single-stranded DNA molecule used in laboratory experiments to detect the presence of 
complementary sequence among a mixture of other single-stranded DNA molecules. 
22 Pfam (http://pfam.sanger.ac.uk) is a large collection of multiple sequence alignments and hidden Markov 
models covering many common protein domains and families. For each Pfam family, users are able to 
check for multiple alignments, view protein domain architectures, examine species distribution, connect to 
other databases, and study known protein structures. 
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 Genomic Research (TIGR23) Human Gene Index as a reference for clustering the results 
after aligning ESTs to genomic DNA. The partial gene structures generated by spliced 
alignment were merged whenever they shared consecutive splicing sites spanning an 
intron. The superstructures corresponded to all possible gene structures for which each 
complete exon was supported by at least one of the alignments (142). 
In 2000, Brett and his colleagues aligned ESTs to mRNA to identify insertions 
and deletions. Through analyzing the data, they identified alternative splicing genes 
(141). In the same year, Croft and his team created an intron database based on GenBank 
release 111. They identified ESTs that matched region previously only designated as 
intronic. With further examination, they found many unrecognized alternatively spliced 
exons, especially those in regions conserved between species (152). 
In 2001, Kan and his colleagues aligned ESTs and genomic sequences to create 
transcripts for gene prediction. They elucidated gene structure as a complex problem that 
incorporated the splice junctions, gene boundaries, and alternative splicing. In addition, 
they analyzed shared regions of alternative splicing between the human and mouse 
genomes (146). In the same year, Modrek et al. aligned ESTs to genomic sequences 
using UniGene cluster information to detect alternative splices (137;153). 
Lee and his group displayed alternative splicing graphically in 2003. Users can 
choose a cluster annotation and view splice variants within the same cluster (154). 
Johnson et al. further created a survey of exon junction microarrays based on known data 
(147). 
                                                            
23 TIGR was a non-profit genomics research institute founded in 1992 by Craig Venter in Rockville, 
Maryland. It is now part of the J. Craig Venter Institute (http://www.tigr.org). 
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 In 2004, Sorek’s group distinguished alternative splices from constitutive exons 
(155). The next year, Hiller et al. used Pfam information to analyze alternative splicing 
events (150). Florea incorporated annotation integration resources for analysis in 
alternative splicing (151). Chen and his colleagues compared data across human, mouse 
and rat genomes the following year (140). Castrignano et al. established a database 
resource called ASPicDB for alternative splicing analysis in 2008. They updated their 
database based on NCBI Entrez gene and UniGene databases (156).  
 
4.3 Applications for Alternative Splicing 
Research in alternative splicing helps to identify genes and define the functional 
roles of genes. It also serves to analyze the complexity of alternative splices, particularly 
on the proteome. Moreover, it reveals the regulation of alternative splice forms across the 
whole genome and recognizes different terms of genes. Alternative splices can help to 
differentiate tissue specificities. Comparative genomics studies the evolution of 
alternative splicing. Recently, alternative splicing events have been studied in relation to 
diseases.  
 
4.4 Case Study in Phosphodiesterase 4 (PDE4) 
In order to determine how ESTs can be used to detect isoforms and tissue 
specificity with alternative splicing, a case study of PDE4 in the rat genome was 
conducted. This was a joint work with Mr. Christopher M. Whitaker from Dr. Nigel G. F. 
Cooper’s laboratory in the Department of Anatomical Sciences and Neurobiology at the 
University of Louisville. 
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 4.4.1 Phosphodiesterases (PDEs) 
Phosphodiesterases (PDEs) are enzymes which act as regulators for signal 
transduction. Currently, there are 11 known families of PDEs. Each family includes three 
to four genes and each gene has three to eleven splice variants.  PDEs degrade cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Some 
PDEs, such as PDE4, PDE7 and PDE8, degrade cAMP only. Some of them degrade 
cGMP only, including PDE5, PDE6, and PDE9. The rest of the PDEs – PDE1, PDE2, 
PDE3, PDE10, and PDE11 – degrade both cAMP and cGMP (Figure 4.4). 
 
 
Figure 4.4: General scheme of cyclic 3', 5' nucleotide metabolism. 
Image modified from Figure 1 in (157). Abbreviations are: cAMP, cyclic adenosine 
monophosphate; cGMP, cyclic guanosine monophosphate; PDE1-PDE11, types (gene 
families) of PDE isozymes. The lines reflect the catalytic capacity of the pathway. 
 
In general, all the PDE isoforms contain a catalytic site. PDEs are differentiated 
based on the N-terminus regions. The PDE4 family represents the largest PDE family, 
constituted by four genes (PDE4A, PDE4B, PDE4C and PDE4D). Moreover, PDE4 




Phosphodiesterase 4 (PDE4) is an enzyme that has been targeted for inflammatory 
disorders, including asthma and chronic obstructive pulmonary disease (COPD), as well 
as central nervous system (CNS) injury/disease. PDE4 has a large number of potential 
isoforms with apparent tissue and functional specificity. Potential roles of the different 
PDE4 isoforms within the CNS and other tissue types were studied using four known rat 
PDE4 paralogs (PDE4A, PDE4B, PDE4C and PDE4D) and their known isoforms. A 
computational method was designed to align rat ESTs to the corresponding chromosomal 
and mRNA sequences. The splice pattern and tissue type for each EST was examined in 
order to gain more insight into PDE4 isoform tissue specificity. 
 
4.4.3 Phosphodiesterase 4 (PDE4) 
PDE4, the most abundant PDE within the CNS (158), hydrolyzes cAMP (159) 
and selective inhibition by the drug rolipram (160). Recent studies have implicated PDE4 
in many injury/disease models mostly through its role in inflammation (161) and have 
linked the enzyme to asthma, COPD and spinal code injury (162-164), making it 
important for study. Some researchers have even shown that PDE4D is found in the 
blood of African American females who have had strokes (165). 
In the human genome, the PDE4 family contains four known genes (PDE4A-D). 
Each gene has about three to eleven splice variants, or isoforms. Each isoform is defined 
by its unique N-terminus region. All have two to three conserved regions depending on 
the isoforms. These splice variants can be grouped into either long or short isoforms. 
78 
 
 Currently, there are four PDE4 isoform classes in the human genome. They are 
long, short, super-short and dead-short isoforms (See Figure 4.5). Long isoforms have 
upstream conserved region 1 (UCR1) and 2 (UCR2) domains. Short isoforms do not 
contain UCR1. Super-short isoforms have an N-terminally truncated UCR2. The dead-
short isoforms lack UCR1 and UCR2 and have an inactive catalytic unit that is both N- 
and C- terminally truncated. 
 
 
Figure 4.5: PDE4 isoform diversity: long, short, super-short and dead-short. 




 4.5 Methods for Computational Detection 
A project for detecting PDE4 splice variants in the rat genome was designed and 
implemented in silico in order to discover how PDE4 is spliced and determine tissue 
specificity of the splice variants 
 
4.5.1 Genomic Data 
Curated mRNA sequences for the rat PDE4A, PDE4B, PDE4C and PDE4D genes 
and known isoforms were downloaded from NCBI/RefSeq (73-76). Release 18, dated 7-
17-2006 (http://www.ncbi.nlm.nih.gov/RefSeq/). The size of the sequences ranged from 
1,000 to 3,000 base pairs. GenBank ids for each of these sequences are provided in Table 
4.1. Each of the mRNAs were positioned within the UCSC rn4 goldenpath assembly of 
the rat genome (81) using WU blastn (70;167) and BLAT (168).  
PDE4A localized to chromosome 8; PDE4B to chromosome 5; PDE4C to 
chromosome 16; and PDE4D to chromosome 2 (Table 4.1). The corresponding repeat-
masked genomic regions were downloaded from the UCSC rn4 goldenpath assembly (77-
81) (http://genome.ucsc.edu/), dated 11-2004 including 30,000 bases flanking the 5’ 




 Table 4.1: Rat PDE4 Family mRNA Sequence Information 






Chromosome Chromosomal Length (bp) 
PDE4A RefSeq NM_013101.3 9681345 2,914 chr8 68,640
1 L36467.1 703258 2,778
2 L27057.1 3334904 2,914
3 AF110461.2 12057232 2,315
4 L27062.1 436013 2,433
5 M26715.1 203982 2,202
6 M26716.1 203984 2,106
7 M26717.1 203986 2,071
8 M25348.1 206131 1,077
  9 M28411.1 206053 1,077    
PDE4B RefSeq NM_017031.2 19923679 3,133 chr5 573,258
1 AF202732.1 16930142 3,022
2 U95748.1 2352051 3,133
3 BC085704.1 55716044 2,511
4 AF202733.1 16930144 2,433
5 J04563.1 203967 2,158
6 L27058.1 950096 2,647
7 M25350.1 206126 1,080
  8 M28413.1 206055 1,080    
PDE4C   XM_214325.4 19220990 2,140 chr16 23,713
1 L27061.1 436011 1,764
  2 M25347.1 206129 1,077    
PDE4D RefSeq NM_017032.1 8393931 2,077 chr2 *1,118,153
1 AF536979.1 22901889 2,348
2 AF031373.1 2625099 2,470
3 EF102484.1 118500411 2,285
4 U09457.1 2564961 2,077
5 AY388961.1 37256003 2,157
6 EF121818.1 118772243 2,122
7 L27059.1 436007 2,142
8 L27060.1 3334454 2,834
9 U09455.1 517501 1,963
10 U09456.1 517416 1,821
  11 AF536974.1 22901879 1,756     
Abbreviations: bp, base pair; chr, chromosome.  
*Mapping of the rat PDE4D gene indicates sequence assembly errors within chromosome 2. 
The total region covered includes 1,114,915 bp of chromosome 2, 154 bp of chromosome 18 
random fragments, and 3,084 bp of chromosome 2 random fragments. 
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 4.5.2 Splice Detection 
Expressed sequence tags (ESTs) were downloaded from GenBank/dbEST release 
154.0, dated 6-15-2006 (http://www.ncbi.nlm.nih.gov/dbEST/) for the purpose of 
understanding how the sequences were spliced for each of the four PDE4 genes. PDE4 
mRNA sequences were downloaded from NCBI/RefSeq release 17, dated 5-5-2006 
(http://www.ncbi.nlm.nih.gov/RefSeq/). Each EST passed through five steps in the 
detection of splice patterns: data preprocessing, sequence comparison, fine tuning, data 
analysis and pattern recognition. Figure 4.6 illustrates this process. 
 
Step 1: Data Preprocessing 
EST sequences were parsed to include only those from the species Rattus 
norvegicus. Raw EST and PDE4 mRNA sequences were masked for repetitive elements 
using RepeatMasker (87;88). Low complexity regions for the resulting rat ESTs and 
mRNAs were then masked using the DUST (70), SEG (70;90) and XNU (70) filters 
available from the wuBLAST software (70;167). 
 
Step 2: Sequence Comparison 
The four PDE4 mRNA sequences were aligned to their corresponding genomic 
regions using sim4 (107), which determines the most likely intron/exon boundaries of the 
mRNAs by taking into account known donor/acceptor sites. An initial alignment of the 











 Step 3: Fine Tuning 
EST sequences with less than 95% of percentage identity were filtered out, since 
these were not likely to be their true genomic locations. Remaining ESTs were realigned 
to the genome using sim4 (107), which returns the position where each EST appears in a 
chromosomal segment in accordance with known intron/exon boundary properties. The 
sim4 results were parsed to determine if the ESTs matched one contiguous region or if 
they spanned multiple regions, or exons. Each hit was therefore categorized as a single-
exon hit or a multi-exon hit. Single-exon hits with a length less than 100bp were further 
filtered based on the number of hits in the region. If more than five ESTs hit the same 
region, all of ESTs for that region were discarded, since they most likely resulted from a 
previously uncharacterized repetitive element. 
 
Step 4: Data Analysis 
The ESTs remaining from Step 3 were divided into single-exon and multi-exon 
hit groups according to the gene to which they correspond: PDE4A, PDE4B, PDE4C or 
PDE4D. Each EST accession was searched against dbEST and UniGene (169). to 
determine the tissue type from which the EST was extracted, if known. 
 
Step 5: Pattern Recognition 
EST sequences that mapped to the same genomic location were placed in similar 
clusters. Overlapping patterns were examined for the maximum coverage length for each 
intron and exon. Each individual EST was examined for the pattern of exon and/or intron 





determining previously undetected exonic regions. Single-exon hits were further 
condensed, since it was unknown if these were spurious, or actual hits to exonic regions.  
 
4.6 Results in Exon Predictions 
Predicted exon locations for each of the four known PDE4 classes were 
determined based on the sim4 (107) and BLAT (168) alignments of the RefSeq and 
alternatively spliced mRNA sequences to the genomic regions. PDE4A splits into thirty-
three regions (exons) on chromosome 8 (Table 4.2), with a noticeable gap between 
patterns twelve and eighteen. Examination of the genomic assembly for this region 
indicates an unsequenced gap that should be closed with future sequencing and assembly. 
Regions of the RefSeq and nine known isoforms corresponding to this gapped region 
were multiply aligned using clustalW (170) to produce five aligned regions where a gap 
exists in the genome assembly. PDE4B maps to chromosome 5, and is split into 15 exons 
(Table 4.3) while PDE4C divided into 16 exons on chromosome 16 (Table 4.4). The 
results for the PDE4D class are more puzzling. One large 897 bp gap in the mRNA 
sequence exists after the predicted location for exon 11. There are 16.7 Mb that separates 
the predicted terminal exon from the rest of the structure (Table 4.5). In addition, the 
most likely hits for this 897 bp region are to unassembled fragments assigned to 
chromosome 18 of the rat genome. The most likely explanation for this missing region is 
incorrect assembly of the rat genome.  
Table 4.2: PDE4A Exon Locations 
Region 
CHROMOSOME 8 
NM_013101.3 L36467.1 L27057.1 AF110461.2 L27062.1 M26715.1 M26716.1 M26717.1 M25348.1 M28411.1 
  
14-1  14-1 
Num. (2914 BP) (2778 BP) (2914 BP) (2315 BP) (2433 BP) (2202 BP) (2106 BP) (2071 BP) (1077 BP) (1077 BP) Testes (F) Testes (R) 
1 
CHR1  




              14-121           206,689,447 
206,689,554 
3 20,176,941-20,176,964   7-30                       
4 20,185,770-20,185,837   31-98                       
5 20,189,322-20,189,507   99-284                       
6 20,192,677-20,193,048 23-394   23-394                     
7 20,210,557-20,210,642       1-86                   
8 20,216,974-20,217,165 395-586 285-476 395-586 87-278                   
9 20,218,045-20,218,081 587-623 477-513 587-623 279-315                   
10 20,218,173-20,218,243 624-694 514-584 624-694 316-386                   
11 20,221,145-20,221,194 695-744 585-634 695-744 387-436                   
12 20,221,284-20,221,396 745-857 635-747 745-857 437-549                   
13 xx,xxx,xxx-xx,xxx,xxx         1-266                 
14 xx,xxx,xxx-xx,xxx,xxx         267-387 1-121               
15 xx,xxx,xxx-xx,xxx,xxx 858-901 748-791 858-901 550-593 388-431 122-165 26-69             
16 xx,xxx,xxx-xx,xxx,xxx 902-930 792-820 902-930 594-622 432-460 166-194 70-98 134-162           
17 xx,xxx,xxx-xx,xxx,xxx         461-480 195-214 99-118 163-182           
18 20,227,838-20,227,857 931-950 821-840 931-950 623-642                   
  20,230,313-20,230,392                       3-83   
19 20,230,483-20,230,572 951-1040 841-930 951-1040 643-732 481-570 215-304 119-208 183-272       84-172 150-240 
20 20,230,573-20,230,680 1041-1148 931-1038 1041-1148 733-840 571-678 305-412 209-316 273-380 1-108 1-108   173-280 241-348 
21 20,232,551-20,232,649 1149-1247 1039-1137 1149-1247 841-939 679-777 413-511 317-415   109-207 109-207   281-379 349-450 
22 20,232,738-20,232,902 1248-1412 1138-1302 1248-1412 940-1104 778-942 512-676 416-580 381-545 208-372 208-372   380-544 451-615 
23 20,234,075-20,234,124 1413-1512 1303-1352 1413-1512 1105-1154   677-726 581-630 546-595 373-422 373-422   545-595 616-665 
24 20,234,125-20,234,174   1353-1402   1155-1204 943-1042 727-776 631-680 596-645 423-472 423-472   596-645 666-715 
25 20,234,682-20,234,836 1513-1667 1402-1557 1513-1667 1205-1359 1043-1197 777-931 681-835 646-800 473-627 473-627   
646-711… 716-769… 
20234745 20,234,735 
26 20,235,014-20,235,136 1668-1790 1558-1680 1668-1790 1360-1482 1198-1320 932-1054 836-958 801-923 628-750 628-750       
27 20,236,456-20,236,638 1791-1973 1681-1863 1791-1973 1483-1665 1321-1503 1055-1237 959-1141 924-1106 751-933 751-933       
28 20,240,619-20,240,762 1974-2117 1864-2007 1974-2117 1666-1809 1504-1647 1238-1381 1142-1285 1107-1250 934-1077 934-1077       
29 20,240,763-20,241,268 2118-2623 2008-2513 2118-2623 1810-2315 1648-2153 1382-1887 1286-1791 1251-1756           
30 20,241,269-20,241,527 2624-2882 2514-2772 2624-2882   2154-2411 1888-2148 1792-2052 1757-2017           
31 20,241,528-20,241,541 2883-2896   2883-2896   2412-2425 2149-2162 2053-2066 2018-2031           
32 20,241,542-20,241,557 2897-2912   2897-2912     2163-2178 2067-2082 2032-2047           
33 20,241,558-20,241,581           2179-2202 2083-2106 2048-2071           
Regions 8, 9, 10 (in red) correspond to the UCR1 region. Regions 12-17 (blue) correspond to the UCR2 region. Regions 20-29 (green) correspond to the catalytic 




 Table 4.3: PDE4B Exon Locations 
Reg CHR 5 
NM_017031 AF202732 U95748 BC085704 AF202733 J04563 L27058 M25350 M28413 15-1 F 15-1 F 23-1  23-1  23-1  23-1 23-1 F 23-1 (R) 
3133 BP 3022 BP 3133 BP 2511 BP 2433 BP 2158 BP 2647 BP 1080 BP 1080 BP Cereb. Cerv.  F R F R Retina Retina 
                              Cord  Brain Brain Cereb. Cereb.      
1 122,960,641-122,960,883   10-253                               
2 123,067,107-123,067,219   254-366                               
3 123,079,695-123,079,933   367-605                               
4 123,158,156-123,158,605 16-465   16-465                             
5 123,158,606-123,158,887 466-747   466-747 1-282                           
  123,168,982-123,168,984                     1-3             
  123,168,985-123,169,154                   1-172 4-174             
  123,169,166-123,169,172                   173-179 175-181             
6 123,351,697-123,351,999         8-311                         
7 123,416,343-123,416,537 748-942 606-800 748-942 283-477 312-506                         
8 123,426,319-123,426,355 943-979 801-837 943-979 478-514 507-543                         
9 123,426,452-123,426,460 980-988 838-846 980-988 515-523 544-552                         
10 123,426,461-123,426,522 989-1050 847-908 989-1050 524-585 553-614 1-62                       
11 123,434,704-123,434,753 1051-1100 909-958 1051-1100 586-635 615-664 63-112                       
12 123,497,052-123,497,057             1-6                     
13 123,497,150-123,497,802             7-659                     
14 123,497,803-123,497,915 1101-1213 959-1071 1101-1213 636-748 665-777 113-225 660-772                     
15 123,517,627-123,517,629                                 2-4 
  123,517,630-123,517,648                         1-19   1-19   5-23 
  123,517,649-123,517,656                       8-15 20-27   20-27   24-31 
  123,517,657-123,517,663                       16-22 28-34 22-28 28-34   32-38 
  123,517,664-123,517,899                       23-259 35-270 29-264 35-272 25-260 39-275 
16 123,518,627-123,518,720 1214-1307 1072-1165 1214-1307 749-842 778-871 226-319 773-866         260-354 271-365 265-358 273-369 261-354 276-370 
17 123,523,794-123,523,861 1308-1375 1166-1233 1308-1375 843-910 872-939 320-387 867-934         355-422 366-433 359-426 370-437 355-422 371-438 
18 123,523,862-123,523,972 1376-1486 1234-1344 1376-1486 911-1021 940-1050 388-498 935-1045 1-111 1-111     423-497 434-486 427-496 438-487 423-497 439-489 
19 123,525,516-123,525,614 1487-1585 1345-1443 1487-1585 1022-1120 1051-1149 499-597 1046-1144 112-210 112-210                 
20 123,525,751-123,525,915 1586-1750 1444-1608 1586-1750 1121-1285 1150-1314 598-762 1145-1309 211-375 211-375                 
21 123,527,679-123,527,778 1751-1850 1609-1708 1751-1850 1286-1385 1315-1414 763-862 1310-1409 376-475 376-475                 
22 123,529,535-123,529,689 1851-2005 1709-1863 1851-2005 1386-1540 1415-1569 863-1017 1410-1564 476-630 476-630                 
23 123,529,781-123,529,903 2006-2128 1864-1986 2006-2128 1541-1663 1570-1692 1018-1140 1565-1687 631-753 631-753                 
24 123,530,570-123,530,752 2129-2311 1987-2169 2129-2311 1664-1846 1693-1875 1141-1323 1688-1870 754-936 754-936                 
25 123,533,054-123,533,197 2312-2455 2170-2313 2312-2455 1847-1990 1876-2019 1324-1467 1871-2014 937-1080 937-1080                 
26 123,533,198-123,533,335 2456-2593 2314-2451 2456-2593 1991-2128 2020-2157 1468-1605 2015-2152                     
27 123,533,336-123,533,612 2594-2870 2452-2728 2594-2870   2158-2433 1606-1882 2153-2429                     
28 123,533,613-123,533,832 2871-3090 2729-2948 2871-3090     1882-2101 2430-2647                     
29 123,533,833-123,533,877 3091-3133 2949-2993 3091-3133     2102-2146                       
30 123,533,878-123,533,890   2994-3006       2146-2158                       
31 123,533,891-123,533,899   3007-3015                               
Regions 7-10 (in red) correspond to the UCR1 region. Regions 14-16 (blue) correspond to the UCR2 region. Regions 18-26 (green) 
correspond to the catalytic region. Abbreviations: F, forward strand; R: reverse strand. 
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 Table 4.4: PDE4C Exon Locations 
Region CHR 16 
XM_214325.4 L27061.1 M25347.1 
2140 BP 1764 BP 1077 BP 
1 19,220,990-19,220,909 1-82     
2 19,209,993-19,209,849 83-227     
3 19,202,151-19,201,990 228-389     
4 19,201,989-19,201,960 390-419 7-36   
5 19,201,551-19,201,515 420-456 37-73   
6 19,201,430-19,201,360 457-527 74-144   
7 19,201,236-19,201,184 528-580 145-197   
8 19,200,897-19,200,785 581-693 198-310   
9 19,200,708-19,200,615 694-787 311-404   
10 19,200,243-19,200,191 788-840 405-457   
11 19,200,190-19,200,083 841-948 458-565 1-108 
12 19,199,997-19,199,899 949-1047 566-664 109-207 
13 19,199,679-19,199,515 1048-1212 665-829 208-372 
14 19,199,436-19,199,337 1213-1312 830-929 373-472 
15 19,199,125-19,198,971 1313-1467 930-1084 473-627 
16 19,198,573-19,198,451 1468-1590 1085-1207 628-750 
17 19,198,259-19,198,077 1591-1773 1208-1390 751-933 
18 19,197,643-19,197,500 1774-1917 1391-1534 934-1077 
19 19,197,499-19,197,277 1918-2140 1535-1757   
Regions 3-6 (in red) correspond to the UCR1 region. 
Regions 8-9 (blue) correspond to the UCR2 region. 






Table 4.5: PDE4D Exon Locations 
Region CHR 2 
NM_017032.1 AF536979.1 AF031373.1 EF102484.1 U09457.1 AY388961 EF121818.1 L27059.1 L27060.1 U09455.1 U09456.1 AF536974.1 
2077 BP 2348 BP 2470 BP 2285 BP 2077 BP 2157 BP 2122 BP 2142 BP 2834 BP 1963 BP 1821 BP 1756 BP 
1 40,196,097-40,196,221   1-125                     
2 40,394,274-40,394,503   126-355                     
3 40,496,293-40,496,732     1-440                   
4 40,644,734-40,645,025       1-292                 
5 40,820,287-40,820,333 1-47       1-47               
6 41,010,800-41,010,928                         
7 41,063,673-41,063,737           1-65 1-129           
8 41,114,936-41,115,127 48-239 356-547 441-632 293-484 48-239 66-257 130-321           
9 41,131,201-41,131,237 240-276 548-584 633-669 485-521 240-276 258-294 322-358           
10 41,136,439-41,136,449 277-287 585-595 670-680 522-532 277-287 295-305 359-369           
11 41,136,450-41,136,512 288-350 596-658 681-743 533-595 288-350 306-368 370-432 7-69         
12 41,139,162-41,139,211 351-400 659-708 744-793 596-645 351-400 269-418 433-482 70-119         
13 41,275,198-41,275,253                   1-241     
14 41,275,254-41,275,397                   242-285 1-144   
15 41,275,398-41,275,446                   201-249     
16 41,275,447-41,275,483                 13150 250-286     
17 41,275,484-41,275,596 401-513 709-821 794-906 646-758 401-513 419-531 483-595 120-232 37-150 287-399 145-257   
18 41,299,092-41,299,320                       1-229 
19 41,305,886-41,305,979 514-607 822-915 907-1000 759-852 514-607 532-625 596-689 233-326 151-244 400-493 258-351 230-323 
20 41,307,257-41,307,429 608-780 916-1088 1001-1173 853-1025 608-780 626-798 690-862 327-499 245-417 494-666 352-524 324-496 
21 41,308,372-41,308,470 781-879 1089-1187 1174-1272 1026-1124 781-879 799-897 863-961 500-598 418-516 667-765 525-623 497-595 
22 41,309,604-41,309,768 880-1044 1188-1352 1273-1437 1125-1289 880-1044 898-1062 962-1126 599-763 517-681 766-930 624-788 596-760 
23 41,310,913-41,311,012 1045-1144 1353-1452 1438-1537 1290-1389 1045-1144 1063-1162 1127-1226 764-863 682-781 931-1030 789-888 761-860 
  CHR 18 RANDOM                         
24 266,263-266,417 1145-1299 1453-1607 1538-1692 1390-1544 1145-1299 1163-1317 1227-1381 864-1018 782-936 1031-1185 889-1043 861-1015 
  CHR 2 RANDOM                         
25 1,582,343-1,582,465 1300-1422 1608-1730 1693-1815 1545-1667 1300-1422 1318-1440 1382-1504 1019-1141 937-1059 1186-1308 1044-1166 1016-1138 
26 1,583,164-1,583,346 1423-1605 1731-1913 1816-1998 1668-1850 1423-1605 1441-1623 1505-1687 1142-1324 1060-1242 1309-1491 1167-1349 1139-1321 
27 1,583,844-1,584,278 1606-2040 1914-2348 1999-2433 1851-2285 1606-2040 1624-2058 1688-2122 1325-1759 1243-1677 1492-1925 1350-1784 1322-1756 
28 1,584,279-1,584,308 2041-2070   2434-2463   2041-2070 2059-2088   1760-1789 1678-1707 1926-1955 1785-1814   
29 1,584,309-1,584,377           2089-2157   1790-1858 1708-1776       
30 1,584,378-1,584,630               1859-2111 1777-2029       
31 1,584,631-1,584,638 2071-2077   2464-2470   2071-2077     2112-2119 2030-2037 1956-1963 1815-1821   
32 1,584,639-1,584,644               2120-2126 2038-2043       
33 1,584,645-1,585,427                 2044-2827       
89 
4.6.1 Spliced Pattern Observation 
A total of 812,497 rat ESTs were extracted from dbEST and compared to the 
genomic regions for the PDE4 families (See Section 4.5). ESTs directly correlate to 
processed mRNA sequences expressed in the cell, and therefore yield information 
pertaining to the spliced exon patterns. While EST sequences contain information about 
adjacent exons alternatively spliced, they normally do not contain the whole isoform due 
to their short length (normally 200-500 bp). A breakdown of the tissue types in which 
ESTs were found for each of the four PDE4 families is given in Figure 4.7. 
 
 
Figure 4.7: Tissue distribution of ESTs for each of the four PDE4 families. 




 Variant tissue types were found in each PDE4 gene, when tracing the information 
from the GenBank data. Brain, genitourinary, heart and pancreas tissues were found in all 
PDE4 genes. Adipose and embryonic tissues were only associated with PDE4A; 
endocrine and vestibular end organs tissues were found specifically for PDE4B; the tissue 
types of cervix, dorsal root ganglia, hippocampus, hypothalamus and insulinoma were 




An initial filtering of EST hits with a percentage identity of 95% or greater yields 
742 ESTs for the PDE4A region. After additional filtering and clustering, 27 ESTs were 
shown to map uniquely to the PDE4A region of chromosome 8. Eighteen of these were 
found to be unspliced ESTs, involving four different single-exon patterns. Another nine 
were spliced ESTs, representing nine separate multiple exon patterns (Tables 4.6 and 
4.7). The ESTs for PDE4A were found in following tissues: four each for the brain and 
genitourinary system and one each for heart, adipose, embryonic, placenta, pineal gland, 
testis, pancreas, kidney and eye with the remainder coming from unknown, 
uncharacterized or mixed tissue. 
Twelve of the single exon hits represented possible extensions of the 3’ 
untranslated region (UTR) of known PDE4A isoforms. Another EST hit, from accession 
BG372498.1 (pattern 1), indicated a potential new exon between regions six and seven 
from Table 4.2. This EST was derived from eye tissue, and therefore might have some 
tissue specificity.  
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 Table 4.6: Single Exon Splicing Patterns and Tissue Types for PDE4A 
Pattern Accession Tissue Type Regions Covered Notes Chromosomal locations 
1 BG372498.1 eye (6-7) new exon 20,197,794 20,198,264 
2 CB797062.1 adipose 28-29 20,240,617 20,240,944 
2 CA506060.1 embryonic 29 20,240,875 20,241,552 
2 CR458483.1 uncharacterized 29-30-31 20,241,248 20,241,539 
2 BF413211.1 brain 29-30-31-32 20,241,264 20,241,552 
3 BG378996.1 brain 30-31-32-33 20,241,302 20,241,574 
3 CV111386.1 genitourinary 30-3132-33-(33-) 3' UTR extension 20,241,477 20,242,162 
4 AW507088.1 brain (33-) 3' UTR extension 20,241,883 20,242,178 
4 BF545214.1 mixed (33-) 3' UTR extension 20,242,103 20,242,242 
4 CR459446.1 uncharacterized (33-) 3' UTR extension 20,242,379 20,242,721 
4 AI029179.1 mixed (33-) 3' UTR extension 20,242,531 20,242,727 
4 AA999059.1 unknown (33-) 3' UTR extension 20,242,535 20,242,721 
4 BE120273.1 mixed (33-) 3' UTR extension 20,242,546 20,242,723 
4 BG381367.1 heart (33-) 3' UTR extension 20,242,547 20,242,727 
4 BQ192530.1 uncharacterized (33-) 3' UTR extension 20,242,556 20,243,158 
4 BF399702.1 mixed (33-) 3' UTR extension 20,242,560 20,242,721 
4 BE107614.1 mixed (33-) 3' UTR extension 20,242,697 20,243,128 
4 CR465548.1 uncharacterized (33-) 3' UTR extension 20,242,792 20,243,158 
 
Five of the spliced EST patterns revealed potential new exons (Table 4.7). These 
occurred between regions two and three (pattern 10 from genitourinary tissue); between 
regions six and seven (pattern 13 from kidney tissue); between regions 18 and 19 (pattern 
14 from genitourinary tissue); between regions 22 and 23 (pattern 8 from pancreas 
tissue); and between regions 24 and 25 (pattern 6a derived from whole brain tissue). The 
first three splice patterns (patterns 1, 10 and 13) occurred upstream of the UCR1 in the 
hypervariable N-terminal region. Pattern 14 produces a novel exon in the linker region 
between UCR2 and the conserved catalytic core while patterns 8 and 6a produced novel 
exons in the catalytical core of PDE4A. In addition, a new splicing pattern incorporating 







Table 4.7: Multiple Exon Splicing Patterns and Tissue Types for PDE4A 
Pattern Accession Tissue Type Regions Covered Notes Chromosomal locations 
5 CB770386.1 peneal gland 27-28-29   20,236,527 20,236,638 
          20,240,619 20,240,896 
6 CB702066.1 placenta 18-19 20,227,838 20,227,858 
20,230,484 20,230,531 
6a DY312415.1 whole brain 18-19-20-21-22-23-24-(24-25) new exon 20,227,838 20,227,858 
          20,230,484 20,230,680 
          20,232,551 20,232,649 
          20,232,738 20,232,902 
          20,234,075 20,234,170 
          20,234,614 20,234,623 






8 BP485815.1 pancreas (22-23)-23-24-25-26-27 new exon 20,233,889 20,234,174 
          20,234,682 20,234,836 
          20,235,014 20,235,136 
          20,236,456 20,236,569 
10 CV120906.1 genitourinary (2-3)-3-5-8-9-10-11-12 










13 CK482793.1 kidney (6-7)-7-8 new exon 20,210,157 20,210,642 
          20,216,974 20,217,154 





15 CK652857.1 testis 21-22-23-24-25-26-27   20,232,640 20,232,649 
          20,232,738 20,232,902 
          20,234,075 20,234,174 
          20,234,682 20,234,836 
          20,235,014 20,235,136 
          20,236,456 20,236,638 
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Figure 4.8: PDE4A isoforms, EST patterns and sequenced regions. 




Initial filtering resulted in 5,112 ESTs which matched the PDE4B genomic 
region. After clustering and filtering again, 49 ESTs were found to map completely and 
uniquely to the PDE4B region of the rat chromosome 5. Thirty-eight of these ESTs were 
from single-exon hits covering 14 different regions of PDE4B while 11 were from 
multiple-exon hits representing seven different regions (Tables 4.8 and 4.9). Fifteen of 
the ESTs originated from brain, seven from heart, three from pancreas, two each from 
endocrine and genitourinary, and one each from vestibular end organs, lung, and 
placenta. The remaining were mixed, uncharacterized or unknown. 
Eighteen of the single-exon hits indicated extensions of the 3’ UTR region 
(pattern 10). Another 11 provide evidence for an exon between regions five and six 
(patterns 1, 2, 3, 4, 5, 6 and 17). Pattern 16 indicated a new exon between regions six and 
seven, while pattern 22 indicated a new exon between regions 11 and 12. In addition, two 
supported a previously discovered exon between regions 14 and 15 (patterns 7 and 8), 
and another indicated a novel exon between regions 20 and 21 (pattern 9). 
Three of the spliced EST patterns indicated previously discovered exons. These 
include two exons between regions five and six (pattern 15), one exon between regions 
11 and 12 (pattern 24), one exon between regions 14 and 15 (pattern 23), two exons 
between regions 15 and 16 (pattern 23), and one novel exon between regions 16 and 17 
(pattern 23). 
Of the novel predicted exons, a number were in the N-terminal domain (patterns 
1, 2, 3, 4, 5, 6, 15, 16 and 17) while two were in the linker region between UCR1 and 




Table 4.8: Single Exon Splicing Patterns and Tissue Types for PDE4B 
Pattern Accession Tissue Type Regions Covered Notes Chromosomal locations 
13 BF542776.1 mixed 4-5 123,158,439 123,158,759 
13 AI535520.1 mixed 4-5 123,158,459 123,158,763 
1 BP471352.1 pancreas (5-6) new exon 123,168,205 123,168,508 
1 BP471550 pancreas (5-6) new exon 123,168,205 123,168,703 
17 BF386412.1 mixed (5-6) new exon 123,169,509 123,169,999 
2 BE107554 mixed (5-6) new exon 123,229,629 123,230,075 
3 BF566271 mixed (5-6) new exon 123,246,032 123,246,713 
3 BF412632 brain (5-6) new exon 123,246,202 123,246,736 
3 BF390665 brain (5-6) new exon 123,246,238 123,246,736 
3 AW527944 brain (5-6) new exon 123,246,283 123,246,735 
4 BF565113 brain (5-6) new exon 123,318,158 123,318,617 
5 AW528686 brain (5-6)  new exon 123,318,771 123,319,133 
6 BE120216 mixed (5-6) new exon 123,324,159 123,324,766 
16 BF390202.1 mixed (6-7) new exon 123,367,916 123,368,339 
22 BF390420.1 mixed (11-12) new exon 123,493,547 123,493,870 
7 DV713714 vestibular end organs 14-(14-15) new exon 123,497,867 123,498,457 
8 CB806131 endocrine (14-15) new exon 123,503,851 123,504,248 
9 CB738137 brain (20-21) new exon 123,526,313 123,526,716 
10 BE097208 uncharacterized 27-28-29-30-31-(31-) 3' UTR extension 123,533,385 123,533,907 
10 AI102296 genitourinary 27-28-29-30 123,533,406 123,533,890 
10 CR469935 genitourinary 27-28 123,533,494 123,533,829 
10 CO399629 brain 27-28-29-30-31-(31-) 3' UTR extension 123,533,552 123,534,298 
10 CB792692 whole brain 28-29-30-31-(31-) 3' UTR extension 123,533,775 123,534,202 
10 AW141098 heart 28-29-30-31-(31-) 3' UTR extension 123,533,819 123,534,392 
10 CB766615 brain 28-29-30-31-(31-) 3' UTR extension 123,533,823 123,534,193 
10 CO405696 brain 29-30-31-(31-) 3' UTR extension 123,533,876 123,534,550 
10 CB765975 lung 31-(31-) 3' UTR extension 123,533,894 123,534,258 
10 CF110282 heart (31-) 3' UTR extension 123,534,213 123,534,898 
10 AI104604 heart (31-) 3' UTR extension 123,534,853 123,535,238 
10 AI104055 heart (31-) 3' UTR extension 123,534,858 123,535,314 
10 AI104808 mixed (31-) 3' UTR extension 123,534,927 123,535,330 
10 BF559266 whole brain (31-) 3' UTR extension 123,534,510 123,534,951 
10 AA858930 mixed (31-) 3' UTR extension 123,534,832 123,535,333 
10 CB720726 mixed (31-) 3' UTR extension 123,534,859 123,535,333 
10 BM387577 mixed (31-) 3' UTR extension 123,534,880 123,535,333 
10 BE120980 mixed (31-) 3' UTR extension 123,534,895 123,535,333 
10 BE119478 mixed (31-) 3' UTR extension 123,534,902 123,535,324 






Table 4.9: Multiple Exon Splicing Patterns and Tissue Types for PDE4B 
Pattern Accession Tissue Type Regions Covered Notes Chromosomal locations 
11 CB807697.1 brain 20-21-22   123,525,756 123,525,915 
          123,527,679 123,527,778 
          123,529,535 123,529,598 




12 CB784576.1 mixed 5-7-8   123,158,708 123,158,887 
          123,416,343 123,416,537 
          123,426,319 123,426,338 





15 BP483665.1 pancreas (5-6)-(5-6) 
new 
exons 123,168,478 123,169,118 
          123,169,135 123,169,249 
19 CK599213..1 heart 13-14-15-16-17-18 123,497,581 123,497,915 
123,518,627 123,518,720 
123,523,794 123,523,973 
19 CV109674.1 placenta 13-14-15-16-17-18-19-20   123,497,681 123,497,915 
          123,518,627 123,518,720 
          123,523,794 123,523,972 
          123,525,516 123,525,615 
          123,525,753 123,525,814 
20 AA799729.1 heart 13-14-(31-) 
new 
splice 123,497,541 123,497,915 
123,535,118 123,535,311 
24 CB718665.1 brain (11-12)-14-16-17-18-19   123,496,114 123,496,167 
          123,497,803 123,497,915 
          123,518,627 123,518,720 
          123,523,794 123,523,972 
          123,525,516 123,525,596 
23 BF563905.1 brain (14-15)-15-(15-16)-16 
new 
exons 123,517,507 123,517,899 
123,518,627 123,518,710 
23 AW531150.1 brain (15-16)-16-(16-17)-17 
new 
exons 123,517,692 123,517,899 
          123,518,627 123,518,836 
 
pattern 23), one in the linker region between UCR2 and the catalytic core (pattern 23), 
and one was inside the catalytic core itself (pattern 23). In addition, a novel splicing 




Figure 4.9: PDE4B isoforms, multiple EST patterns and sequence hits. 




A total of 50 ESTs initially mapped to the PDE4C region. Clustering and filtering 
reduced this number to twelve ESTs, four representing single-exon hits and eight 
representing spliced exons (Table 4.10). Four of these ESTs orginate from pancreas 
tissue, two from insulinoma, and one each from kidney, lung and placenta. The remaining 
ESTs came from mixed or unknown tissue types. 
A total of three separate single-exon patterns were detected. Each represented a 
potential novel exon between regions one and two. Seven separate multiple exon patterns 
appeared. Up to eleven previously uncharacterized exons between regions one and two 
exist, as indicated by patterns 2, 23, 24, 26, 27 and 28. In addition, there appear to be two 
new exons between patterns four and five (pattern 1), one between regions five and six, 
and one between regions six and seven (pattern 1). The new exons predicted between 
regions one and two occur in the N-terminal domain, while the exons predicted between 
regions four and five, and between five and six occur in UCR1. The exon predicted 
between regions six and seven occur in the linker region between UCR2 and the 
conserved catalytic core. The detection of a large number of potentially uncharacterized 
exons in the N-terminal domain provides great insight since only three isoforms were 




 Table 4.10: Splicing Patterns and Tissue Types for PDE4C 
  Pattern Accession Tissue Type Regions Covered Notes Chromosomal locations 
single 
exon 3 AW921872.1 mix (1-2) new exon 19,216,126 19,216,545 
4 BP498358.1 insulinoma (1-2) new exon 19,217,290 19,217,705 
4 BP502440.1 insulinoma (1-2) new exon 19,217,292 19,217,839 
  25 BP484004.1 pancreas (1-2) new exon 19,218,256 19,218,972 
multi 
exon 1 BP471523.1 pancreas (6-7)-6-(5-6)-5-(4-5)-(4-5) new exons 19,201,287 19,201,766 
          19,201,883 19,201,887 
1 BP478640.1 pancreas (6-7)-6-(5-6)-5-(4-5)-(4-5) new exons 19,201,335 19,201,766 
19,201,883 19,201,887 
2 AI233747.1 kidney (1-2)-(1-2) new exons 19,214,941 19,215,074 
          19,215,431 19,215,680 
23 CF114754.1 lung (1-2)-(1-2) new exons 19,217,002 19,217,281 
19,217,832 19,218,050 
24 BM389421.1 mix (1-2)-(1-2) new exons 19,217,276 19,217,788 
          19,217,987 19,218,032 
26 BP474083.1 pancreas (1-2)-(1-2) new exons 19,218,709 19,218,990 
19,219,043 19,219,241 
27 CV126227.1 placenta (1-2)-(1-2)-1-(1-) new exons 19,218,107 19,218,147 
          19,218,828 19,219,238 
          19,220,903 19,221,016 
28 BQ200281.1 unknown (1-2)-(1-2)-(1-2)-1 new exons 19,217,317 19,217,783 
19,219,088 19,219,196 
19,219,201 19,219,238 
            19,220,903 19,220,985 
 
 





PDE4D had an inordinately large number of EST hits (38,742). However, most of 
these fell into a single exonic region that appeared to be a previously uncharacterized rat 
repetitive element. Once these hits are removed, 18 single-exon and three multiple-exon 
hits remain (Table 4.11). 
The 18 single-exon hits produced 15 unique patterns, each of which suggested 
novel exons. Up to seven novel exons were detected between regions five and six 
(patterns 1, 2, 3, 4, 5 and 22) with an additional five between regions six and seven 
(patterns 6, 7, 8 and 9), three between regions 12 and 13 (patterns 11, 12 and 13), and one 
each between regions eight and nine (pattern 10) and between regions 17 and 18 (pattern 
14). 
The three spliced EST hits create three separate patterns. Pattern 21 suggested two 
new exons, one between regions six and seven, and one between regions seven and eight. 
Pattern 16 suggested a single novel exon between regions 12 and 13, while pattern 17 
revealed an exon between regions 20 and 21. 
Fourteen of the predicted exons occurred in the 5’ N-terminal domain (as 
indicated from patterns 1, 2, 3, 4, 5, 6, 7, 8, 9, 21 and 22), one was in the UCR1 region 
(pattern 10), five were in the linker region between UCR1 and UCR2 (patterns 11, 12, 13 







Table 4.11: Splicing Patterns and Tissue Types for PDE4D 
  Pattern Accession Tissue Type Regions Covered Notes Chromosomal locations 
single 
exon 1 CF106982.1 lung (5-6) new exon 40,821,601 40,822,129 
2 CB735250.1 brain (5-6) new exon 40,844,702 40,845,000 
3 BF561343.1 mixed (5-6) new exon 40,928,435 40,928,658 
3 AA99742.1 mixed (5-6) new exon 40,928,541 40,929,191 
4 CR471157.1 uncharacterized (5-6) new exon 40,938,872 40,939,138 
22 CF114850.1 lung (5-6) new exon 40,962,055 40,962,763 
5 CR460313.1 uncharacterized (5-6) new exon 40,988,404 40,988,701 
6 BF567734.1 brain (6-7) new exon 41,018,068 41,018,402 
6 AW522698.1 brain (6-7) new exon 41,018,068 41,018,471 
7 CF107424.1 lung (6-7) new exon 41,055,789 41,056,469 
8 BG379252.1 brain (6-7) new exon 41,060,267 41,060,631 
9 AW434715.1 heart (6-7) new exon 41,063,099 41,063,498 
10 BF401594.1 mixed (8-9) new exon 41,119,841 41,120,456 
11 BQ192875.1 uncharacterized (12-13) new exon 41,145,546 41,145,899 
12 CF113676.1 lung (12-13) new exon 41,272,381 41,272,835 
13 BG377764.1 genitourinary (12-13) new exon 41,274,996 41,275,383 
13 BE118751.1 mixed (12-13) new exon 41,274,997 41,275,392 
  14 BE103213.1 brain (17-18) new exon 41,284,770 41,285,306 
multi 
exon 16 BP469236.1 pancreas 11-12-(12-13)-17-19-20 new exon 41,136,455 41,136,512 
          41,139,162 41,139,211 
          41,153,803 41.153,963 
          41,275,484 41,275,548 
          41,275,555 41,275,596 
          41,305,886 41,305,979 
          41,307,257 41,307,301 
17 BF566977.1 heart 19-20-(20-21) new exon 41,305,945 41,305,979 
41,307,257 41,307,451 
21 CB322599.1 cartilage (6-7)-7-(7-8) new exon 41,063,589 41,063,737 





Figure 4.11: PDE4D isoforms, multiple EST patterns and sequence hits (chromosome 2). 
 
 
 Figure 4.12: PDE4D isoforms, multiple EST patterns and sequence hits 
(chromosome 2 RANDOM). 
 
4.7 Wet Lab Methods 
Select sequence patterns found by computational methods were further tested for 
verification in the wet lab using reverse transcriptase polymerase chain reaction (RT-
PCR) and DNA sequencing.  
 
4.7.1 Polymerase Chain Reaction (PCR) 
PCR, or polymerase chain reaction, amplifies specific DNA segments by 
exploiting certain features of DNA replication in vitro24. The method was developed by 
the Cetus25 scientist Kary Mullis in 1983 (171;172). The PCR technique won Mullis a 
shared Nobel Prize in Chemistry “for his invention of the polymerase chain reaction 
                                                            
24 In vitro is a test performing in glass or plastic vessels in the laboratory. 
25 Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, 
California in 1971. Cetus Corp. developed several significant pharmaceutical drugs as well as a 
revolutionary DNA amplification technique. Cetus Corp. was merged with Chiron Corporation in 1991 and 
Chiron Corp. was further integrated into Novartis Pharmaceuticals  (http://www.novartis.com/) in 2006. 
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 (PCR) method,” along with Michael Smith “for contribution to the developments of 
methods within DNA-based chemistry.”  
The PCR technique uses a pair of primers, which are DNA segments 
approximately 20 bp long that complement to the DNA being synthesized and a thermo 
stable DNA polymerase to achieve near-exponential enzymatic amplification of target 
DNA. PCR proceeds in three stages: denature double-stranded DNA, anneal primer, and 
extend the annealed primers (171-174). Figure 4.13 shows the basic PCR cycle. 
 
 
Figure 4.13: Basic steps in the PCR cycle. 
Hatched lines indicate target DNA. Filled boxes represent annealed primers. 
 
4.7.2 RT-PCR 
RT-PCR, abbreviated for reverse transcriptase polymerase chain reaction, is a 
highly sensitive technique for the detection and quantization of mRNA. This technique 
includes two parts: the synthesis of cDNA from RNA by reverse transcript and the 
amplification of a specific cDNA by the polymerase chain reaction.  
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 4.7.3 DNA Sequencing 
Sequences which had been amplified by the RT-PCR method were extracted and 
run through DNA sequencing. If the target sequences found from computation matched 
the sequences from the wet lab, it would highly to be verified the presence of novel exons 
and which had not been reported.  
 
4.7.4 Splice Exon Verification 
The novel exons predicted from computation with a length of at least 25 bases and 
a sequence similarity of at least 98% to the genomic regions were studied using RT-PCR 
and DNA sequencing techniques. PCR primer pairs were detected using MPrime 1.3 
(175). Since each of the predicted exons were located upstream of the catalytic core 
which should be expressed in all viable variants, one primer was localized within the 
predicted exon and the other anchored inside of the catalytic core. A primer min, max, 
and opt size of 20 bp was incorporated with a primer GC%26 min of 30%, max of 60% 
and opt of 50%. The melting temperature was set to a minimum of 57, max of 63, and 
optimum of 60. A product minimum size of 395 bases was used with a maximum of 405 
and an optimum of 400, except for those cases where one primer could not be found 
anchored in the predicted exon. For those cases, a min value of 195 was used with a max 
of 205 and an opt of 200. A GC clamp of 2 was incorporated. 
   
                                                            
26 GC% represents the percentage of  total number of G's and C's in the sequence. For instance, GC% 30% 
means that the number of G's and C's occur 30% in the sequence 
106 
 
 4.8 Results in Verified Predicted Exons 
4.8.1 Tissue Types 
The tissue types were found for the splice patterns in each PDE4 gene in 
computational methods were sequenced using RT-PCR. Tissues from rat liver, lung, 
sciatic nerve, testes, heart, brain (cortex), cerebellum, spinal cord, skeletal muscle, 
spleen, optic nerve, kidney, small intestine, retina, aorta and seminal vesicle were 
extracted and verified. 
 
4.8.2 Predicted Exons Verification 
In order to validate the proposed computational approach as an accurate predictor 
of novel isoforms, three novel splice patterns showing the potential for tissue specificity 
were chosen for further study. These included pattern 14 from PDE4A, patterns 15 and 
23 from PDE4B, and patterns 21 and 22 from PDE4D. PCR primers were designed using 
MPrime (175). (See Section 4.7.4). All primers (Shown in Table 4.12) were then used to 
perform RT-PCR on RNA extracted from rat liver, lung, sciatic nerve, testes, heart, brain 
(cortex), cerebellum, spinal cord, skeletal muscle, spleen, optic nerve, kidney, small 





 Table 4.12: PCR Primer Pairs for Selected Predicted Exons 
Gene Family Pattern Forward Primer Reverse Primer 
PDE4A 14-1 CCAGAACCATCCCTAAGACC TGTCGCAGTTCTCTTCTTGC 
PDE4B 15-1 GTGTGCTCTGGAATTTTTGG TACATGATGCATGTGAGGGG 
PDE4B 23-1 ATAAGCAGGGAGCCCATAGG GACTCCAAAGCGTGAGATGC 
PDE4D 21-1 CACAACAACATCCATGCTGC TCACCTTCTTCGTTTCAACC 
PDE4D 21-2 CTCCTTATGCCACTGACACG CACAGTTTTCTTCCTGGAGC 
PDE4D 22-1 TCAGTCCAAGAAGATTGCCG CAGCCAGCAGATTCATGTGC 
PDE4D 22-2 CACAACAACATCCATGCTGC TCACCTTCTTCGTTTCAACC 
 
Reverse transcriptase PCR results indicate that PDE4A pattern 14 is tissue 
specific to testes with a single band occurring at approximately 900 bp (Figure 4.14). 
PDE4B pattern 23 is expressed in brain cortex, cerebellum and retina with a strong band 
between 500 and 600 bp and additional two lighter bands appearing for brain and 
cerebellum (Figure 4.15, lower panel). PDE4B pattern 15 appears for cerebellum and 
spinal cord at approximately 300 bp (Figure 4.15, upper panel). PDE4D patterns 21 and 
22 show very strong banding patterns at 400 bp for every tissue type, with the exception 
of seminal vesicle for pattern 22 (Figure 4.16). The results for the PDE4D patterns were 
















Figure 4.16: RT-PCR for PDE4D patterns 21 and 22. 
 
Next, DNA sequencing was used to confirm that the observed bands corresponded 
to the gene region of interest using the forward and reverse PCR primers as independent 
sequencing primers (See Section 4.7.4). The resulting sequences are shown in Tables 
4.13-4.15. 
For PDE4A pattern 14, the band found in testes corresponded to the PDE4A 
region of chromosome 8. Mapping of the sequence is shown in Table 4.2 and Figure 4.3. 
The sequencing confirmed additional exons for PDE4A pattern 14 that were not found in 
any known isoforms. 
Two patterns were considered for PDE4B. The resulting sequence maps are 
provided in Table 4.3 and Figure 4.4. For PDE4B pattern 15, two bands were extracted 
and sequenced: the cerebellum and spinal cord bands occurring at 300 bp. Pattern 23 had 
three bands extracted and sequenced, for the brain, cerebellum, and retina. Sequencing 
confirmed that all of these bands were unique to PDE4B and revealed new exons 
previously uncharacterized for PDE4B isoforms. 
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 The strong banding patterns for patterns 21 and 22 of PDE4D were extracted and 
sequenced as well (results not shown). The resulting sequences map uniquely back onto 
the catalytic region for PDE4D. 
 









































































































































Computational mapping of publicly available rat ESTs to genomic regions for the 
PDE4A, PDE4B, PDE4C and PDE4D genes yields more than 25 previously unreported 
exonic regions. In actuality, the number may be smaller since a number of these regions 
could be non-overlapping ESTs that would be merged into a single exon if the complete 
sequence was known. The majority of the novel found patterns are located in the N-
terminal region (32 patterns) with additional seven occurring in the UCR1-UCR2 linker 
region, four mapping to the UCR1 region, six occurring in the UCR2 region, two 
occurring in the linker region between UCR2 and the catalytic core, and four occurring in 
the catalytic core itself. The locations of these previously undetected patterns is in line 
with previous research showing that the aminyl end of the protein is more susceptible to 
variability, producing long and short isoforms of PDE4 proteins (157;163). However, this 
study indicates additional exons in the carboxyl end, which was typically thought to be 
highly conserved due to the presence of a catalytic region. Molecular techniques verify 





A potential shortcoming of looking at ESTs for alternative splicing is that the 5’ 
ends of the mRNAs are underrepresented, due to the fact that the majority of EST 
libraries are constructed using poly-T primers that anneal to the 3’ end of the mRNAs. As 
a result, a number of exons in the variable region of the PDE4 family of genes are 
potentially missed. 
CHAPTER V 
COMPUTATIONAL METHOD FOR PSEUDOGENE DETECTION AND 
CHARACTERIZATION
5.1 Pseudogenes 
Genes are the basic unit to transfer hereditary information. They provide 
structure, function and regulation to a biological system. The genetic blueprint of an 
organism can be understood by studying the architecture of these genes. Pseudogenes, on 
the other hand, are regions sharing a level of sequence homology to functional genes that 
have somehow lost their ability to operate as genes. Pseudogenes may contain stop 
codons27, have frame shifts28 and a lack of transcription. However, they might retain 
gene-like features, such as promoters, CpG islands29 and splice sites, and are therefore of 
interest to biologists who wish to study the effects of evolutionary processes. 
As discussed in Section 1.6, a gene must go through several steps from a genetic 
DNA sequence to a fully-functional protein: transcription, pre-mRNA processing, 
translation and protein folding (Figure 5.1). If any of these steps fails, the sequence may 
be considered nonfunctional. The most commonly identified disablements are stop 
codons and frame shifts, which almost universally stop the translation of a functional 
protein product. 
                                                            
27 Stop codons are TAA, TAG and TGA. 
28 A frame shifting is a genetic mutation that inserts or deletes a number of nucleotides that is not evenly 
divisible by three from a DNA sequence. 
29 CpG islands are short genomic regions that contain a high frequency of CG dinucleotides than in other 




Figure 5.1: Central Dogma. 
 
 
Figure 5.2: Pseudogene formation. 
 
5.1.1 Processed Pseudogenes 
Processed pseudogenes are generated by retrotransposition, which involves 
reverse transcription of an mRNA transcript and subsequent re-integration into genomic 
DNA. For human chromosome 22, 19% of the coding sequence corresponds to 
pseudogenes, 82% of which are processed pseudogenes (176;177). Processed 
pseudogenes represent the vast majority of inactivated gene sequences found in the 
human genome. 
There are three basic features of a processed pseudogene. They are 
1. A lack of non-coding intervening sequences (introns), 
2. The presence of a poly-A tail at the 3’ end, and 
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 3. Homological extension (flanking direct repeats, which are associated with 
movable genetic elements) (176;178). 
In the human genome, there are a number of different estimations for the total 
number of processed pseudogenes. Zhang et al. predicts ~7,800 processed pseudogenes 
(179) while Torrents et al. estimates there are ~13,800 (180). Ohshima et al. report 3,664 
processed pseudogenes in the human genome and estimate a total number ~7,000 
processed pseudogenes, based on an estimation of ~35,000 human genes (181-183).  
 
5.1.2 Unprocessed Pseudogenes 
In the process of duplication, genetic sequences can go through various 
modifications, including mutation30, frame shifting, insertions and deletions. Any 
significant modification during the translational or transcriptional stage could result in a 
loss of genetic function. Hence, if the duplication of a gene is incomplete, the new 
sequence could be a pseudogene. Those pseudogenes derived from duplication are called 
unprocessed pseudogenes (65;176;184). It arises when a cell is replicating its own DNA 
and inserts an extra copy of a gene into a genome in a new location (185).  
Unprocessed pseudogenes may have introns retained (as shown in Figure 5.2). 
They can be a complete or partial copy from the parent gene. Sometimes, the unprocessed 
pseudogenes contain an extra copy of the gene. The unnecessary extra copy “could 
accumulate mutations without harming the organism” (178).  
                                                            
30 A mutation is a change of the DNA sequence within a gene or chromosome of an organism resulting in 
the creation of a new character or trait not found in the parental type. Mutation can also mean the process 
by which such a change occurs in a chromosome, either through an alternation in the nucleotide sequence 
of the DNA coding for a gene or through a change in the physical arrangement of a chromosome. 
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 In addition, the unprocessed pseudogene can be created secondarily from pre-
existing processed pseudogenes. In other words, the parental source gene may be 
intronless. In this case, the duplication occurred after transcription (176). 
 
5.1.3 Disabled Pseudogenes 
A third type of pseudogenes, known as disabled or unitary pseudogenes, are 
becoming more widely studied (186;187). When various mutations occur, they can 
disrupt transcription or translation of a gene. Moreover, if these mutations become fixed 
in a population, it is possible the gene may become nonfunctional or deactivated in a 
mechanism similar to unprocessed pseudogenes. The difference between the two is that 
disabled pseudogenes are not duplicated before becoming disabled (188).  
 
5.1.4 Functional Pseudogenes 
Up to this point, pseudogenes have been defined as having no function in Sections 
1.8.3 and 5.1.1-5.1.3. However, in 2003, Hirotsune et al. in Japan found that a 
retrotransposed pseudogene whose transcript plays a trans-regulatory role in the 
expression of its homologous gene, Makorin1. They suggested a general model that 
pseudogenes may play an important biological role (189;190). In 2004, Hirotsune and his 
team reported that about 2-3% of human processed pseudogenes are expressed using the 
strict criteria based on their algorithm and wet laboratory experimentation (191). 
However, their result has been strong contested by Gray’s team due to the inability to 
reproduce Hirotsune’s experiment (192). Therefore, the functional role of pseudogenes is 
of current interest. 
119 
 
 5.1.5 Motivations for Pseudogene Detection and Characterization 
Computational sequence analysis can be complicated by the presence of 
pseudogenes. For instance, it is possible that a researcher wants to amplify a certain gene 
by using polymerase chain reaction (PCR) but accidently and simultaneously amplifies a 
pseudogene due to their share similar sequences. Another example is in ab initio31 gene 
prediction where processed pseudogenes are often misidentified as real genes or exons. 
Identification of pseudogenes will help to improve the accuracy of gene prediction (183). 
In addition, identifying pseudogenes may lead to a better understanding of gene 
evolution. 
 
5.2 Current Automatic Pseudogene Detecting Methods 
5.2.1 Harrison’s Approach 
Harrison et al. from Yale University developed a pseudogene annotation pipeline 
in 2001 (193). They used Caenorhabditis elegans genome to test their seven-step process. 
First, they downloaded annotated pseudogene sequences from Sanger Centre and 
analyzed those sequences. They found about 6% of the annotated pseudogenes are not 
detectable when considering simple disablement, such as a frameshift or premature stop 
codon. Second, they aligned protein sequences (Wormpep18, SCOP and PROTOMAP) 
to the genome sequences using FASTA in order to find potential pseudogenes. All six-
frame sequences (three forward and three backward strands) were analyzed. Third, 
alignment results were filtered for overlapping matches in genomic sequences, if the size 
                                                            
31 In computation, ab initio means an extra, transform, load tool used to manipulate data. In Bioinformatics, 
ab initio is a term used to define methods for making predictions about biological features using only a 
computational model without extrinsic comparison to existing data. In this context, it may be sometimes 
interchangeable with the Latin term de novo. 
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 of the overlap is over 30 nucleotides. Fourth, to avoid over-counting for worm protein 
hits, the initial matches were further filtered for adjacent matches. Fifth, the potential 
pseudogenes were filtered for overlap with any other annotations in the Sanger Centre 
files such as exons of genes, tandem or inverted repetitive and transposable elements. 
Sixth, they refined the data for additional repeat elements and any match to proteins. 
Seventh, they increased the threshold e-value from 0.01 to 0.001 (193).  
In 2002, using the same methodology, Harrison et al. released their results for 
detecting pseudogenes in human chromosome 21 and 22. They found 77 processed 
pseudogenes on chromosome 21 and 112 on chromosome 22 (194). For unprocessed 
pseudogenes, they found 72 on chromosome 21 and 123 on chromosome 22 (194). 
 
5.2.2 Sakai’s Approach 
In 2003, Sakai et al. from Japan introduced a method to detect processed 
pseudogenes based on cDNA mapping to the human genome (195). Their methods were 
divided into two sections. The first section is the cDNA mapping. They aligned all cDNA 
sequences against human genome using blastn. Then they extracted corresponding 
genomic regions for each query sequence. Next, they set up cut values of ≥ 95% identity 
and ≥ 80% coverage to filter those sequence hits based on the est2genome. 
The second stage of the experiment is pseudogene detection. All the candidate 
sequences collected from the first stage were classified into six classes according to the 





Figure 5.3: Flow chart of Sakai et al. method for processed pseudogene detection. 
 
Sakai and his team found 6,549 possible processed pseudogenes using 113,196 
human cDNA with their automated pipeline including novel intron-containing 




PPFINDER was released in 2006 to find processed pseudogenes (183). The 
purpose for the program is to improve the accuracy of gene prediction methods, if 
processed pseudogenes can be identified. A gene model was first established in order to 
collect the gene information. Two methods were used in order to find pseudogenes: 
intron location and conserved synteny. In the intron location method, it started to align 
pre-established gene model to cDNA database using blastn. The best scoring hits were 
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 kept. Then, these transcripts were further aligned to genome locus. If the transcript hits 
more than one location in the genome, the transcript will be marked as pseudogene-
derived for further testing. The segments of predicted gene will only hit themselves in the 
genome, if they are not pseudogene-derived. But if they are pseudogene-derived, the best 
hit score will be with the parental gene location. The other hit locations in the genome 
can be potential pseudogenes. 
In the synteny method, the candidate pseudogene-derived sequences were split 
into exons and translated into amino acids. Then these translated sequences were aligned 
to the protein database using blastp. If the sequence identity of the hit is ≥ 65% and the 
length of the hit is at least 10 amino acids, these sequences were kept. Then the sequences 
were examined if their hit location is the same as the gene model. If the answer is no, the 
information of conserved syntenic region will be recorded. Once again, they aligned the 
original created gene model to the recorded information to find orthologous region. If the 
orthologous regions were found, the gene model is said to contain a pseudogene. 
However, if it is a single-exon gene, without locating introns, the sequence might 




Zhang et al. from Yale University proposed an automated pseudogene 
identification pipeline in 2006 (196). Their method was based on Harrison’s approach 
(both Harrison and Zhang were post-docs training in Gerstein’s laboratory at Yale 
University). This pipeline began by aligning protein sequences to genomic sequences 
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 using tblastn. Then the sequences overlapping with the gene sequences in ENSEMBL 
database were removed. Smith-Waterman was used to optimize the alignment to merge 
and extend candidate sequences. Fourth, false positive, repeats, low complexity 
sequences and potential functional gene candidates were removed. The pseudogene 
candidate is considered a false positive if its BLAST e-value is ≤ 10-10 or an amino acid 
sequences identity is ≤ 40%. Finally, sequences are separated into different classes – 
retrotransposed pseudogenes, duplicated pseudogenes (or unprocessed pseudogenes in 
our definition), or pseudogeneic fragments based upon exon structure (179;182;196;197).  
 
5.2.5 Pseudogenes Analysis in ENCODE Project 
In Section 1.7.4, the ENCODE project was discussed. It brought dozen of 
laboratories together to participate to analyze and identify the functional elements in the 
human genome. Studies were focused on transcripts and gene models, protein-binding 
sites, epigenetic markers, and promoters and enhancers, evaluating the existing methods 
and creating new methods if necessary. One group focused on methods for detecting 
pseudogenes. 
As a subgroup of ENCODE, the pseudogene research team focused on 
establishing methods to decide consensus annotation, analyze transcription and study 
evolution. The first goal was to “obtain an accurate list of pseudogenes in order to 
facilitate the creation of a comprehensive catalog of structural and functional elements in 
the ENCODE regions” (47;56). They evaluated five developed methods: GIS-PET (198), 




 The pseudogene research team found that all five methods detect pseudogenes 
based on sequence similarity to “at least one entry in a collection of query sequences 
representing known human genes (referred to as the parent genes).” The main two 
differences among these five methods are in (1) type of queries, either nucleotides or 
proteins, used to search for pseudogenes and (2) strategies used to assess a sequence’s 
coding potential and methods for distinguishing processed from unprocessed 
pseudogenes (56). 
The second task was to establish a consensus procedure including manual 
curation in order to get the correct and reliable list of pseudogenes. The research team 
only considered those pseudogenes that match known proteins from the UniProt database 
(202). 
After evaluating the five computational methods, they characterized the sequences 
they found and sequenced these pseudogene transcripts. They realized that in the 
ENCODE gene-rich regions, more pseudogenes were found. In addition, most sequences 
are decayed gene copies that contain frame shift mutations (56).  
 
5.3 Characteristics for Pseudogene Detection 
In the previous sections, different types of pseudogenes and the current 
computational methods have been discussed. Based on the biological factors and other’s 
work, there are some features that need to be investigated when evaluating pseudogene 
candidate sequences. They are start and stop codons, poly-A signals and poly-A tails, 
G+C composition, and mutational events. Each of these features is considered in a newly 
developed method to score sequences for their likelihood of being a pseudogene. The rest 
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 of Section 5.3 covers in detail the features considered for the method constructed in 
Section 5.5.  
 
5.3.1 Start Codon 
When a fully-functional protein is translated from a genetic sequence, it goes 
through transcription, pre-mRNA processing, translation and protein folding (Figure 5.1). 
By default, ATG, or AUG in RNA sequences, serves as a start codon or initiator to 
translate genes to proteins (203). There are rare cases in eukaryotes initiated by codons 
other than ATG/AUG (204-209), such as GTG/GUG. The standard code currently allows 
initiation from TTG/UUG and CTG/CUG in addition to ATG/AUG (203). 
When detecting pseudogenes, locating a conserved or mutated ATG in an open 
reading frame is a good starting point. It is possible that ATG will be located in a different 
or a later place other than the first position in a sequence. The alternative patterns of ATG 




 Table 5.1: Start Codon Alternative Patterns and Their Scores 
Main pattern Alternative patterns 
ATG 1.00 ATN  ATA ATC ATT 0.25 
ANG  AAG ACG AGG 0.25 
ANN  
AAN ACN AGN 
0.0625 
AAA ACA AGA 
AAC ACC AGC 
AAT ACT AGT 
  NTG  CTG GTG TTG 0.25 
NNG  
CNG GNG TNG 
0.0625 
CAG GAG 
CCG GCG TCG 
CGG GGG TGG 
NTN  
CTN GTN TTN 
0.0625 
CTA GTA TTA 
CTC GTC TTC 
CCT GGT TTT 
      NNN        0.015625 
 
5.3.2 Stop Codons 
A terminator is present to tell the cell to end the translation process and release 
the amino acid chain. TGA, TAG and TAA (or UGA, UAG, and UAA in RNAs) are three 
well-known stop codons (210-212). Stop codon insertion and mutation is one of the 
common features differentiating pseudogenes from regular genes. Pseudogenes are 
caused by either retrotranscription or duplication. Frame shift, mutation, insertion or 
deletions may cause the terminating signal relocate earlier in the sequences. In such a 
case, in the open reading frame, the premature stop codon causes translation to terminate. 
Finding premature stop codons is the most common feature to consider a sequence being 
a pseudogene sequence. Two conditions are considered:  
• Presence of a start codon near the beginning of a sequence 
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 • Presence of a stop codon located downstream the start codon 
Besides the most widely found stop codons, TGA/UGA, TAG/UAG, and TAA/UAA, 
an additional thirteen mutational patterns were inspected as well (Table 5.2). 
 
Table 5.2: Stop Codon Alternative Patterns and Their Scores 
Main pattern Alternative patterns 
TGA 1.00 TGN  TGC TGG TGT 0.25 
TAG 1.00 TNG  TCG   TTG 0.25 
TAA 1.00 TAN  TAC   TAT 0.50 
  TNA  TCA   TTA 0.50 
  
TNN  
TCN   TTN 
0.25   TCC TTC 
  TCT   TTT 
  NAA  AAA CAA GAA 0.25 
  NAG  AAG CAG GAG 0.25 
  NGA  AGA CGA GGA 0.25 
  
NNA  
ANA CNA GNA 
0.0625   ACA CCA GCA 
  ATA CTA GTA 
  
NNG  
ANG CNG GNG 
0.0625 
  ACG CCG GCG 
  AGG CGG GGG
    CTG GTG 
  
NAN  
AAN CAN GAN 
0.0625   AAC CAC GAC 
  AAT CAT GAT 
  
NGN  
AGN CGN GGN 
0.0625   AGC CGC GGC 
  AGT CGT GGT 
    NNN        0.015625 
 
5.3.3 Poly-A Signals and Poly-A Tails 
Polyadenylation is the covalent linkage of a poly-A tail to an mRNA molecule in 
order to stabilize the molecule so a mature mRNA will be ready for translation and 
produce an amino acid. The process starts by finding a cleavage site which is 
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 characterized by the presence of a poly-A signal sequence near the cleavage site, mostly 
commonly found to be AATAAA (or AAUAAA in RNA). When the mRNA has been 
cleaved, a number of adenine (A) residues (50-250) will be attached in the 3’ end at the 
cleavage site. The reaction is catalyzed by polyadenylate polymerase (213).  
When pseudogenes are formed through retrotranscription or duplication, the 
incompletely translated sequences may be re-inserted into the genomic sequences. Those 
sequences may contain a poly-A site, just like processed mRNAs. It is also possible they 
have a number of adenines (A) in the 3’ end of the sequence. In fact, most processed 
pseudogenes have shown the presence of a poly-A tail in the 3’ end.  
 
Table 5.3: Poly-A Signal Patterns 
polyA site % sites  polyA site % sites 
AATAAA 58.2 AATAGA 0.7 
ATTAAA 14.9 AAAAAG 0.8 
AGTAAA 2.7 ACTAAA 0.6 
TATAAA 3.2 AAGAAA 1.1 
CATAAA 1.3 AATGAA 0.8 
GATAAA 1.3 TTTAAA 1.2 
AATATA 1.7 AAAACA 0.5 
AATACA 1.2  GGGGCT 0.3 
Abbreviations: poly-A, polyadenine;  
%, percentage. These 16 poly-A sites are collected 
from Table 2 in (214).
 
AATAAA is the most common poly-A signal in human genome, found in close to 
60% of gene sequences. ATTAAA is also relatively common, occurring 14.9% of the 
time. There are fourteen other patterns been identified as poly-A signals (Table 5.3). 




 For poly-A tails, finding a large number of adenine (A) residues in a sequence is 
too difficult since these regions can also be counted as low complexity. Instead, we detect 
regions with a run of at least ten adenines, increasing the score according to the total 
number of A's found. If a candidate sequence owns a poly-A signal and a poly-A tail of 
length ten or more, the possibility being a pseudogene is greatly increased. 
 
5.3.4 G+C Composition 
In Harrison et al.’s research, they found the pseudogenes have higher G+C 
composition than the background genomic DNA in general (215;216). The G+C 
composition ranges from 36 to 54 percent in the sequences (217). Therefore, the 
candidate sequences will be reviewed to see how many G’s and C’s are involved in the 
sequences.  
 
5.3.5 Similar, Synonymous vs. Nonsynonymous Mutations 
When two sequences are counted as homologous, they share a certain percentage 
of similarity. Both of them have originated from a common ancestral sequence but 
accumulated various mutations. Figure 5.4 shows the types of mutations occurring an 
example pair of sequences. Although there are three differences between these two 
sequences, a single substitution, sequential substitution, coincidental substitution, parallel 
substitution, convergent substitution and back substitution have red.   also occur
In Section 1.4, the genetic code was discussed. The 4 ൈ 4 ൈ 4 or 64 different 
combinations of codons from A, C, G and T represent the twenty common amino acids. 
Based on Table 5.4, we can translate these two descendant sequences into amino acids. 
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 Although there are only three nucleotides changed in each descendant sequence, some of 
the amino acids have been changed. 
 
Figure 5.4: Mutations occurring in two homologous sequences. 
Image adopted and modified from Figure 3.6 in (218).  
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 Table 5.4: The Genetic Code (RNA to Amino Acids) 
Second letter 






















UUC UCC UAC UGC C 
UUA 
Leu 
UCA UAA Stop UGA Stop A 











CUC CCC CAC CGC C 
CUA CCA CAA 
Gln 
CGA A 











AUC ACC AAC AGC C 
















GUC GCC GAC GGC C 
GUA GCA GAA 
Glu 
GGA A 
GUG GCG GAG GGG G 
 
In descendant sequence (1), the 5th, 7th, 9th and 11th bases have been changed after 
mutations. Although it does not look like a lot of changes in the nucleotide acid sequence, 
the amino acids which contain these four mutational nucleotides respectively have been 
changed (Figure 5.5).  
 
Thr Glu Arg Asn Ala 
A C T G A A C G T A A C G C T 
    ↕ ↕ ↕ ↕     
A C T G G A G G A A T C G C T 
Thr Gly Gly Ile Ala 
base 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 5.5: Comparison between ancestral sequence and descendant sequence (1). 
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 In descendant sequence (2), there are also three mutations locating in the 2nd, 7th, 
9th and 11th bases. Two of the three amino acids which contain the three mutational 
nucleotides respectively have been changed (Figure 5.6).  
 
Thr Glu Arg Asn Ala 
A C T G A A C G T A A C G C T 
  ↕   ↕ ↕ ↕     
A A T G A A A G A A T C G C T 
Asn Glu Arg Ile Ala 
base 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 5.6: Comparison between ancestral sequence and descendant sequence (2). 
 
The 7th and 9th nucleotides changed in descendant sequence (2) can be counted as 
synonymous mutations because the amino acid does not change. However, the other 
mutational nucleotides shown in Figures 5.5 and 5.6 that change the amino acids have to 
be studied further in order to distinguish if they produce nonsynonymous or similar 
synonymous mutation. 
Those mutations at the nucleic level that result in a similar but not identical amino 
acid are called similar synonymous mutations. Although the mutational nucleotide does 
change the amino acid, the functionality of the amino acid is close to the original one. But 
if mutations at the nucleic level change the amino acid to something unrelated, it is called 
a nonsynonymous mutation. To find out how similar or how close the amino acids are 
between each other, the PAM250 matrix generated by Dayhoff (97) and the BLOSUM62 
matrix generated by Henikoff (219;220) are the two matrices widely used. In WU 
BLAST, BLOSUM62 matrix is chosen by default when comparing protein sequences. If 
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 the comparison results a same amino acid, it will display the amino acid. But if the 
comparison returns a close amino acid, it will give a plus ‘+’ sign. 
 
Subject 
G A G A A T C C C A A G A A G T A C A T C 
  E     N     P     K     K     Y     I   
blastx   E           P     K     K     +     I   
Query 
G A G A C T C C C A A G A A G C A C A T C 
  E     T     P     K     K     H     I   
base 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
Figure 5.7: Similar synonymous mutation vs. nonsynonymous mutation. 
Subject, subject sequences (nucleotide and amino acid); blastx, results returned by blastx; Query, query 
sequences (nucleotide and amino acid). 
 
In Figure 5.7, the nucleotides located at the 5th and 16th bases have mutated. Both 
amino acids which contain these two mutational nucleotides are changed as well. 
According to the blastx result, the amino acid changed from N (Asn) to T (Thr) is not 
related (blank in the blastx result row). The nucleotide substitution is a 
nonsynonymous mutation. But the amino acid changed from Y (Tyr) to H (His) is 
related (plus ‘+’ sign in the blastx result row). Thus, the nucleotide substitution is 
called a similar synonymous mutation. 
To evaluate the pseudogene candidates, determining the number of similar 
synonymous mutations (the amino acid is changed to a close amino acid), synonymous 
mutations (the amino acid is not changed) and nonsynonymous mutations (the amino acid 




 5.4 Sequence Data 
All the approaches discussed in Section 5.2 begin pseudogene analysis by 
aligning sequences to genomic regions. Besides Sakai et al. who use cDNA sequences, 
all other approaches use protein sequences or RefSeq sequences for alignments. 
Similar to the methods that have been discussed in Section 5.2, the pseudogene 
detection and characterization in this project begins with sequence alignment. Rather than 
using cDNA, RefSeq or protein sequences in as other approaches, EST sequences were 
chosen in this project. Compared to cDNA, RefSeq or protein sequences, ESTs are 
relatively short, ranging from 300 to 600 bp in length. The size of cDNA, RefSeq or 
protein sequences could range from 1000 to 4000 bp. Aligning ESTs to genomic 
sequences will return more hits from different locations of genomic regions due to their 
smaller size. It is possible to return the high scoring pairs (HSP) from the genomic 
locations that are never reported before from the previous methods due to longer query 
sequences.  
Although it will increase the amount of data for further analysis, it is possible to 
provide more candidate locations in genomic regions as pseudogenes. Moreover, with the 
choices of alternative splicing (which has been studied in Chapter 4), it will bring an 
additional possibility to locate genomic hits other than the parental hit itself.  
In the current approaches, EST sequences have not been used for identifying 
pseudogenes. Hence, using ESTs for initial alignment for searching and determining 











 Pseudogenes can be detected in the steps out-lined in Figure 5.8. After 
downloading the necessary sequence files, each sequence will go through data 
preprocessing, sequences alignment, clustering and pseudogene detection. The detailed 
information for the methodology will be discussed in Section 5.6. 
Expressed sequence tags (ESTs) were downloaded from GenBank/dbEST release 
158.0, dated 4-18-2007 (http://www.ncbi.nlm.nih.gov/dbEST/) (72) for the purpose of 
detecting and characterizing pseudogenes. RefSeq sequences were downloaded from 
NCBI/RefSeq release 22, dated 3-13-2007 (http://www.ncbi.nlm.nih.gov/RefSeq/) (73-




5.5.1 Data Preprocessing 
EST sequences downloaded from GenBank/dbEST are parsed to include only 
those from the species of interest. Raw EST sequences are masked for repetitive elements 
using RepeatMasker (87;88). Low complexity regions for ESTs are then masked using 
the DUST (70) filter available from the wuBLAST software (70;167). 
 
5.5.2 ESTs to Genome Alignment 
After organism sequences are filtered, ESTs are aligned to genomic regions using 
wublastn with parameters W=15 topComboN=5 –nogaps –gspmax=100 –hspmax=500 
filter=dust –warning –notes –error –links. The results run by blastn are then filtered by 
a Perl script to parse out the necessary information (Figure 5.9).  
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 =gi|5555714|gb|AV175813.1|/gbest46.seq.gz AV175813 Yuji Kohara unpublished 
cDNA: Strain N2 hermaphrodite embryo Caenorhabditis elegans cDNA clone yk487b3 
3' (300 letters; record 79)  
>chrIII 741 5971574 5971723 33 182 1 (1)-2 0.99 0.50 0.50 
>chrIII 593 5972503 5972622 181 300 1 1-(2) 0.99 0.40 0.40 
>chrIII 136 12875675 12875730 36 91 2 (3)-4 0.71 0.19 0.13 
>chrIII 95 13163938 13163974 84 120 2 3-(4) 0.73 0.12 0.09 
>chrIII 124 13114293 13114342 58 107 3 (5) 0.72 0.17 0.12 
>chrII 123 12241150 12241215 46 111 1 (1) 0.65 0.22 0.14 
>chrII 120 15033827 15033868 69 110 2 3-(2) 0.76 0.14 0.11 
>chrII 97 1139631 1139653 44 66 2 (3)-2 0.91 0.08 0.07 
>chrV 130 19475058 19475101 76 119 1 2-(1)-3 0.77 0.15 0.11 
>chrV 103 8552104 8552129 39 64 1 (2)-1-3 0.88 0.09 0.08 
>chrV 94 20038590 20038642 173 225 1 2-1-(3) 0.64 0.18 0.11 
>chrIV 128 11169253 11169310 88 145 1 2-(1)-3 0.69 0.19 0.13 
>chrIV 103 7401906 7401958 42 94 1 (2)-1-3 0.66 0.18 0.12 
>chrIV 93 12955563 12955595 195 227 1 2-1-(3) 0.76 0.11 0.08 
>chrIV 124 1160745 1160812 45 112 2 (4)-5 0.65 0.23 0.15 
>chrIV 102 9483397 9483483 97 183 2 4-(5) 0.57 0.29 0.17 
>chrIV 124 959701 959768 37 104 3 (6) 0.65 0.23 0.15 
Figure 5.9: Sample blastn result for GI 5555714. 
Column 1, chromosome; column 2, high scoring pair score; columns 3 and 4, begin and end locations in 
genomic regions; columns 5 and 6, begin and end locations in ESTs; column 7, group; column 8, links; 
columns 9, 10 and 11, percent identity, percent coverage and match value. 
 
Each record starts with an equal sign ‘=’ followed by a description of the EST. 
The following rows, starting a greater sign ‘>’ represents a sequence hit, including the 
chromosome number, HSP score, begin and end locations of the hits in the genomic 
sequences, begin and end locations of the hit in EST, the group number, the links, the 
percent identity of the hit, the percent coverage of the hit and the match value of the hit. 
Since pseudogenes have a high similarity to the genome sequence of origin and 
ESTs have a 2-5% sequence error rate (221), only sequences whose identified similarities 
are greater than or equal to 95% are reserved. Ideally, these sequences are closer to the 
target pseudogenes. However, the hit size has to be considered as well. If the HSP is 




 The blastn computational results were filtered based on the following criteria: 
if it is a single splice hit, discard hits with length less than 50 bp. If it is multiple-splice 
hit, the sequence hit has exactly two splices, and the gap between two hits are over 
1,000,000 bp, discard the record. Otherwise, measure the size of the hit with each splice 
and discard the record whose percent identity is less than 70%. Results are compared 
(single-splice hits and multiple-splice hits) and sorted by: accession number, 
chromosome number and genomic begin location. A flowchart of this process is provided 
in Figure 5.10. 
As discussed in Sections 1.8 and 4.1.3 to 4.1.5, a gene sequence is derived from 
the combination of exons after the introns are removed. Those highly similar sequences 
which have been filtered might be the splices of genes themselves. Therefore, additional 
sequence comparison is needed. The set of spliced nucleotide sequences will be aligned 
to an unspliced genomic DNA sequence. Through this process, beginning and ending 
locations of exons and introns will be discovered. 
In addition, GT/AG and CT/AG are commonly found at exon/intron boundaries 
known as donor and acceptor sites. Once the beginning and ending locations of exons and 
introns are known, the splice patterns of the gene can be detected. Most introns begin 
with GU (or GT in DNA) and end with AG patterns. With this information, the exact 
boundary between any two exons can be found by mapping ESTs back to the genome. 
However, the frequency of GU-AG combinations of bases is fairly common, occurring on 
an average about 1/16 of the time. A number of programs help distinguish these 





Figure 5.10: Flow chart for filtering blastn results. 
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 In Section 3.3.5, EXALIN (118) was discussed as a powerful method for 
determining sequence similarity and splice site. EXALIN can also align sequences 
blocked within a given range in the genome. After blastn results were filtered based on 
size and percent identity and sorted according to the genomic begin location, the hit is 
further refined to determine the leftmost and rightmost locations in genome in order to set 
up a searchable boundary in EXALIN. If the blocked range is over 1,000,000 bases, the 
search will be broken into pieces with a size of 500,000 bases. Otherwise, both 
boundaries will be extended to the closest thousand number. For instance, the hit after 
running blastn for GI 5555714 to C. elegans chromosome III were split into two 
pieces: 5971574-5971723 and 5972503-5972622. To use EXALIN for fine tuning, the 
search range will be 5971571-5972622. To extend both ends to the closest thousand 
number, it is actually comparing 5555714 against chromosome III between the genomic 
locations 5971000-5973000 when running EXALIN. 
The comparison results calculated by EXALIN to find exon/intron junctions are 
then split into two groups: single-splice hit and multiple-splice hit. If it is a single-splice 
hit, sequences of length < 50 bp are discarded. If it is a multiple-splice hit, the number of 
segments, the left and right ends of each segment is recorded. All the single-splice and 
multiple-splice hits are merged and sorted in these order: accession number, chromosome 
number and genomic begin location. 
Before processing fine tuning in sequence comparison, the searchable boundary 
for running EXALIN is based on the blastn result. Thus, if the two blocked boundaries 
in the same chromosome generated by blastn results are different, ideally EXALIN 
should return different computational outcomes. For example, blastn returns two 
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 groups of HSP after comparing GI no. 18288550 against chromosome V for C. elegans 
(Figure 5.11). The boundaries found by blastn were 2230674-9303595 and 2230017-
5705627, respectively, and the EXALIN blocked boundaries are 2230000-9304000 and 
2230000-5706000 (Figure 5.12). Figures 5.12 and 5.13 show the results returned by 
EXALIN that is differing from what blastn has generated in Figure 5.11. 
 
=gi|18288550|gb|BJ128393.1|/gbest148.seq.gz BJ128393 unpublished oligo-capped cDNA library 
(722 letters) 
>chrV 212 2230674 2230764 31 121 10 (12)-15-16-13-14 0.70 0.13 0.09 
>chrV 92 2713536 2713593 263 320 10 12-(15)-16-13-14 0.62 0.08 0.05 
>chrV 86 8716204 8716231 331 358 10 12-15-(16)-13-14 0.79 0.04 0.03 
>chrV 199 8971491 8971708 335 552 10 12-15-16-(13)-14 0.55 0.30 0.16 
>chrV 97 9303573 9303595 562 584 10 12-15-16-13-(14) 0.91 0.03 0.03 
>chrV 616 2230017 2230141 722 598 1 (18)-17-19 0.99 0.17 0.17 
>chrV 2938 2230196 2230793 599 2 1 18-(17)-19 0.99 0.83 0.82 
>chrV 99 5705583 5705627 78 34 1 18-17-(19) 0.69 0.06 0.04 
 
 
Figure 5.11: Sample blastn result GI no. 18288550. 
(partial result sorted by genomic begin location) 
Column 1, chromosome number; column 2, high-scoring pair score; columns 3 and 4, begin and end 
locations in genomic regions; columns 5 and 6, begin and end locations in ESTs; column 7, group; column 
8, links; columns 9, 10 and 11, percent identity, percent coverage and match value. 
 
EXALIN [06-May-2005] 
ARGS: -i 0 -s 3 -p /biodata/bin/exalin.linux24-i686/C.elegansSPM.par -A 2230000 -B 9304000 
/biodata1/elizabeth/elegansSeq/chrSeq/masked/ce2-Mar2004/chrV.fa 
/biodata1/elizabeth/testResults/elegansGenome/chr_vs_est/blast/4-18-07Re158extend/BJ128393.fa  








EXON: 722 - 600 (2230017 - 2230139)    153.8   N/A   -3.71   100.00% 
EXON: 599 - 2 (2230196 - 2230794)    740.8   -1.45   N/A   99.67% 




EXON: 722 - 600 (2230017 - 2230139)    153.8   N/A   4.47   100.00% 
EXON: 599 - 2 (2230196 - 2230794)    740.8   5.22   N/A   99.67% 
 
EXIT 0 
Figure 5.12: Sample EXALIN result for GI 18288550. 





ARGS: -i 0 -s 3 -p /biodata/bin/exalin.linux24-i686/C.elegansSPM.par -A 2230000 -B 5706000 
/biodata1/elizabeth/elegansSeq/chrSeq/masked/ce2-Mar2004/chrV.fa 
/biodata1/elizabeth/testResults/elegansGenome/chr_vs_est/blast/4-18-07Re158extend/BJ128393.fa  








EXON: 722 - 600 (2230017 - 2230139)    153.8   N/A   -3.71   100.00% 
EXON: 599 - 2 (2230196 - 2230794)    740.8   -1.45   N/A   99.67% 




EXON: 722 - 600 (2230017 - 2230139)    153.8   N/A   4.47   100.00% 
EXON: 599 - 2 (2230196 - 2230794)    740.8   5.22   N/A   99.67% 
 
EXIT 0 
Figure 5.13: Sample EXALIN result for GI 18288550. 
(Blocked search range is 2230000-5706000.) 
 
After the fine tuning process using EXALIN, duplicate results are removed. 
Figure 5.14 gives a flow chart of the process to remove redundant records generated by 
EXALIN. 
The records are further reviewed and split into two groups: records which hit 
single locations and records which hit multiple locations. If the same EST accession 
number hits multiple locations, either in the same or different chromosome, it will be 
assigned into the group whose records hit multiple locations. Otherwise, it is assigned 
into the group whose records hit single location. Because the sequence only hits the 
genome once, it is highly believed to be a gene itself or can be a disabled pseudogene. 
Disabled pseudogenes cannot be detected using this approach. The information will be 
saved for further usage. Records belonging to the group whose records hit multiple 











The purpose of clustering is to incorporate overlapping ESTs that tag the same 
transcript of the same gene in a single cluster. Thus, measuring the similarity between 
any two sequences is used to cluster sequences into suitable groups. It requires a simple 
Boolean measurement: accept (yes) or reject (no) two sequences in the same cluster. 
Multiple-location records gathered from fine tuning are further sorted by 
chromosome number and genomic begin location. The sequence hits are then reviewed in 
a “DNA walking” method: the sequence hit is reviewed base to base. If the sequences 
overlap each other, they are grouped together and the leftmost and rightmost boundaries 
will be the left end of the first sequence and the right end of the second sequence (Figure 
5.15). Both single-splice and multiple-splice hits are reviewed in the same format. The 
ESTs belong to the same cluster will be recorded in the table for information tracing. The 
only exception is when a distance between left and right boundaries of a record is over 
500,000 bases will be assigned in an individual group. In such group, each segment of the 
hit will be examined by size of the segment, distance between segments, begin and end 





Figure 5.15: Clustering by DNA walking. 
 
5.5.4 Pseudogene Detection and Characterization 
After clustering EST hits into groups, each cluster will contain information 
pertaining to the left and right ends in genomic regions, length of the cluster and the 
number of ESTs in the cluster. Clusters containing gap(s) will be marked. 
The left and right boundaries of each cluster are used to retrieve the 
corresponding genomic sequences. Each sequence is run against the RefSeq protein 
databases using blastx and processed to get scores for both forward and reverse 
directions. Each factor discussed in Section 5.3 will be examined:  
1. Look for start codon (ATG), 
2. Look for stop codon(s) (TGA, TAG and TAA) in open reading frames, 
3. Search for poly-A signal, 
4. Add up the number of adenine (A) in the poly-A tail if found,  
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 5. Calculate G+C composition, and  
6. Calculate values for similar synonymous mutations, synonymous mutations 
and nonsynonymous mutations.  
 
5.6 Results 
In order to demonstrate the effectiveness of this approach for pseudogene 
detection, a set of cytochrome32 gene and pseudogene sequences from the human genome 
were considered. Thirteen sequences, including one known gene and twelve pseudogenes 
were retrieved from different chromosomal regions and the size of sequences ranges from 
~1,000 to ~2,700 bp. The percentages of N and G+C composition have been calculated 
(Table 5.5). If the Ns are included in sequences, the percentage of G+C composition 
ranges from 26.23% to 41.45%. If Ns are not counted in sequences, the percentage of 
G+C composition ranges from 33.78% to 44.62%. 
   
                                                            
32 Cytochrome is a class of hemoprotein. The major biological function is for electron transport by virtue of 





Table 5.5: Percentage of N and G+C Composition in Sequences 
estGroupID length N pctN G+C pctG+C   
BC005299-1 2427 0 0.00% 1006 41.45% (41.45%) 
BC005299-2 1564 314 20.08% 442 28.26% (35.36%) 
BC005299-3 1219 0 0.00% 413 33.88% (33.88%) 
BC005299-4 1237 4 0.32% 425 34.36% (34.47%) 
BC005299-5 1210 0 0.00% 419 34.63% (34.63%) 
BC005299-6 1215 3 0.25% 413 33.99% (34.08%) 
BC005299-7 2686 436 16.23% 957 35.63% (42.53%) 
BC005299-8 1247 0 0.00% 433 34.72% (34.72%) 
BC005299-9 1216 0 0.00% 414 34.05% (34.05%) 
BC005299-10 1548 346 22.35% 406 26.23% (33.78%) 
BC005299-11 1784 233 13.06% 692 38.79% (44.62%) 
HUMCYCPS1-1 1060 0 0.00% 379 35.75% (35.75%) 
HUMCYCPS1-2 1366 310 22.69% 389 28.48% (36.84%) 
Column 1, estGroup; column 2, sequence length; column 3, number of Ns in sequence; column 4, 
percentage of Ns in sequence; column 5, number of G+C composition in sequence; column 6, 
percent of G+C composition in sequence; column 7, percentage of G+C composition (without Ns) 
in sequence. 
 
The start codon (ATG) and its alternative patterns (Table 5.1) were reviewed and 
the number of occurrences was detected. All thirteen sequences (including forward and 
reverse strands) contain the standard start codon ATG (Table 5.6).  
The stop codons (TGA, TAG and TAA) and their alternative patterns (Table 5.2) 
were reviewed. Among the standard stop codon patterns, the frequency of TAA is greater 
than other stop patterns in most cases. The number of counts for each estGroup is listed 






Table 5.6: Frequency of Start Codon Patterns 
estGroupID 
ATG ATN ANG ANN NTG NNG NTN NNN   
counts # patterns counts # patterns counts # patterns counts # patterns counts # patterns counts # patterns counts counts score 
BC005299-1F 30 3 136 3 107 9 399 3 103 8 156 9 399   4.8906 
BC005299-1R 41 3 124 3 116 9 387 3 132 8 243 9 379   4.8906 
BC005299-2F 26 3 86 3 57 11 225 3 57 9 83 9 201 104 5.0781 
BC005299-2R 20 3 92 3 46 9 208 3 53 9 59 9 228 104 4.9531 
BC005299-3F 17 3 98 2 41 9 202 3 59 7 55 9 218   4.5781 
BC005299-3R 32 3 84 3 57 9 219 3 53 6 64 9 193   4.7656 
BC005299-4F 32 3 82 3 54 10 226 3 58 7 72 9 178 1 4.8906 
BC005299-4R 18 3 94 3 40 9 204 3 59 9 56 9 220 1 4.9531 
BC005299-5F 18 3 85 3 37 9 207 3 58 8 56 9 223   4.8906 
BC005299-5R 20 3 84 2 54 9 226 3 62 9 74 8 186   4.6406 
BC005299-6F 19 3 87 3 44 10 222 3 58 7 49 9 216 1 4.8906 
BC005299-6R 26 3 83 3 58 11 214 3 58 7 65 9 202 1 4.9531 
BC005299-7F 48 3 109 3 102 10 375 3 117 9 195 9 328 144 5.0156 
BC005299-7R 34 4 121 3 89 9 350 3 138 9 168 10 339 144 5.2656 
BC005299-8F 23 3 87 3 54 9 222 3 62 8 78 9 197   4.8906 
BC005299-8R 17 3 93 3 48 9 206 3 65 8 258 9 222   4.8906 
BC005299-9F 23 3 90 3 41 9 210 3 55 5 57 9 216   4.7031 
BC005299-9R 24 3 89 3 53 9 217 3 63 6 64 9 194   4.7656 
BC005299-10F 20 3 91 3 42 9 204 3 49 7 55 10 222 114 4.8906 
BC005299-10R 30 3 82 3 58 11 212 3 56 7 57 9 196 114 4.9531 
BC005299-11F 37 3 76 3 103 9 240 3 66 8 155 10 180 77 4.9531 
BC005299-11R 28 3 82 3 41 11 204 3 88 8 110 9 257 77 5.0156 
HUMCYCPS1-1F 17 3 82 3 38 9 179 3 51 7 53 9 174   4.8281 
HUMCYCPS1-1R 28 3 69 3 47 9 178 3 48 3 66 9 172   4.5781 
HUMCYCPS1-2F 23 3 71 3 48 10 180 3 47 9 76 9 171 103 5.0156 
HUMCYCPS1-2R 18 3 75 3 42 9 173 3 45 8 54 9 181 103 4.8906 
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F, forward strand; R, reverse strand; #, number. The patterns of start codon were listed in Table 5.1. 
Formula to calculate score:  
score = ATG × 1.00 + # of ATN patterns × 0.25 + # of ANG patterns × 0.25 + # of ANN patterns × 0.0625 + # of NTG patterns × 0.25 





Table 5.7: Frequency of Stop Codon Patterns 
estGroupID 
TGA TAG TAA TGN TNG TAN TNA TNN NAA 
counts counts counts # patterns counts # patterns counts # patterns counts # patterns counts # patterns counts # patterns counts 
BC005299-1F 42 21 71 3 89 2 51 2 68 2 111 4 215 3 154 
BC005299-1R 44 29 67 3 125 2 64 2 65 2 113 4 165 3 146 
BC005299-2F 23 16 44 3 56 2 27 2 45 2 69 4 86 3 89 
BC005299-2R 21 15 48 3 51 2 24 2 42 2 67 5 125 3 75 
BC005299-3F 25 12 49 3 51 1 25 2 41 2 67 4 124 3 70 
BC005299-3R 25 13 42 3 57 1 20 2 46 2 74 4 81 3 97 
BC005299-4F 26 14 40 3 61 2 24 2 43 2 69 4 79 3 94 
BC005299-4R 28 13 41 3 49 2 25 2 45 2 66 4 126 3 76 
BC005299-5F 23 13 42 3 51 2 21 2 44 2 62 4 128 3 76 
BC005299-5R 20 17 42 3 60 2 27 2 39 2 65 4 77 3 91 
BC005299-6F 25 12 46 3 50 1 22 2 42 2 65 4 118 3 81 
BC005299-6R 23 15 42 3 58 2 27 2 40 2 71 4 85 3 87 
BC005299-7F 40 28 50 3 123 2 31 2 53 2 105 5 164 3 132 
BC005299-7R 48 20 57 3 124 2 41 2 56 2 90 6 198 3 119 
BC005299-8F 25 17 42 3 57 2 25 2 43 2 72 4 83 3 92 
BC005299-8R 25 10 47 3 45 2 23 2 45 2 67 4 124 3 78 
BC005299-9F 29 15 43 3 49 1 24 2 40 2 66 4 117 3 79 
BC005299-9R 24 13 42 3 60 2 21 2 43 2 72 4 89 3 88 
BC005299-10F 23 14 47 3 44 2 22 3 39 2 72 5 121 3 76 
BC005299-10R 26 15 46 3 57 2 23 2 38 2 70 4 82 3 85 
BC005299-11F 28 24 29 4 74 2 28 2 30 2 50 5 93 3 103 
BC005299-11R 29 20 21 3 85 2 32 2 45 2 47 4 167 3 78 
HUMCYCPS1-1F 24 9 40 3 44 1 19 2 33 2 54 4 101 3 66 
HUMCYCPS1-1R 23 11 31 3 50 2 19 2 39 2 64 2 78 3 75 
HUMCYCPS1-2F 21 13 33 3 46 2 23 2 38 3 57 4 76 3 129 
HUMCYCPS1-2R 19 12 38 3 44 2 19 2 35 2 54 5 100 3 64 
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 Table 5.7: Frequency of Stop Codon Patterns (Continued) 
estGroupID NAG NGA NNA NNG NAN NGN NNN   
# patterns counts # patterns counts # patterns counts # patterns counts # patterns counts # patterns counts counts score 
BC005299-1F 3 120 3 75 6 219 8 172 6 242 6 145   11.1406 
BC005299-1R 3 144 3 120 5 138 8 225 6 216 6 171   11.0781 
BC005299-2F 3 69 4 60 6 108 9 77 7 131 6 62 104 11.5156 
BC005299-2R 3 57 3 38 6 117 9 61 6 133 6 61 104 11.4531 
BC005299-3F 3 56 2 31 6 116 7 57 6 134 5 57   10.5156 
BC005299-3R 3 66 2 52 6 104 7 63 6 128 5 55   10.5156 
BC005299-4F 3 71 3 57 6 107 7 67 6 129 6 58 1 11.0781 
BC005299-4R 3 53 3 27 6 118 9 62 6 135 5 59 1 11.1406 
BC005299-5F 3 53 3 28 6 116 8 62 6 124 5 58   11.0781 
BC005299-5R 3 68 3 58 6 108 7 75 6 127 6 55   11.0781 
BC005299-6F 3 57 3 31 6 113 8 57 6 131 5 56 1 10.8281 
BC005299-6R 3 70 2 53 6 104 7 64 7 127 6 56 1 10.8906 
BC005299-7F 4 158 4 105 7 202 9 170 7 211 7 151 144 12.1406 
BC005299-7R 3 132 4 76 6 204 9 179 6 218 6 138 144 11.9531 
BC005299-8F 3 66 3 45 6 100 8 79 6 127 6 66   11.1406 
BC005299-8R 3 58 3 30 6 117 8 64 6 131 6 65   11.1406 
BC005299-9F 3 66 3 31 6 116 6 49 6 105 5 64   10.7031 
BC005299-9R 3 66 3 73 5 84 6 69 6 132 5 52   10.8906 
BC005299-10F 3 61 3 29 6 110 7 48 6 127 6 63 114 11.8281 
BC005299-10R 3 66 3 57 7 98 7 64 7 132 6 39 114 11.2031 
BC005299-11F 3 124 3 96 6 150 8 143 6 145 6 98 77 11.6406 
BC005299-11R 3 62 3 42 7 128 8 114 7 133 7 88 77 11.3281 
HUMCYCPS1-1F 3 50 3 31 6 100 8 58 6 122 6 49   10.8906 
HUMCYCPS1-1R 3 61 2 45 6 86 8 58 6 107 6 56   10.3906 
HUMCYCPS1-2F 2 34 2 16 6 91 9 67 7 107 6 57 103 11.2656 
HUMCYCPS1-2R 3 51 3 35 6 97 8 57 6 112 6 53 103 11.3906 
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F, forward strand; R, reverse strand. The patterns of stop codon were listed in Table 5.2. 
Formula to calculate score: 
score = TGA × 1.00 + TAG × 1.00 + TAA × 1.00 + # of TGN patterns × 0.25 + # of TNG patterns × 0.50  
      + # of TAN patterns × 0.50 + # of TNA patterns × 0.25 + # of TNN patterns × 0.25 + # of NAA patterns  × 0.25  
             + # of NAG patterns × 0.25 + # of NGA patterns × 0.25 + # of NNA patterns × 0.0625  




Table 5.8: Frequency of Poly-A Signal Patterns 
estGroupID AATAAA ATTAAA AGTAAA TATAAA CATAAA GATAAA AATATA AATACA AATAGA AAAAAG ACTAAA AAGAAA AATGAA TTTAAA AAAACA GGGGCT score 
BC005299-1F 2 3 2 2 2 2 2 3 3 1 3 3 9 2 6.80 
BC005299-1R 1 7 1 1 1 1 2 1 3 2 2 1 9 3 7.05 
BC005299-2F  4 1 1 1 1 1 3 2 2 1 6 1 3.95 
BC005299-2R 2 2 1 1 2 2 2 1 1 1 6 1 4.75 
BC005299-3F 3 2 1 2 2 2 1 1 1 2 7 1 5.95 
BC005299-3R 3  1 1 1 2 3 2 2 1 7 5.00 
BC005299-4F  3 1 1 2 1 1 4 1 1 5 1 3.25 
BC005299-4R 1 1 1 4 1 3 2  1 5 5 2 3.80 
BC005299-5F 2 1  4 2 3 1 1 1 1 5 1 4.35 
BC005299-5R  2 1 1 1 1 1 3 2 2 1 5 1 2.85 
BC005299-6F 2 1 1 3 2 4 2  1 1 2 6 1 4.75 
BC005299-6R  3 1 1 1 2 1 1 6 2 2.90 
BC005299-7F 
 3 1 1 1 1 1 2 4 1 2.65 
BC005299-7R 1 1 1 4 3 4 2 2 3 1 2 4 1 4.15 
BC005299-8F 1 1 1 2 2 1 2 2 1 7 1 3.35 
BC005299-8R 2 2 1 5 1 3 2 1 1 2 7 1 5.35 
BC005299-9F 1 3 2 3 1 3 1 1 1 1 5 1 4.35 
BC005299-9R  2 1 2 1 2 1 3 1 2 5 1 2.85 
BC005299-10F 1 2  5 2 2 2 1 1 2 5 2 4.10 
BC005299-10R  3 1 1 1 1 1 1 1 3 1 1 5 1 3.25 
BC005299-11F 3  1 1 1 2  1 2 3 3.95 
BC005299-11R    1 4 2 1 1 1 1 1 1.10 
HUMCYCPS1-1F 3 2 1 2 2 2 1 1 1 3 5 1 5.85 
HUMCYCPS1-1R  2 1 1 1 2 1 1 1 5 2.30 
HUMCYCPS1-2F  2 1 1 1 2 1 1 1 4 1 2.25 
HUMCYCPS1-2R 2 2 1 1 2 2 1 1 1 1 4 1 4.45 
30 54 25 40 33 18 50 23 11 47 24 25 32 139 32 1 
152 
Formula to calculate score:  
score = # of AATAAA × 1.00 + # of ATTAAA × 0.50 + # of AGTAAA × 0.1 + # of TATAAA × 0.1 + # of GATAAA × 0.1  
 + # of AATATA × 0.1 + # of AATACA × 0.1 + # of AATAGA × 0.1 + # of AAAAAG × 0.1 + # of ACTAAA × 0.1  
























BC005299-1 2427 1140 TAA 1556 59.25% Reverse ATTAAA 2137 
BC005299-2 1564 68 TAA 698 38.18% Forward ATTAAA 1272 
BC005299-3 1219 27 TAA 342 29.76% Reverse ATTAAA 919 
BC005299-4 1237 64 TAA 382 30.20% Forward ATTAAA 1160 
BC005299-5 1210 17 TAA 323 29.54% Reverse ATTAAA 1114 
BC005299-6 1215 21 TTG 333 29.66% Reverse ATTAAA 1120 
BC005299-8 1247 65 TAC 368 30.44% Forward AGTAAA 585 
BC005299-9 1216 17 TAC 315 29.69% Reverse ATTAAA 1123 
BC005299-10 1548 27 TAC 318 37.79% Reverse ATTAAA 1455 
HUMCYCPS1-1 1060 76 TAA 391 25.88% Reverse ATTAAA 968 
HUMCYCPS1-2 1366 70 TAA 700 33.35% Forward ATTAAA 1274 





Sixteen patterns of poly-A signals were reviewed as well. The number of times 
each of the patterns was occurred were accumulated and listed in Table 5.8. In most 
cases, AATAAA, ATTAAA and AGTAAA were found. CATAAA was only found in 
BC005299-11 (marked in blue). In addition, that was the only sequence found the 
GGGGCT poly-A signal (marked in pink). 
After running blastx, BC005299-7 and BC005299-11 were found to relate to 
other protein sequences. These two sequences were removed from pseudogene 
candidates. Based on the blastx results, the strand direction for each sequence was 
found. In addition, the start and stop codon locations for remain eleven sequences were 
recognized. Since the poly-A site is a six-base pattern, it has 46 = 4096 combinations. The 
percentage of finding a poly-A signal is calculated (% of finding poly-A site = sequence 
length ÷ 4096). With the information where the stop codons were located, the poly-A 
sites were found in the 3’ UTR. It is surprising to find that ten out of eleven sequences 
have ATTAAA as the poly-A sites. Only BC005299-8 has AGTAAA as its poly-A signal. 
None of the sequences has found the most common poly-A signal AATAAA in the 3’ 
UTR, using the stop codon location as a reference (Table 5.9). In addition, seven out of 
thirteen sequences have found TAA as stop codons. One has TTG and three have TAC as 
stop codons. 
Based on the comparison results provided by blastx, the nucleotide sequences 
of each estGroup were retrieved. Each was compared to the cytochrome sequence at the 
nucleotide level in order to calculate the number of mutational events (similar 
synonymous, synonymous and nonsynonymous mutations) defined in Section 5.3.5. The 
similar synonymous mutation is marked with lower case ‘s’. The synonymous mutation is 
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 marked with upper case ‘S’. The nonsynonymous mutation is marked with upper case 
‘N’. In addition, if a gap was inserted in the blastx alignment result, either in the 
subject or query sequence, the number of gaps for each estGroup was also counted. If the 
insertion occurs in the subject sequence, it is marked with caret sign‘^‘. If the insertion 
occurs in the query sequence, it is marked with minus sign ‘-’ sign. If a premature stop 
codon was found in the query sequence, the nonsynonymous mutation was marked as 
lower case ‘p’. But if a premature stop codon was found in the query sequence and there 
is an insertion found in the subject sequence, the nonsynonymous mutation was marked 
as lower case ‘q’. In addition, the number of non-mutational nucleotide is marked as a 
blank ‘ ‘. The results are shown in Table 5.10. 
 
Table 5.10: Counts of Similar Synonymous Mutations, Synonymous Mutations, 
Nonsynonymous Mutations, and Insertion for Each Sequence 
estGroupID N S s - ^ p q     
BC005299-1 0 0 0 0 0 0 0 315 315 
BC005299-2 7 3 2 0 0 0 0 303 315 
BC005299-3 5 5 0 0 0 0 0 305 315 
BC005299-4 11 10 5 0 0 0 0 289 315 
BC005299-5 11 7 5 9 0 0 0 283 315 
BC005299-6 18 6 5 3 0 2 0 281 315 
BC005299-8 14 6 9 3 0 1 0 273 306 
BC005299-9 15 5 12 0 0 0 0 262 294 
BC005299-10 52 6 13 15 0 0 0 220 306 
HUMCYCPS1-1 5 5 0 0 0 0 0 305 315 
HUMCYCPS1-2 7 3 2 0 0 0 0 303 315 
N, nonsynonymous mutation; S, synonymous mutation; s, similar synonymous mutation;  
-, insertion in query sequence; ^, insertion in subject sequence; p, nonsynonymous mutation 
when a stop codon appears in the query sequence; q, insertion occurs in the subject sequence 
when a stop codon occurs in the query sequence; blank ‘ ‘, the number of non-mutational 






In Section 5.3.3, a poly-A tail was defined as having a length of ten or more 
adenine (A) residues. However, the computational program did not return results for 
eleven candidate sequences. It is possible that none of the sequences have a poly-A tail. It 
is necessary to study the sequence file manually in order to check if the sequence does 
not have a poly-A tail in the 3’ UTR. In fact, there are poly-A tails in the 3’ UTR. 
However, the longest size of adenine (A) residues is seven bases. Since the program 
requires having ten adenines (A) as a minimum number, if a sequence pattern is like 
AAAAAAAGAAA, the program will not count it as a poly-A tail because the nucleotide G 
has broken the length. Therefore, eight out of eleven pseudogene candidate sequences 
have poly-A tails, after reviewing the sequence file. The size of poly-A tails ranges from 
eleven to 29 bases (Table 5.11). 
A score was generated and each pseudogene factor was assigned a value as 
defined in Section 5.3. Table 5.11 provides the scoring results for each candidate 
pseudogene sequence. The unit score for each column is shown in the bottom of the table. 
The score for start codon, stop codon and poly-A sites have been defined in Tables 5.1 to 
5.3. For poly-A tails, if the size is less than twenty adenines (A), each base is giving a 
0.1. If the poly-A tail has more than twenty adenines (A), then 2.0 is given.  
  
Table 5.11: Score for Pseudogene Candidate Sequences 






tails N S s - ^ p q   
score 
BC005299-1 ATG TAA ATTAAA 0 0 0 0 0 0 0 0 315 5.65 
BC005299-2 ATG TAA ATTAAA 15 7 3 2 0 0 0 0 303 7.86 
BC005299-3 ATG TAA ATTAAA 23 5 5 0 0 0 0 0 305 8.10 
BC005299-4 ATG TAA ATTAAA 15 11 10 5 0 0 0 0 289 8.34 
BC005299-5 ATG TAA ATTAAA 13 11 7 5 9 0 0 0 283 8.95 
BC005299-6 ATG TTG ATTAAA 11 18 6 5 3 0 2 0 281 8.27 
BC005299-8 ATG TAC AGTAAA 26 14 6 9 3 0 1 0 273 8.64 
BC005299-9 ATG TAC ATTAAA 29 15 5 12 0 0 0 0 262 8.77 
BC005299-10 ATG TAC ATTAAA 29 52 6 13 15 0 0 0 220 13.61 
HUMCYCPS1-1 ATG TAA ATTAAA 0 5 5 0 0 0 0 0 305 6.10 
HUMCYCPS1-2 ATG TAA ATTAAA 0 7 3 2 0 0 0 0 303 6.36 
unit score Table 5.1 Table 5.2 Table 5.3 1.0~2.0  0.1 0.01 0.05 0.1 0.05 0.1 0.05 0.01   
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N: nonsynonymous mutation; S: synonymous mutation; s: similar synonymous mutation; -: gap insertion in the query 
sequence; ^: gap insertion in the subject sequence; p: nonsynonymous mutation occurred to make the coding codon becomes 
stop codon in query sequence; gap insertion in the subject sequence because stop codon is found in query sequence. 
Formula to calculate score:  #, number 
score = start codon + stop codon + poly-A site + score of poly-A tail (1.0~2.0) + # of N's × 0.1 + # of S's × 0.01  





BC005299-1 was retrieved from chromosome 7. It is the only sequence that does 
not contain any mutation in the 315-base aligning to the cytochrome protein sequence, 
when running blastx. The blastx returned the alignment results in two pieces of 
100% sequence identity, with a gap of 100 bases. It is most likely to be a gene itself. In 
fact, these 100 bases represent an intron.  
BC005299-2 and HUMCYCPS1-2 are another two sequences whose blastx 
results return two pieces. Both of them were retrieved from chromosome 6. After 
reviewing the sequences themselves, the sequences in between the two segments are 
mainly Ns. The size ranges from ~50 to ~310 bases. In fact, both sequences were 
retrieved from overlapping regions in chromosome 6 with a ~1100- base overlap. 
BC005299-3 and HUMCYCPS1-1 yield similar blastx results. Both of them came 
from chromosome 8. The only difference is that BC005299-3 has a poly-A tail but 
HUMCYCPS1-1 does not. After reviewing the sequences in genome, they were found 
have a ~1000-base overlap. BC005299-9 which was retrieved from chromosome 2 is 
another sequence that has four bases inserted between two segments. Otherwise, the rest 
of five sequences are all in one piece. The size ranges from 291 to 315. 
Besides BC005299-1, the sequence similarity for the rest of the sequences in 
Table 5.11 ranges from 63% to 95%. All of them contain poly-A signals. Eight out of the 
ten sequences have poly-A tails. BC005299-10 from chromosome 3 has been found the 
most number of nonsynonymous mutations. In addition, when compared to the 
cytochrome protein sequence, the sequence has to carry more gaps in order to receive the 
158 
 
 best scoring results. BC005299-6 from chromosome 8 and BC005299-8 from 
chromosome 9 have premature stop codons.  
The nonsynonymous mutations (marked as upper case ‘N’ in Table 5.11) are 
assigned a higher score (0.1) than the synonymous mutation (marked as upper case ‘S’ 
and lower case ‘s’, scored 0.05) because of corresponding changes to the amino acid. 
Similar synonymous mutations have higher score (0.05) than the synonymous mutation 
(0.01). Although the amino acid is changed to a close genetic code, the amino acid is not 
the same one anymore. If the error occurs again when sequences are duplicated, the 
correct nucleotide(s) would not only be copied.  
Insertions occurred in the query sequence in blastx result (marked as minus 
sign ‘-‘) are assigned a higher score (0.1) than the insertion in subject sequence (marked 
as caret sign ‘^’, scored 0.05). Gap insertions are only for the computational purpose in 
order to calculate the best comparison result. In addition, when comparison made 
between the query and subject sequence, if gaps are inserted to the query sequence, there 
are a number of nucleotides deleted in the query sequence.  
The premature stop codon which is found in the query sequence causes the 
nonsynonymous mutation (marked as lower case ‘p’). It gets assigned a score of 0.1. If 
the premature stop codon is found in the query sequence, but the subject sequence is 
inserted a gap in order to get a better score in sequence comparison, this nonsynonymous 
mutation (marked as lower case ‘q’) has a score of 0.05. 
The scores for start codons, stop codons and poly-A sites are given in Tables 5.1 
to 5.3. After adding up single score for each sequence, the score ranges from 5.65 to 





has the highest score due to having the highest number of nonsynonymous mutations 
occurring in the sequence. 
 CHAPTER VI 
CONCLUSIONS AND DIRECTIONS FOR FUTURE RESEARCH
To understand gene regulation and expression, expressed sequence tags (ESTs) 
have been used widely in sequence alignment. This dissertation has discussed the 
implementation of using EST sequences for finding the efficiency of current BLAST 
tools, determining undetected alternative splicing events, and detecting and 
characterizing pseudogenes in genomic sequences in Chapters 3 to 5. These projects yield 
many interesting research directions to explore upon completion of doctoral work. A few 
of these are described in Sections 6.1 to 6.4. 
 
6.1 BLAST Comparison Project 
In the BLAST comparison project (Chapter 3), ESTs serve as short sequences as 
both query and database targets for sequence alignment. Tests were made under default 
settings for all three chosen BLAST tools. In general, without knowing the sequence 
length and file size, WU BLAST was found to be the best for sequence comparison at a 
nucleotide level. Results may vary when comparing amino acid sequences. The BLAST 
comparison project was completed in 2004. All three search tools have since released 
updated versions. New features have been added to provide better and accurate search 
results. There are additional versions, such as PSI-BLAST (101), PHI-BLAST (102) and 
megaBLAST (223) in ncbiBLAST, as well as other parallel implementations (224-227). 
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 These were not tested, and may yield more efficient results. In addition, fine tuning the 
parameters may result in varying efficiencies. 
 
6.2 Rat Phosphodiesterase 4 (PDE4) Project 
In Chapter 4, computational detection of alternative splicing events was 
discussed. Different combinations of exons can produce different mRNA sequences. 
ESTs can provide partial information of the mRNA. Moreover, after high-throughput 
analysis was established, an increasing number of ESTs have been produced from 
different tissue types in the wet lab. In order to find alternative splicing variants, ESTs 
become a good resource. Phosphodiesterase 4 (PDE4) genes were chosen to study in the 
project in order to find the relationship between tissue specificity and isoforms. A 
computational method has been designed and implemented into programs to align rat 
ESTs to the corresponding chromosomal and mRNA sequences. In addition, the splice 
patterns and tissue type for each EST was examined to gain more insight into PDE4 
isoforms tissue specificity.  
Some undetected isoforms were found by the computational method. After using 
primers to sequence these patterns found in the PCR experiments, a number of novel 
isoforms were experimentally verified. Results are shown in Sections 4.8. Further 
collaboration with web lab biologists could result in confirmation of novel tissue specific 
isoforms. Additional primers can be designed and run in gels in order to verify more of 
the predicted patterns. These patterns could be further localized within tissues using in 
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 situ hybridization33. The complete sequence of the isoform is desired, and could be 
determined using techniques such as RACE sequencing34. 
The methodology for finding alternative splicing events in PDE4 has been 
designed and implemented in several scripts. In the future, this process could be 
automated, allowing users to input a gene of interest. The results provided will allow for 
users conduct wet lab experiments for confirmation of predicted isoforms. 
This PDE4 project focused in rat genome. Future extensions could look at 
incorporation of EST information from comparative genomes (such as mouse, 
chimpanzee and human) for detection of rare splicing events. 
 
6.3 Computational Method of Detecting Alternative Splicing Events 
The method developed for finding splicing variants concentrates on finding 
functional alternative splices. Future studies could distinguish non-functional splices 
from functional ones. However, this would require more biological information on the 
difference between functional and non-functional alternative splicing events. 
 
6.4 Computational Method for Pseudogene Detection and Characterization 
In addition to finding alternative splicing sequences in genomic regions, ESTs 
were also used to determine pseudogenes in genome. Pseudogenes have been defined as 
                                                            
33 In situ hybridization is a technique in which single-stranded DNA are permitted to interact so that hybrids 
are formed by molecules with sufficiently similar, complementary sequences. It involves hybridizing a 
labeled nucleic acid in fluorescent dye to suitably prepared cells or histological sections. In situ 
hybridization is used particularly to look for specific transcription or localization of genes to specific 
chromosomes. 
34 RACE, or rapid amplification of cDNA ends, is a technique used in molecular biology to obtain the 
partial sequence of an RNA transcript found within a cell. RACE begins through RT-PCR to produce a 
cDNA copy of a region of the RNA transcript. An unknown end portion of a transcript is copied using a 
known sequence from the center of the transcript. The copied region is bounded by the known sequence, 
and either the 5’ or 3’ end. 
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 sequences which look like genes (having similar genomic features) but are not able to 
produce proteins as genes. Instead of using cDNA or mRNA sequences to find genes 
themselves in the genomic regions. ESTs can help to locate pseudogene sequences that 
have never been reported before. A computational method was developed to detect and 
characterize pseudogenes in Chapter 5. The biological factors for pseudogenes were 
evaluated, such as finding premature stop codons and calculating the number of 
synonymous and nonsynonymous mutations within sequences. A scoring scheme has 
been established in order to evaluate sequences or not. Based on the scoring scheme 
presented in Section 5.3, it would be easier for users to distinguish pseudogenes from 
gene sequences. 
However, the developed computational method for pseudogene detection and 
characterization still requires manual review. Therefore, it is necessary to modify the 
detecting method to calculate the percentage of the adenine (A) in the sequences.  
In pseudogene detection and characterization, ESTs are used to locate the 
candidate pseudogene locates in genomic regions. For better evaluation, having blastx 
results will help to locate the exact locations of start and stop codons in the candidate 
regions. blastx results also help to calculate the synonymous and nonsynonymous 
mutation with the sequences. Therefore, to detect and characterize pseudogenes, the 
known information from protein sequences is necessary. In addition, based on where the 
start codons of pseudogene candidate sequences are located, it would be necessary to 
retrieve either upstream or downstream sequence from the genomic sequences to further 





The methodology discussed in Chapter 5 was developed step-by-step and 
implemented into computer programs, including data preprocessing, sequence alignment, 
clustering and pseudogene evaluation. To extend the research in pseudogene detection 
and characterization, a pipeline process is planned from data preprocessing all the way to 
evaluation so pseudogene analysis can be performed in an automated fashion. The 
pipeline could be implemented to accommodate multiple genomes. The bottleneck in this 
process is currently the time it takes for sequence comparison. Future research could look 
into parallel and distributed computing applications to speed up this process.
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ASN.1 – abstract syntax notation one 
BLOSUM – blocks of amino acid substitution matrix 
bp – base pair 
cAMP – cyclic adenosine monophosphate 
cDNA – complementary DNA 
CDS – coding sequence 
cGMP – cyclic guanosine monophosphate 
CNS – central nervous system 
COPD – chronic obstructive pulmonary disease 
CSHL – Cold Spring Harbor Laboratory 
CPU – central process unit 
dbEST - expressed sequence tags database 
DDBJ – DNA DataBank of Japan 
ddNTP – dideoxynucleotide triphosphate 
DNA – deoxyribonucleic acid 
ELSI – ethical, legal, and social issues 
EMBL – European Molecular Biology Laboratory 
ENCODE – ENCyclopedia of DNA Elements 
EST – expressed sequence tag 
GI – GenInfo Identifier 
GMAP – genomic mapping and alignment program 
HGP – Human Genome Project 
HSP – high-scoring pair 
INSDC – International Nucleotide Sequence Database Collaboration 
IUB – International Union of Biochemistry 
IUPAC – International Union of Pure and Applied Chemistry 
MPI – message passing interface 
mRNA – messenger RNA 
miRNA – microRNA 
NAS – National Academy of Science 
NCBI – National Center for Biotechnology Information 
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 NIH – National Institutes of Health 
NLM – National Library of Medicine 
ORF – open reading frame 
PAM – point accepted mutation 
PBS – portable batch system 
PCR – polymerase chain reaction 
PDE – phosphodiesterase 
PDE4 – phosphodiesterase 4 
PPi – pyrophosphate  
PSSM – position specific scoring matrix 
RACE – rapid amplification of cDNA ends 
RefSeq – Reference Sequence 
RNA – ribonucleic acid 
RNAi – RNA interference 
rRNA – ribosomal RNA 
SARS – severe acute respiratory syndrome 
siRNA – silencing RNA, short interfering RNA or small interfering RNA 
snRNA - small nuclear RNA  
tRNA – transfer RNA 
TIGR – The Institute for Genomic Research 
UCSC – University of California Santa Cruz 
UCR - upstream conserved region 
UTR – untranslated region 
WU - Washington University at Saint Louis 






3’ and 5’– Directionality in molecular biology refers to the end-to-end chemical 
orientation of a single strand of nucleic acid. The chemical convention of naming 
carbon atoms in the nucleotide sugar-ring numerically gives rise to a 5’ end and a 
3’ end (usually pronounce “five prime end” and “three prime end”). Therefore, 
the 5’ end designates the end of the DNA or RNA strand that has the fifth carbon 
in the sugar-ring of the (deoxy)ribose at its terminus. The 3’ end has the third 
carbon in the sugar-ring as its terminus (Figure 1.1). 
ab initio – In computation, ab initio means an extra, transform, load tool used to 
manipulate data. In Bioinformatics, ab initio is a term used to define methods for 
making predictions about biological features using only a computational model 
without extrinsic comparison to existing data. In this context, it may be sometimes 
interchangeable with the Latin term de novo. 
alternative splicing – process of mRNA transcription through which the coding regions 
for a eukaryotic gene, called exons, are extracting and connected to produce 
alternative mRNA molecules. 
amino acid – the basic elements of proteins. Amino acids form short polymer chains 
called peptides or longer sequences called polypeptides. 
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 BLAST – stands for basic local alignment search tool which is widely used in 
Bioinformatics and Computational Biology to find out the basic alignment results 
between two sequences. 
BLOSUM – stands for blocks of amino acid substitution matrix. It is a substitution 
matrix used for sequence alignment of proteins. It was generated by Henikoff and 
Henikoff in 1992. The most commonly used matrix is BLOSUM62. 
cDNA – stands for complementary DNA. It is a single-stranded DNA made in a 
laboratory so that its base sequence is complementary to a messenger RNA 
template. It is assembled by the enzyme reverse transcriptase and may be used in 
gene cloning or as a gene probe. 
central dogma – a process to derive a genetic DNA sequence to a fully-functional 
protein that contains transcription, pre-mRNA processing, translation and protein 
folding. 
cleavage – a series of mitotic cell divisions that produces a blastula from a fertilized 
ovum. It is the basis of the multi-cellularity of complex organisms. It can be 
called segmentation as well. 
cleavage site – a DNA sequence that can be recognized and cut by a specific restriction 
enzyme. 
codon – a sequence of three adjacent nucleotides constituting the genetic code that 
determines the insertion of a specific amino acid in a polypeptide chain during 
protein synthesis or the signal to stop protein synthesis. 
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 contig – a continuous sequence of DNA created by assembly overlapping sequenced 
fragments of a chromosome. It is also a group of clones representing overlapping 
regions of a genome. 
CpG islands – short genomic regions that contain a high frequency of CG dinucleotides 
than in other regions. ‘p’ indicates that ‘C’ and ‘G’ are connected by 
phosphodiesterase bond. 
cytochrome – a class of hemoprotein. The major biological function is for electron 
transport by virtue of a reversible valency change of the heme iron. 
dbEST –a division of GenBank that collects ESTs submitted from around the world. It 
contains sequence data and its annotation information from numerous organisms.  
ddNTP – stands for dideoxynucleotide, represents one of the four portions: ddATP, 
ddCTP, ddGTP  and ddTTP. 
 de novo – anew, afresh, the same as if it had not been heard before and as if no decision 
previously had been rendered. 
DNA – stands for deoxyribonucleic acid. It carries the genetic information in the cell and 
is capable of self-replication and synthesis of RNA. It has four bases –adenine 
(A), cytosine (C), guanine (G) and thymine (T). DNA consists of two long chains 
of nucleotides twisted into a double helix and joined by hydrogen bonds between 
the complementary bases A to T or C to G. The sequence of nucleotides 
determines individual hereditary characteristics. 
DNA sequencing – a method to determine the order of the nucleotide bases, A, C, G and 
T, in a DNA oligonucleotide.  
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 DUST – is a computational program used for masking or filtering low complexity 
regions in nucleic acids. 
dynamic programming – a method of solving problems when the solutions can be 
determined recursively by building upon known solutions of a subspace. 
electrophoresis – a method of separating substances, especially proteins, and analyzing 
molecular structure based on the rate of movement of each component in colloidal 
suspension while under the influence of an electric field. This method was 
introduced by Arne Tiselius in 1937 for separating proteins in solution. 
ENCODE – stands for encyclopedia of DNA elements. It is an international-wide 
research to identify the functional elements in the human genome. ENCODE 
project contains three phase, a pilot phase, a technology development phase and a 
production phase. 
EST – stands for expressed sequence tag, which is a segment of cDNA. The size ranges 
from 300 to 600 base pair. They are used to identify gene transcripts and are 
instrumental in gene discovery and gene sequence determination. 
exon – is coding region in the genomic sequence. It is a discontinuous sequence of DNA 
that codes for protein synthesis and carries the genetic code for the final 
messenger RNA molecule. 
e-value – is the sum of all possible values for a random variable, each value multiplied 
by its probability of occurrence. It is also the integral of the probability density 
function and a continuous random variable over its range of values. 
FASTA – stands for FAST-ALL. It was developed by Pearson and Lipman. The method 
combines local search with a heuristic algorithm to search a database for sequence 
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 homology. FASTA compares protein or nucleotide sequences to report the best 
matches of sequences for local alignment. 
FASTA format – the data format begins with a greater-than symbol ‘>’, followed by 
single line description. The next few lines are sequence data, the combination of 
A, C, G and T nucleic acids or twenty different amino acids. 
frame shifting – a genetic mutation that inserts or deletes a number of nucleotides that is 
not evenly divisible by three. 
GC% - the percentage of total number of G's and C's in the sequence. 
GenBank – is a sequence data bank which was established in 1982 by the National 
Institutes of Health to help advance scientific discovery worldwide. GenBank 
collects DNA and RNA sequences and exchanges data to European Molecular 
Biology Laboratory and the DNA Data Bank of Japan daily. 
GenBank format – the data format contains complete sequence information including 
locus, definition, accession, version, keywords, source, reference, comment, 
features, base count, and origin. 
gene – the basic unit to transfer hereditary information in genome. Genes provide 
structure, function and regulation to a biological system. 
GI – stands for GenInfo Identifier which is used as a unique sequence identifier for 
nucleotide and proteins. The GI number has been used by NCBI to track sequence 
histories in GenBank and the other sequences databases it maintains. The 
VERSION system of identifiers was adopted in 1999 by the International 
Nucleotide Sequence Database Collaboration (GenBank, EMBL and DDBJ).
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 genome annotation – a process of assigning biological information to sequences. The 
process is based on two main steps: identifying elements on the genome and 
adding the biological information to the elements. An annotation is a note added 
by way of commentary and explanation. Once a genome is sequenced, it needs to 
be annotated and clarified. 
global alignment – is aligning the entire length of two sequences to find out sequence 
similarity. 
Hamming distance – if two sequences of length N differ from each other at n sites, then 
the proportion of differences, n/N, is referred to as the Hamming distance or the 
degree of divergence. 
heuristic algorithm – an algorithm that can make an approximation of the best solution 
without exhaustively considering every possible outcome. It tries to reduce time 
and space complexity in calculation. 
high-throughput sequencing - a fast method of determining the order of bases in DNA. 
homology – similar characteristics in two animals that are a product of descent from a 
common ancestor rather than a product of a similar environment. 
Human Genome Project – a project was to sequence the human genome. The project 
began in 1990 to determine genes in the human genome. In 2001, the first draft 
was published. In 2003, 95% of the gene-containing part of the human sequence 
was mapped to 99.99% accuracy. 




 in situ hybridization – a technique in which single-stranded DNA are permitted to 
interact so that hybrids are formed by molecules with sufficiently similar, 
complementary sequences. It involves hybridizing a labeled nucleic acid in 
fluorescent dye to suitably prepared cells or histological sections.  In situ 
hybridization is used particularly to look for specific transcription or localization 
of genes to specific chromosomes. 
in vitro – a test performing in the glass or plastic vessels in the laboratory 
intron – non-coding region in the genomic sequence. Introns are sections of DNA that 
are not expressed in the gene product. 
isoform – a version of protein with only small differences to another isoform of the same 
protein. Different forms of a protein may be produced from different by related 
genes. It may also arise from the same gene by alternative splicing. 
IUB – stands for International Union of Biochemistry. It provides recommendations on 
biochemical and organic nomenclature, symbols and terminology. 
IUPAC – stands for International Union of Pure and Applied Chemistry. It serves to 
advance the worldwide aspects of the chemical sciences and to contribute to the 
application of chemistry in the service of Mankind. 
local alignment – an algorithmic technique that looks for significant similarities in 
smaller sections of the sequences. 
locus – the position that a given gene occupies on a chromosome . 
low complexity region – the region of biased composition including homopolymeric 




 MALDI-TOF-MS – stands for matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry. 
MPI – stands for message passing interface which is a library specification for message 
passing. It is a standard application programming interface (API) that can be used 
to create parallel applications.  
mpiBLAST – a parallel implementation using message passing interface to conduct 
NCBI BLAST in multi-processor cluster.  
mRNA – stands for messenger RNA. It is the form of RNA that mediates the transfer of 
genetic information from the cell nucleus to ribosomes in the cytoplasm, where it 
serves as a template for protein synthesis. mRNA is synthesized from a DNA 
template during the process of transcription. 
miRNA – stands for microRNA which are single-stranded RNA molecules about 21-23 
nucleotides in length and regulates gene expression. 
mutation – a change of the DNA sequence within a gene or chromosome of an organism 
resulting in the creation of a new character or trait not found in the parental type. 
Mutation can also mean the process by which such a change occurs in a 
chromosome, either through an alternation in the nucleotide sequence of the DNA 





 NCBI – stands for National Center for Biotechnology Information. It is established in 
1988 as a national resource for molecular biology information. NCBI creates 
public databases, conducts research in computational biology, develops software 
tools for analyzing genome data and disseminates biomedical information – all for 
the better understanding of molecular processes affecting human health and 
disease. 
NIH – stands for National Institute of Health, which is the nation’s medical research 
agency.NIH provides resources and financial support for scholars to conduct 
researches in medical related science. 
nonsynonymous mutation – a mutation that occurs in the nucleotide level but affects the 
amino acid in translation. 
oligonucleotide (or oligo) – a short polymer segment of RNA or DNA, the length ranges 
from two to twenty bases. 
orthologous locus – genes that have evolved directly from an ancestral gene. 
PAM – shorts for point accepted mutation. It is a matrix of score to consider the 
replacement of one amino acid in a protein by another residue that has been 
accepted by natural selection. It was released by Dayhoff and her colleagues in 
1970s. The common used matrix for amino acid sequence comparison is 
PAM250. 
PBS – stands for portable batch system. It is a scheduling system to conduct processes 
running on multi-processors in the Unix/Linux system. PBS provides additional 
controls over initiating or scheduling execution of batch jobs and allows routing 
of those jobs between different hosts.  
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 PCR – stands for polymerase chain reaction. It is a method to amplify specific DNA 
segments by exploiting certain features of DNA replication in vitro. The PCR 
technique was developed by Kary Mullis in 1983. This technique uses a pair of 
primers, which are DNA segments approximately 20 bp long complement the 
DNA being synthesized and a thermo stable DNA polymerase to achieve near-
exponential enzymatic amplification of target DNA. 
PDE – stands for phosphodiesterase. PDEs are enzymes which act as regulators for signal 
transduction. Currently, there are eleven known families of PDEs. PDEs degrade 
cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate 
(cGMP). 
PDE4 – stands for phosphodiesterase 4 which is an enzyme being targeted for 
inflammatory disorders, including asthma and chronic obstructive pulmonary 
disease and central nervous system injury. PDE4 has a large number of potential 
isoforms with apparent tissue and functional specificity. 
Pfam – Pfam (http://pfam.sanger.ac.uk) is a large collection of multiple sequence 
alignments and hidden Markov models covering many common protein domains 
and families. For each Pfam family, users are available to check for multiple 
alignments, view protein domain architectures, examines species distribution, 
connect to other databases, and study known protein structures. 
polyadenyl (polyA) signal – a six-base sequence which appears in the 3’ UTR. AATAAA 
is the most found pattern in mammalian genomes. 
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 polyadenyl (polyA) tail – a sequence of 50 to 250 adenine (A) residues that are added to 
the 3’ end of an mRNA sequence after being cleaved. This reaction is catalyzed 
by polyadenylate polymerase. 
polymerase – a polymerase is an enzyme that can synthesize new DNA strands using a 
DNA template while several such enzymes exist. 
primer – a segment of DNA or RNA that is complementary to a given DNA sequence 
and that is needed to initiate replication by DNA polymerase. 
probe – a single-stranded DNA molecule used in laboratory experiments to detect the 
presence of complementary sequence among a mixture of other single-stranded 
DNA molecules. 
promoter – a sequence of DNA that specifies the sites of transcription initiation for an 
RNA polymerase. 
protein – a linear polymer built from amino acids. Proteins carry out all of a cell’s 
activities. 
pseudogene – a genomic sequence that looks like gene but does not have any 
functionality as gene. Currently there are three known types of pseudogenes: 
processed pseudogene, unprocessed pseudogene and disable pseudogene. 
RACE – short for rapid amplification of cDNA ends, is a technique used in molecular 
biology to obtain the partial sequence of an RNA transcript found within a cell. 
RACE begins through RT-PCR to produce a cDNA copy of a region of the RNA 
transcript. An unknown end portion of a transcript is copied using a known 
sequence from the center of the transcript. The copied region is bounded by the 
known sequence, and either the 5’ or 3’ end. 
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 RefSeq – Reference Sequence database is a collection of annotated DNA, RNA and 
protein sequences from major organisms, including plasmids, organelles, viruses, 
archaea, bacteria and eukaryotes. RefSeq contains data extracted from GenBank 
and involves varying levels of computational and experimental verification from 
authoritative groups. 
repetitive element – a sequence that appears more than once in a genome. 
RepeatMasker – a software package designing to screen DNA sequences for repeats. 
retrotransposition – a process occurring in the intermediate RNA stage that a transposon 
is created by reverse transcription of an RNA molecule. 
ribosome – a minute round particle composed of RNA and protein. It is found in the 
cytoplasm of living cells and serves as the site of assembly by polypeptides 
encoded by messenger RNA. 
RNA – stands for ribonucleic acid. It is a polymeric constituent of all living cells and 
many viruses. RNA consists of a long and single-stranded chain of alternative 
phosphate and ribose units with the bases adenine (A), cytosine (C), guanine (G), 
and uracil (U) bonded to the ribose. The structure and bases sequence of RNA are 
determinants of protein synthesis and the transmission of genetic information. 
RNAi – stands for RNA interference. It is a specific, potent and highly successful 
approach for loss-of-functional studies in eukaryotic organisms. The process by 
which foreign, double-stranded RNA is recognized and degraded by specialized 
protein complex within many eukaryotic cells. It is believed to be an 




 rRNA – stands for ribosomal RNA, which is a permanent structural part of a ribosome. 
RT-PCR – reverse transcriptase polymerase chain reaction. It is a highly sensitive 
technique for the detection and quantization of mRNA. This technique includes 
two parts: the synthesis of cDNA from mRNA by reverse transcript and the 
amplification of a specific cDNA by the polymerase chain reaction. 
SARS – stands for severe acute respiratory syndrome, is a severe form of pneumonia 
which appeared in outbreaks in 2003. It is transmitted especially by contact with 
infectious material (as respiratory droplets or body fluids), and is characterized by 
fever, headache, body aches, a dry cough, hypoxia and usually pneumonia. 
SEG – a computational program for masking or filtering low-complexity regions in 
amino acids. 
siRNA – stands for silencing RNA, short interfering RNA or small interfering RNA. 
siRNA results in high levels of knockdown for transient knockdown experiments. 
Smith-Waterman Algorithm – is a well-known algorithm for performing local sequence 
alignment in order to determine similar regions between two nucleotide or protein 
sequences. Instead of looking at the total sequence, the Smith-Waterman 
algorithm compares segments of all possible length and optimizes the similarity 
measure. 
snRNA – stands for small nuclear RNA and is a small RNA molecule that functions in 
the nucleus by guiding the assembly of macromolecular complexes on the target 
RNA to allow site-specific modifications or processing reactions to occur. 




 splice variant – an active mRNA that results from cutting and resealing by precise 
breakage of phosphodiester bonds at 5’ and 3’ splice sites (exon/intron junction). 
It also indicates a recombinant DNA molecule derived from cutting and resealing 
of DNA from different sources. 
splice site – located in either 5’ or 3’ ends of the intron sequence that spliceosome 
complex will bind on the sequence to conduct the splicing events in order to get 
the coding region sequences united. It is also called exon/intron junction. The 
most common splice site in mammalian genomes is GT/AG. 
start codon – the initiating signal of translation and the first amino acid in a polypeptide 
chain. 
stop codon – the terminating signal in genomic sequence to notify the gene to stop 
translation. There are three common stop codons: TGA, TAG, and TAA. 
synonymous mutation – a mutation that occurs in the nucleotide level but does not 
affects the amino acid in translation. 
synteny – the occurrence of two or more genes on the same chromosome, whether or not 
they are linked. 
thread – a portion of a program that can run independently of and concurrently with 
other portions of the program. 
TIGR – short for The Institute for Genomic Research. It was a non-profit genomics 
research institute founded in 1992 by Craig Venter in Rockville, Maryland. It is 





transcription – the process that messenger RNA is synthesized from a DNA template 
resulting in the transfer of genetic information from the DNA molecule to the 
messenger RNA. 
translation – the process by which messenger RNA directs the sequence of amino acids 
assembled by a ribosome during protein synthesis. 
tRNA – stands for transfer RNA which is one of a class of RNA molecules that transport 
amino acids to ribosomes for incorporation into a polypeptide undergoing 
synthesis. 
UCR – stands for upstream conserved region which are the regions being protected from 
harm or decay. 
UniGene – an organized view of the transcriptome. UniGene provides sequence 
information in clusters that each UniGene entry is a set of transcript sequences 
that appear to come from the same transcription locus (gene or expressed 
pseudogene), together with information on protein similarities, gene expression, 
cDNA clone reagents and genomic location. 
UTR – stands for untranslated region. It is a non-coding RNA that does not translated 
into a protein. It is located either in the 5’ end before the start codon of a gene or 
3’ end after the stop codon is recognized in gene regulation. 
XNU – a computational program for masking or filtering low-complexity regions in 
amino acids.   
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20-21, 2005. 
 
E. C. Rouchka and I. E. Cha, “Bioinformatics”, National Engineers Days 2005, 
University of Louisville, February 20-21, 2005. 
 
E. C. Rouchka and I. E. Cha, “Bioinformatics”, National Engineers Days 2004, 
University of Louisville, March 26-27, 2004. 
 
Invited Presentations: 
I. E. Cha, “In silico Prediction of Novel Tissue Specific Isoforms”, Center for 
Computational Biology and Bioinformatics, Indiana University – Purdue 
University Indianapolis, Indianapolis, Indiana, May 9, 2008.  
 (Dr. Sean Mooney, Host) 
 
I. E. Cha, “Computational Method for Recognition of Alternative Splicing”, Genomic 
Research Center, Academia Sinica, Taipei, Taiwan, R.O.C., August 24, 2007. 
 (Dr. C. Y. Lin, Host) 
 
I. E. Cha, “Computational Method for Splice Pattern Recognition in Rat PDE4 
Sequences”, Section of Computer and Information Science, Kentucky Academy 
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Association of Computing Machinery (ACM) 
Institute of Electrical and Electronic Engineers (IEEE) 
Upsilon Pi Epsilon Honor Society 
Sigma Delta Epsilon, Graduate Women in Science 
Toastmasters International at University of Louisville 
 
WORK EXPERIENCE 
Graduate Research Assistant 
Bioinformatics Research Laboratory, Computer Engineering and Computer 
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2005 – present 
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 Engineering Analysis Core (ENCORE), University of Louisville 
 January 2002 – August 2002 
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 ALSTOM Signaling Inc. (Formerly General Railway Signaling) – Taiwan 
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 ALSTOM Signaling Inc. (Formerly General Railway Signaling) – Taiwan 
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Research Assistant 
 Dr. C. T. Chen Laboratory, Institute of Chemistry, Academia Sinica 
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